MULTISPECIFIC MOLECULES AND USES THEREOF

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 6, 2018, is named E2070-7020WO_SL.txt and is 603,541 bytes in size.

BACKGROUND

Multispecific molecules targeting tumor associated macrophages (TAMs) or myeloid derived suppressor cells (MDSCs) and methods of using the same, are disclosed.

SUMMARY OF THE INVENTION

The disclosure relates, inter alia, to novel multispecific molecules comprising: (i) a first immunosuppressive myeloid cell (IMC) binding moiety (e.g., a first tumor associated macrophage (TAM) binding moiety; or a first myeloid derived suppressor cell (MDSC) binding moiety) (e.g., an antibody molecule); and (ii) a second IMC binding moiety (e.g., a first TAM binding moiety; or a second MDSC binding moiety) (e.g., an antibody molecule), wherein the first and the second IMC (e.g., TAM or MDSC) binding moieties are different. Without being bound by theory, the multispecific molecules disclosed herein are expected to deplete TAMs and/or MDSCs. Accordingly, provided herein are, inter alia, multispecific molecules (e.g., multispecific antibody molecules) that include the aforesaid moieties, nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

In one aspect, provided herein are isolated multispecific, e.g., a bispecific, molecules, comprising: (i) a first immunosuppressive myeloid cell (IMC) binding moiety (e.g., a first tumor associated macrophage (TAM) binding moiety; or a first myeloid derived suppressor cell (MDSC) binding moiety) (e.g., an antibody molecule); and (ii) a second IMC binding moiety (e.g., a second TAM binding moiety; or a second MDSC binding moiety) (e.g., an antibody molecule), wherein the first and the second IMC (e.g., TAM or MDSC) binding moieties are different.

In some embodiments, the first IMC binding moiety is a first MDSC binding moiety; and the second IMC binding moiety is a second MDSC binding moiety. In some embodiments, the first IMC binding moiety is a first TAM binding moiety; and the second IMC binding moiety is a second TAM binding moiety. In some embodiments, the first TAM binding moiety binds to CSF1R, CCR2, CXCR2, CD86, CD163, CX3CR1, MARCO, CD204, CD52 or folate receptor beta; and the second TAM binding moiety binds to CSF1R, CCR2, CXCR2, CD86, CD163, CX3CR1, MARCO, CD204, CD52 or folate receptor beta. In some embodiments, the first TAM binding moiety binds to CSF1R, CCR2, or CXCR2 (e.g., human CSF1R, CCR2, or CXCR2) and the second TAM binding moiety binds to CSF1R, CCR2, or CXCR2 (e.g., human CSF1R, CCR2, or CXCR2). In some embodiments, the first TAM binding moiety binds to CSF1R and the second TAM binding moiety binds to CCR2. In some embodiments, the first TAM binding moiety binds to CSF1R and the second TAM binding moiety binds to CXCR2. In some embodiments, the first TAM binding moiety binds to CCR2 and the second TAM binding moiety binds to CXCR2.

In some embodiments, the first TAM binding moiety binds to CSF1R, CCR2, or CXCR2 with a dissociation constant of less than about 10 nM, and more typically, 10-100 pM; and the second TAM binding moiety binds to CSF1R, CCR2, or CXCR2 with a dissociation constant of less than about 10 nM, and more typically, 10-100 pM. In some embodiments, the first TAM binding moiety binds to a conformational or a linear epitope on CSF1R, CCR2, or CXCR2; and the second TAM binding moiety binds to a conformational or a linear epitope on CSF1R, CCR2, or CXCR2.

In some embodiments, the multispecific molecule comprises at least two non-contiguous polypeptide chains. In some embodiments, the first IMC binding moiety comprises a first anti-IMC antibody molecule and/or the second IMC binding moiety comprises a second anti-IMC antibody molecule. In some embodiments, the first anti-IMC antibody molecule and the second anti-IMC antibody molecule are, independently, a full antibody (e.g., an antibody that includes at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g., a Fab, F(ab′)2, Fv, a scFv, a single domain antibody, or a diabody (dAb)).

In some embodiments, the first anti-IMC antibody molecule and/or the second anti-IMC antibody molecule comprises a heavy chain constant region chosen from IgG1, IgG2, IgG3, or IgG4, or a fragment thereof.

In some embodiments, the first anti-IMC antibody molecule and/or the second anti-IMC antibody molecule comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda, or a fragment thereof. In some embodiments, the first anti-IMC antibody molecule comprises a kappa light chain constant region, or a fragment thereof, and the second anti-IMC antibody molecule comprises a lambda light chain constant region, or a fragment thereof. In some embodiments, the first anti-IMC antibody molecule comprises a lambda light chain constant region, or a fragment thereof, and the second anti-IMC antibody molecule comprises a kappa light chain constant region, or a fragment thereof. In some embodiments, the first anti-IMC antibody molecule and the second anti-IMC antibody molecule have a common light chain variable region.

In some embodiments the multispecific molecule further comprises a heavy chain constant region (e.g., an Fc region) chosen from the heavy chain constant regions of IgG1, IgG2, and IgG4, more particularly, the heavy chain constant region of human IgG1, IgG2 or IgG4. In some embodiments, the heavy chain constant region (e.g., an Fc region) is linked to, e.g., covalently linked to, one or both of the first anti-IMC antibody molecule and the second anti-IMC antibody molecule. In some embodiments, the heavy chain constant region (e.g., an Fc region) is altered, e.g., mutated, to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function. In some embodiments, an interface of a first and second heavy chain constant regions (e.g., Fc region) is altered, e.g., mutated, to increase or decrease dimerization, e.g., relative to a non-engineered interface. In some embodiments, the dimerization of the heavy chain constant region (e.g., Fc region) is enhanced by providing an Fc interface of a first and a second Fc region with one or more of: a paired cavity-protuberance (“knob-in-a hole”), an electrostatic interaction, or a strand-exchange, such that a greater ratio of heteromultimer:homomultimer forms, e.g., relative to a non-engineered interface. In some embodiments, the heavy chain constant region (e.g., Fc region) comprises an amino acid substitution at a position chosen from one or more of 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, e.g., of the Fc region of human IgG1, numbered based on the Eu numbering system. In some embodiments, the heavy chain constant region (e.g., Fc region) comprises an amino acid substitution chosen from: T366S, L368A, or Y407V (e.g., corresponding to a cavity or hole), or T366W (e.g., corresponding to a protuberance or knob), or a combination thereof, numbered based on the Eu numbering system.

In some embodiments, the heavy chain constant region (e.g., an Fc region) comprises one or more mutations that increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function, relative to a naturally-existing heavy chain constant region. In some embodiments, the first anti-IMC antibody molecule comprises a first heavy chain constant region (e.g., a first Fc region) and the second anti-IMC antibody molecule comprises a second heavy chain constant region (e.g., a second Fc region), wherein the first heavy chain constant region comprises one or more mutations that increase heterodimerization of the first heavy chain constant region and the second heavy chain constant region, relative to a naturally-existing heavy chain constant region, and/or wherein the second heavy chain constant region comprises one or more mutations that increase heterodimerization of the second heavy chain constant region and the first heavy chain constant region, relative to a naturally-existing heavy chain constant region. In some embodiments, the first and the second heavy chain constant regions (e.g., first and second Fc regions) comprise one or more of: a paired cavity-protuberance (“knob-in-a hole”), an electrostatic interaction, or a strand-exchange, such that a greater ratio of heteromultimer:homomultimer forms, e.g., relative to naturally-existing heavy chain constant regions. In some embodiments, the first and/or second heavy chain constant region (e.g., a first and/or second Fc region, e.g., a first and/or second IgG1 Fc region) comprises an amino acid substitution at a position chosen from one or more of 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, numbered based on the Eu numbering system. In some embodiments, the first and/or second heavy chain constant region (e.g., a first and/or second Fc region, e.g., a first and/or second IgG1 Fc region) comprises an amino acid substitution chosen from: T366S, L368A, Y407V, or Y349C (e.g., corresponding to a cavity or hole), or T366W or S354C (e.g., corresponding to a protuberance or knob), or a combination thereof, numbered based on the Eu numbering system.

In some embodiments, the multispecific molecule further comprises a linker, e.g., a linker between one or more of: the first anti-IMC antibody molecule and the second anti-IMC antibody molecule, the first anti-IMC antibody molecule and the heavy chain constant region (e.g., the Fc region), or the second anti-IMC antibody molecule and the heavy chain constant region. In some embodiments, the linker is chosen from: a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker. In some embodiments, the linker is a peptide linker. In some embodiments, the peptide linker comprises Gly and Ser.

In some embodiments, the heavy chain constant region (e.g., Fc region) induces antibody dependent cellular cytotoxicity (ADCC).

In some embodiments, the first or the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70. In some embodiments, the antibody molecule that binds to CSF1R comprises the heavy chain variable region sequence of: SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69; and/or comprises the light chain variable region sequence of: SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70.

In some embodiments, the first or the second TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 44, SEQ ID NO: 54, SEQ ID NO: 59, SEQ ID NO: 62, SEQ ID NO: 64, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 44, SEQ ID NO: 54, SEQ ID NO: 59, SEQ ID NO: 62, SEQ ID NO: 64; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 45, SEQ ID NO: 57, SEQ ID NO: 60, SEQ ID NO: 63, SEQ ID NO: 65, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 45, SEQ ID NO: 57, SEQ ID NO: 60, SEQ ID NO: 63, SEQ ID NO: 65. In some embodiments, the antibody molecule that binds to CCR2 comprises the heavy chain variable region sequence of: SEQ ID NO: 44, SEQ ID NO: 54, SEQ ID NO: 59, SEQ ID NO: 62, SEQ ID NO: 64, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 44, SEQ ID NO: 54, SEQ ID NO: 59, SEQ ID NO: 62, SEQ ID NO: 64; and/or comprises the light chain variable region sequence of: SEQ ID NO: 45, SEQ ID NO: 57, SEQ ID NO: 60, SEQ ID NO: 63, SEQ ID NO: 65, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 45, SEQ ID NO: 57, SEQ ID NO: 60, SEQ ID NO: 63, SEQ ID NO: 65.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 44, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 44; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 45, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 45; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 48, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 48; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 50, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 50.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 54, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 54; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 57, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 57; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 66, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 66; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 67, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 67.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 54, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 54; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 57, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 57; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 69, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 69; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 70, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 70.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 59, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 59; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 60, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 60; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 66, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 66; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 67, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 67.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 59, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 59; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 60, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 60; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 69, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 69; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 70, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 70.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 62, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 62; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 63, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 63; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 66, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 66; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 67, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 67.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 62, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 62; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 63, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 63; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 69, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 69; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 70, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 70.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 64, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 64; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 65, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 65; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 66, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 66; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 67, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 67.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 64, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 64; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 65, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 65; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 69, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 69; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 70, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 70.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 44, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 44; and/or comprises the light chain variable region sequence of: SEQ ID NO: 45, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 45; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 48, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 48; and/or comprises the light chain variable region sequence of: SEQ ID NO: 50, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 50.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 54, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 54; and/or comprises the light chain variable region sequence of: SEQ ID NO: 57, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 57; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 66, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 66; and/or comprises the light chain variable region sequence of: SEQ ID NO: 67, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 67.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 54, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 54; and/or comprises the light chain variable region sequence of: SEQ ID NO: 57, or a an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 57; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 69, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 69; and/or comprises the light chain variable region sequence of: SEQ ID NO: 70, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 70.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 59, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 59; and/or comprises the light chain variable region sequence of: SEQ ID NO: 60, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 60; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 66, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 66; and/or comprises the light chain variable region sequence of: SEQ ID NO: 67, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 67.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 59, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 59; and/or comprises the light chain variable region sequence of: SEQ ID NO: 60, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 60; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 69, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 69; and/or comprises the light chain variable region sequence of: SEQ ID NO: 70, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 70.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 62, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 62; and/or comprises the light chain variable region sequence of: SEQ ID NO: 63, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 63; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 66, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 66; and/or comprises the light chain variable region sequence of: SEQ ID NO: 67, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 67.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 62, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 62; and/or comprises the light chain variable region sequence of: SEQ ID NO: 63, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 63; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 69, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 69; and/or comprises the light chain variable region sequence of: SEQ ID NO: 70, an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 70.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 64, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 64; and/or comprises the light chain variable region sequence of: SEQ ID NO: 65, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 65; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 66, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 66; and/or comprises the light chain variable region sequence of: SEQ ID NO: 67, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 67.

In one embodiment, the first TAM binding moiety is an antibody molecule that binds to CCR2 and comprises the heavy chain variable region sequence of: SEQ ID NO: 64, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 64; and/or comprises the light chain variable region sequence of: SEQ ID NO: 65, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 65; and the second TAM binding moiety is an antibody molecule that binds to CSF1R and comprises the heavy chain variable region sequence of: SEQ ID NO: 69, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 69; and/or comprises the light chain variable region sequence of: SEQ ID NO: 70, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 70.

In some embodiments, the multispecific molecule further comprises one or more additional binding moieties (e.g., a third binding moiety, a fourth binding moiety, (e.g., a trispecific or a tetraspecific molecule). In some embodiments, the multispecific molecule further comprises one or more additional binding moieties (e.g., a third binding moiety, a fourth binding moiety, (e.g., a trispecific or a tetraspecific molecule). In some embodiments, the multispecific molecule comprises a third TAM binding moiety (e.g., an antibody molecule), wherein the third TAM binding moiety is different from the first and the second TAM binding moieties. In some embodiments, the first TAM binding moiety binds to human CSF1R, the second TAM binding moiety binds to human CCR2, and the third TAM binding moiety binds to CXCR2.

In some embodiments, the multispecific molecule comprises a third binding moiety (e.g., antibody molecule) that is a tumor targeting moiety. In some embodiments, the tumor targeting moiety binds to PD-L1, mesothelin, CD47, gangloside 2 (GD2), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron Kinase, c-Met, Immature laminin receptor, TAG-72, BING-4, Calcium-activated chloride channel 2, Cyclin-B1, 9D7, Ep-CAM, EphA3, Her2/neu, Telomerase, SAP-1, Survivin, NY-ESO-1/LAGE-1, PRAME, SSX-2, Melan-A/MART-1, Gp100/pme117, Tyrosinase, TRP-1/-2, MC1R, β-catenin, BRCA1/2, CDK4, CML66, Fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, MUC-1, CA-125, BAGE, GAGE, NY-ESO-1, β-catenin, CDK4, CDC27, CD47, α actinin-4, TRP1/gp75, TRP2, gp100, Melan-A/MART1, gangliosides, WT1, EphA3, Epidermal growth factor receptor (EGFR), CD20, MART-2, MART-1, MUC1, MUC2, MUM1, MUM2, MUMS, NA88-1, NPM, OA1, OGT, RCC, RUI1, RUI2, SAGE, TRG, TRP1, TSTA, Folate receptor alpha, L1-CAM, CAIX, EGFRvIII, gpA33, GD3, GM2, VEGFR, Intergrins (Integrin alphaVbeta3, Integrin alpha5Beta1), Carbohydrates (Le), IGF1R, EPHA3, TRAILR1, TRAILR2, or RANKL.

In some embodiments, the multispecific molecule is a bispecific molecule, wherein:

(i) the first TAM binding moiety (e.g., a binding moiety that binds to a first TAM antigen, e.g., CSF1R, CCR2, or CXCR2) comprises a first and a second non-contiguous polypeptides, and

(ii) the second TAM binding moiety (e.g., a binding moiety that binds to a second TAM antigen, e.g., CSF1R, CCR2, or CXCR2) comprises a third and a fourth non-contiguous polypeptides, wherein:

(b) the second polypeptide comprises, e.g., in the N- to C-orientation, a first VL and a first CL,

In certain embodiments of the foregoing aspects, the multispecific molecule further comprises a TGF-beta inhibitor. In some embodiments, the TGF-beta inhibitor sequesters TGF-beta such that it can no longer interact and signal through its endogenous membrane-bound receptor. In some embodiments, the TGF-beta inhibitor reduces the activity of one, two, or all of: (i) TGF-beta 1, (ii) TGF-beta 2, or (iii) TGF-beta 3. In some embodiments, the TGF-beta inhibitor reduces the activity of: TGF-beta 1 and TGF-beta 3. In some embodiments, the TGF-beta inhibitor reduces the activity of: TGF-beta 1, TGF-beta 2, and TGF-beta 3.

In some embodiments, the TGF-beta inhibitor is linked, e.g., via a linker, to the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) or the second IMC binding moiety (e.g., a second TAM binding moiety or a second MDSC binding moiety). In some embodiments, the multispecific molecule comprises a first TGF-beta inhibitor and a second TGF-beta inhibitor, wherein the first TGF-beta inhibitor is linked, e.g., via a linker, to the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) and wherein the second TGF-beta inhibitor is linked, e.g., via a linker, to the second IMC binding moiety (e.g., a second TAM binding moiety or a second MDSC binding moiety).

In some embodiments, the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) comprises a first anti-IMC antibody molecule (e.g., a first anti-TAM antibody molecule or a first anti-MDSC antibody molecule) comprising a first heavy chain polypeptide (e.g., a first heavy chain polypeptide comprising a first heavy chain variable region and a first heavy chain constant region (e.g., a first Fc region)) and a first light chain polypeptide (e.g., a first light chain polypeptide comprising a first light chain variable region and a first light chain constant region), and the second IMC binding moiety (e.g., a second TAM binding moiety or a second MDSC binding moiety) comprises a second anti-IMC antibody molecule (e.g., a second anti-TAM antibody molecule or a second anti-MDSC antibody molecule) comprising a second heavy chain polypeptide (e.g., a second heavy chain polypeptide comprising a second heavy chain variable region and a second heavy chain constant region (e.g., a second Fc region)) and a second light chain polypeptide (e.g., a second light chain polypeptide comprising a second light chain variable region and a second light chain constant region), wherein:

(a) the TGF-beta inhibitor is linked, e.g., via a linker, to the first anti-IMC antibody molecule (e.g., a first anti-TAM antibody molecule or a first anti-MDSC antibody molecule) or the second anti-IMC antibody molecule (e.g., a second anti-TAM antibody molecule or a second anti-MDSC antibody molecule),

(b) the multispecific molecule comprises a first TGF-beta inhibitor and a second TGF-beta inhibitor, wherein the first TGF-beta inhibitor is linked, e.g., via a linker, to the first anti-IMC antibody molecule (e.g., a first anti-TAM antibody molecule or a first anti-MDSC antibody molecule) and wherein the second TGF-beta inhibitor is linked, e.g., via a linker, to the second anti-IMC antibody molecule (e.g., a second anti-TAM antibody molecule or a second anti-MDSC antibody molecule),

(c) the TGF-beta inhibitor is linked, e.g., via a linker, to the first heavy chain polypeptide (e.g., the Fc region of the first heavy chain polypeptide, e.g., the C-terminus of the Fc region of the first heavy chain polypeptide) or the second heavy chain polypeptide (e.g., the Fc region of the second heavy chain polypeptide, e.g., the C-terminus of the Fc region of the second heavy chain polypeptide),

(d) the multispecific molecule comprises a first TGF-beta inhibitor and a second TGF-beta inhibitor, wherein the first TGF-beta inhibitor is linked, e.g., via a linker, to the first heavy chain polypeptide (e.g., the Fc region of the first heavy chain polypeptide, e.g., the C-terminus of the Fc region of the first heavy chain polypeptide) and wherein the second TGF-beta inhibitor is linked, e.g., via a linker, to the second heavy chain polypeptide (e.g., the Fc region of the second heavy chain polypeptide, e.g., the C-terminus of the Fc region of the second heavy chain polypeptide),

(e) the TGF-beta inhibitor is linked, e.g., via a linker, to the first light chain polypeptide (e.g., the constant region of the first light chain polypeptide, e.g., the C-terminus of the constant region of the first light chain polypeptide) or the second light chain polypeptide (e.g., the constant region of the second light chain polypeptide, e.g., the C-terminus of the constant region of the second light chain polypeptide), or

(f) the multispecific molecule comprises a first TGF-beta inhibitor and a second TGF-beta inhibitor, wherein the first TGF-beta inhibitor is linked, e.g., via a linker, to the first light chain polypeptide (e.g., the constant region of the first light chain polypeptide, e.g., the C-terminus of the constant region of the first light chain polypeptide) and wherein the second TGF-beta inhibitor is linked, e.g., via a linker, to the second light chain polypeptide (e.g., the constant region of the second light chain polypeptide, e.g., the C-terminus of the constant region of the second light chain polypeptide).

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising a first portion of the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) comprising a first VL and a first CL;

(ii) a second polypeptide comprising (1) a second portion of the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) comprising a first VH, a first CH1, a first CH2, and a first CH3, and optionally (2) a first TGF-beta inhibitor;

(iii) a third polypeptide comprising (1) a first portion of the second IMC binding moiety (e.g., a second TAM binding moiety or a second MDSC binding moiety) comprising a second VH, a second CH1, a second CH2, and a second CH3, and optionally (2) a second TGF-beta inhibitor; and

(iv) a fourth polypeptide comprising a second portion of the second IMC binding moiety (e.g., a second TAM binding moiety or a second MDSC binding moiety) comprising a second VL and a second CL, wherein:

the multispecific molecule comprises at least one of: the first TGF-beta inhibitor or the second TGF-beta inhibitor, optionally wherein the first and the second TGF-beta inhibitors form a homo-dimer or hetero-dimer. In some embodiments, the multispecific molecule has the configuration of any one of FIGS. 1A-1J.

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising a first portion of the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) comprising a first VL and a first CL; (ii) a second polypeptide comprising (1) a second portion of the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) comprising a first VH, a first CH1, a first CH2, and a first CH3, and (2) the second IMC binding moiety (e.g., a second TAM binding moiety or a second MDSC binding moiety) comprising a second VH and a second VL (e.g., an scFv);

(iii) a third polypeptide comprising a first TGF-beta inhibitor, a second CH1, a second CH2, and a second CH3; and

(iv) a fourth polypeptide comprising a second TGF-beta inhibitor, and a second CL, optionally wherein the first and the second TGF-beta inhibitors form a homo-dimer or hetero-dimer. In some embodiments, the multispecific molecule has the configuration of any one of FIGS. 2A-2D and 3A-3D.

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising a first TGF-beta inhibitor and a first CL;

(ii) a second polypeptide comprising (1) a second TGF-beta inhibitor, a first CH1, a first CH2, and a first CH3, and (2) the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) comprising a first VH and a first VL (e.g., a first scFv);

(iii) a third polypeptide comprising (1) a third TGF-beta inhibitor, a second CH1, a second CH2, and a second CH3, and (2) the second IMC binding moiety (e.g., a second TAM binding moiety or a second MDSC binding moiety) comprising a second VH and a second VL (e.g., a second scFv);

(iv) a fourth polypeptide comprising a fourth TGF-beta inhibitor and a second CL,

optionally wherein the first and the second TGF-beta inhibitors form a homo-dimer or hetero-dimer, and/or the third and the fourth TGF-beta inhibitors form a homo-dimer or hetero-dimer. In some embodiments, the multispecific molecule has the configuration of any one of FIGS. 4A-4D.

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising (1) a first TGF-beta inhibitor, a first CH2, and a first CH3, and (2) the first IMC binding moiety (e.g., a first TAM binding moiety or a first MDSC binding moiety) comprising a first VH and a first VL (e.g., a first scFv); and

(ii) a second polypeptide comprising (1) a second TGF-beta inhibitor, a second CH2, and a second CH3, and (2) the second IMC binding moiety (e.g., a second TAM binding moiety or a second MDSC binding moiety) comprising a second VH and a second VL (e.g., a second scFv). In some embodiments, the multispecific molecule has the configuration of any one of FIGS. 5A-5B.

In some embodiments, the multispecific molecule comprises a first TGF-beta inhibitor and a second TGF-beta inhibitor, wherein the first TGF-beta inhibitor and the second TGF-beta inhibitor form a dimer.

In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGF-beta receptor polypeptide (e.g., an extracellular domain of a TGF-beta receptor, or a functional variant thereof). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises one, two, or all of:

(i) a TGFBR1 polypeptide (e.g., 1, 2, 3, or more of a TGFBR1 polypeptide),

(ii) a TGFBR2 polypeptide (e.g., 1, 2, 3, or more of a TGFBR2 polypeptide), or

(iii) a TGFBR3 polypeptide (e.g., 1, 2, 3, or more of a TGFBR3 polypeptide).

In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR1 polypeptide, e.g., the TGF-beta inhibitor comprises an extracellular domain of TGFBR1 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR1 polypeptide, e.g., the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 95, 96, 97, 120, 121, or 122 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR1 polypeptide, e.g., the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 104 or 105, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR2 polypeptide, e.g., the TGF-beta inhibitor comprises an extracellular domain of TGFBR2 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR2 polypeptide, e.g., the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 98, 99, 123, or 124, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR2 polypeptide, e.g., the TGF-beta inhibitor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 100, 101, 102, and 103, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR3 polypeptide, e.g., the TGF-beta inhibitor comprises an extracellular domain of TGFBR3 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR3 polypeptide, e.g., the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 106, 107, 125, or 126, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR3 polypeptide, e.g., the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 108, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In one aspect, disclosed herein is an isolated multispecific molecule comprising:

(i) a CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule),

(ii) a PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule), and

(iii) a TGF-beta inhibitor.

In some embodiments, the TGF-beta inhibitor sequesters TGF-beta such that it can no longer interact and signal through its endogenous membrane-bound receptor.

In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) is a full antibody (e.g., an antibody that includes at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g., a Fab, F(ab′)2, Fv, a scFv, a single domain antibody, or a diabody (dAb)). In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) is a full antibody (e.g., an antibody that includes at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g., a Fab, F(ab′)2, Fv, a scFv, a single domain antibody, or a diabody (dAb)). In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda, or a fragment thereof. In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda, or a fragment thereof. In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises a kappa light chain constant region, or a fragment thereof, and the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises a lambda light chain constant region, or a fragment thereof. In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises a lambda light chain constant region, or a fragment thereof, and the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises a kappa light chain constant region, or a fragment thereof. In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) and the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) have a common light chain variable region.

In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises a heavy chain constant region (e.g., a CH1 region and an Fc region) chosen from IgG1, IgG2, IgG3, or IgG4, or a fragment thereof. In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises a heavy chain constant region (e.g., a CH1 region and an Fc region) chosen from IgG1, IgG2, IgG3, or IgG4, or a fragment thereof. In some embodiments, the heavy chain constant region (e.g., an Fc region) comprises one or more mutations that increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function, relative to a naturally-existing heavy chain constant region.

In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises a first heavy chain constant region (e.g., a first Fc region) and the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises a second heavy chain constant region (e.g., a second Fc region), wherein the first heavy chain constant region comprises one or more mutations that increase heterodimerization of the first heavy chain constant region and the second heavy chain constant region, relative to a naturally-existing heavy chain constant region, and/or wherein the second heavy chain constant region comprises one or more mutations that increase heterodimerization of the second heavy chain constant region and the first heavy chain constant region, relative to a naturally-existing heavy chain constant region. In some embodiments, the first and the second heavy chain constant regions (e.g., first and second Fc regions) comprise one or more of: a paired cavity-protuberance (“knob-in-a hole”), an electrostatic interaction, or a strand-exchange, such that a greater ratio of heteromultimer:homomultimer forms, e.g., relative to naturally-existing heavy chain constant regions. In some embodiments, the first and/or second heavy chain constant region (e.g., a first and/or second Fc region, e.g., a first and/or second IgG1 Fc region) comprises an amino acid substitution at a position chosen from one or more of 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, numbered based on the Eu numbering system. In some embodiments, the first and/or second heavy chain constant region (e.g., a first and/or second Fc region, e.g., a first and/or second IgG1 Fc region) comprises an amino acid substitution chosen from: T366S, L368A, Y407V, or Y349C (e.g., corresponding to a cavity or hole), or T366W or S354C (e.g., corresponding to a protuberance or knob), or a combination thereof, numbered based on the Eu numbering system.

In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70. In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises the heavy chain variable region sequence of: SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69); and/or comprises the light chain variable region sequence of: SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70).

In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 48, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 48; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 50, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 50. In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises the heavy chain variable region sequence of: SEQ ID NO: 48, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 48); and/or comprises the light chain variable region sequence of: SEQ ID NO: 50, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 50).

In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 66, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 66; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 67, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 67. In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises the heavy chain variable region sequence of: SEQ ID NO: 66, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 66); and/or comprises the light chain variable region sequence of: SEQ ID NO: 67, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 67).

In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 69, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 69; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 70, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 70. In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises the heavy chain variable region sequence of: SEQ ID NO: 69, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 69); and/or comprises the light chain variable region sequence of: SEQ ID NO: 70, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 70).

In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 109, SEQ ID NO: 111, or SEQ ID NO: 113, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 109, SEQ ID NO: 111, or SEQ ID NO: 113; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 110, SEQ ID NO: 112, or SEQ ID NO: 114, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 110, SEQ ID NO: 112, or SEQ ID NO: 114 In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises the heavy chain variable region sequence of: SEQ ID NO: 109, SEQ ID NO: 111, or SEQ ID NO: 113, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 109, SEQ ID NO: 111, or SEQ ID NO: 113); and/or comprises the light chain variable region sequence of: SEQ ID NO: 110, SEQ ID NO: 112, or SEQ ID NO: 114, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 110, SEQ ID NO: 112, or SEQ ID NO: 114).

In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 109, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 109; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 110, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 110. In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises the heavy chain variable region sequence of: SEQ ID NO: 109, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 109); and/or comprises the light chain variable region sequence of: SEQ ID NO: 110, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 110).

In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 111, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 111; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 112, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 112. In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises the heavy chain variable region sequence of: SEQ ID NO: 111, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 111); and/or comprises the light chain variable region sequence of: SEQ ID NO: 112, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 112).

In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises one, two, or three CDRs from the heavy chain variable region sequence of: SEQ ID NO: 113, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 113; and/or comprises one, two, or three CDRs from the light chain variable region sequence of: SEQ ID NO: 114, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from a CDR of SEQ ID NO: 114. In some embodiments, the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises the heavy chain variable region sequence of: SEQ ID NO: 113, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 113); and/or comprises the light chain variable region sequence of: SEQ ID NO: 114, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 114).

In some embodiments, the TGF-beta inhibitor reduces the activity of one, two, or all of:

(i) TGF-beta 1,

(ii) TGF-beta 2, or

(iii) TGF-beta 3, optionally wherein the TGF-beta inhibitor reduces the activity of:

(a) TGF-beta 1 and TGF-beta 3, or

(b) TGF-beta 1, TGF-beta 2, and TGF-beta 3.

In some embodiments, the TGF-beta inhibitor is linked, e.g., via a linker, to the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) or the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule). In some embodiments, the multispecific molecule comprises a first TGF-beta inhibitor and a second TGF-beta inhibitor, wherein the first TGF-beta inhibitor is linked, e.g., via a linker, to the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) and wherein the second TGF-beta inhibitor is linked, e.g., via a linker, to the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule).

In some embodiments, the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises a first heavy chain polypeptide (e.g., a first heavy chain polypeptide comprising a first heavy chain variable region and a first heavy chain constant region (e.g., a first Fc region)) and a first light chain polypeptide (e.g., a first light chain polypeptide comprising a first light chain variable region and a first light chain constant region), and the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises a second heavy chain polypeptide (e.g., a second heavy chain polypeptide comprising a second heavy chain variable region and a second heavy chain constant region (e.g., a second Fc region)) and a second light chain polypeptide (e.g., a second light chain polypeptide comprising a second light chain variable region and a second light chain constant region), wherein:

(a) the TGF-beta inhibitor is linked, e.g., via a linker, to the first heavy chain polypeptide (e.g., the Fc region of the first heavy chain polypeptide, e.g., the C-terminus of the Fc region of the first heavy chain polypeptide) or the second heavy chain polypeptide (e.g., the Fc region of the second heavy chain polypeptide, e.g., the C-terminus of the Fc region of the second heavy chain polypeptide),

(b) the multispecific molecule comprises a first TGF-beta inhibitor and a second TGF-beta inhibitor, wherein the first TGF-beta inhibitor is linked, e.g., via a linker, to the first heavy chain polypeptide (e.g., the Fc region of the first heavy chain polypeptide, e.g., the C-terminus of the Fc region of the first heavy chain polypeptide) and wherein the second TGF-beta inhibitor is linked, e.g., via a linker, to the second heavy chain polypeptide (e.g., the Fc region of the second heavy chain polypeptide, e.g., the C-terminus of the Fc region of the second heavy chain polypeptide),

(c) the TGF-beta inhibitor is linked, e.g., via a linker, to the first light chain polypeptide (e.g., the constant region of the first light chain polypeptide, e.g., the C-terminus of the constant region of the first light chain polypeptide) or the second light chain polypeptide (e.g., the constant region of the second light chain polypeptide, e.g., the C-terminus of the constant region of the second light chain polypeptide), or

(d) the multispecific molecule comprises a first TGF-beta inhibitor and a second TGF-beta inhibitor, wherein the first TGF-beta inhibitor is linked, e.g., via a linker, to the first light chain polypeptide (e.g., the constant region of the first light chain polypeptide, e.g., the C-terminus of the constant region of the first light chain polypeptide) and wherein the second TGF-beta inhibitor is linked, e.g., via a linker, to the second light chain polypeptide (e.g., the constant region of the second light chain polypeptide, e.g., the C-terminus of the constant region of the second light chain polypeptide).

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising a first portion of the CSF1R binding moiety comprising a first VL and a first CL;

(ii) a second polypeptide comprising (1) a second portion of the CSF1R binding moiety comprising a first VH, a first CH1, a first CH2, and a first CH3, and optionally (2) a first TGF-beta inhibitor;

(iii) a third polypeptide comprising (1) a first portion of the PD-L1 binding moiety comprising a second VH, a second CH1, a second CH2, and a second CH3, and optionally (2) a second TGF-beta inhibitor; and

(iv) a fourth polypeptide comprising a second portion of the PD-L1 binding moiety comprising a second VL and a second CL, wherein:

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising a first portion of the CSF1R binding moiety comprising a first VL and a first CL;

(ii) a second polypeptide comprising (1) a second portion of the CSF1R binding moiety comprising a first VH, a first CH1, a first CH2, and a first CH3, and (2) the PD-L1 binding moiety comprising a second VH and a second VL (e.g., an scFv);

(iii) a third polypeptide comprising a first TGF-beta inhibitor, a second CH1, a second CH2, and a second CH3; and

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising a first portion of the PD-L1 binding moiety comprising a first VL and a first CL;

(ii) a second polypeptide comprising (1) a second portion of the PD-L1 binding moiety comprising a first VH, a first CH1, a first CH2, and a first CH3, and (2) the CSF1R binding moiety comprising a second VH and a second VL (e.g., an scFv);

(iii) a third polypeptide comprising a first TGF-beta inhibitor, a second CH1, a second CH2, and a second CH3; and

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising a first TGF-beta inhibitor and a first CL;

(ii) a second polypeptide comprising (1) a second TGF-beta inhibitor, a first CH1, a first CH2, and a first CH3, and (2) the PD-L1 binding moiety comprising a first VH and a first VL (e.g., a first scFv);

(iii) a third polypeptide comprising (1) a third TGF-beta inhibitor, a second CH1, a second CH2, and a second CH3, and (2) the CSF1R binding moiety comprising a second VH and a second VL (e.g., a second scFv);

(iv) a fourth polypeptide comprising a fourth TGF-beta inhibitor and a second CL,

In some embodiments, the multispecific molecule comprises:

(i) a first polypeptide comprising (1) a first TGF-beta inhibitor, a first CH2, and a first CH3, and (2) the PD-L1 binding moiety comprising a first VH and a first VL (e.g., a first scFv); and

(ii) a second polypeptide comprising (1) a second TGF-beta inhibitor, a second CH2, and a second CH3, and (2) the CSF1R binding moiety comprising a second VH and a second VL (e.g., a second scFv). In some embodiments, the multispecific molecule has the configuration of any one of FIGS. 5A-5B.

(i) a TGFBR1 polypeptide (e.g., 1, 2, 3, or more of a TGFBR1 polypeptide),

(ii) a TGFBR2 polypeptide (e.g., 1, 2, 3, or more of a TGFBR2 polypeptide), or

(iii) a TGFBR3 polypeptide (e.g., 1, 2, 3, or more of a TGFBR3 polypeptide).

In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR1 polypeptide, e.g., the TGF-beta inhibitor comprises an extracellular domain of TGFBR1 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR1 polypeptide, e.g., the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 95, 96, 97, 120, 121, or 122, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor, or the first, second, third, or fourth TGF-beta inhibitor comprises a TGFBR1 polypeptide, e.g., the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 104 or 105, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In some embodiments, the multispecific molecule comprises a first TGF-beta inhibitor (e.g., an extracellular domain of TGFBR2 or variant thereof) and a second TGF-beta inhibitor (e.g., an extracellular domain of TGFBR2 or variant thereof), wherein:

(i) the CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) comprises a first and a second non-contiguous polypeptides, and

(ii) the PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule) comprises a third and a fourth non-contiguous polypeptides, wherein:

(a) the first polypeptide comprises, e.g., in the N- to C-orientation, a first VH, a first CH1, connected, optionally via a linker, to a first domain (e.g., a first Fc region) that promotes association between the first and the third polypeptides, wherein the C-terminus of the first domain (e.g., the C-terminus of the first Fc region) is connected, optionally via a linker, to the first TGF-beta inhibitor (e.g., an extracellular domain of TGFBR2 or variant thereof),

(b) the second polypeptide comprises, e.g., in the N- to C-orientation, a first VL and a first CL,

(c) the third polypeptide comprises, e.g., in the N- to C-orientation, a second VH, a second CH1, connected, optionally via a linker, to a second domain (e.g., a second Fc region) that promotes association between the first and the third polypeptides, wherein the C-terminus of the second domain (e.g., the C-terminus of the second Fc region) is connected, optionally via a linker, to the second TGF-beta inhibitor (e.g., an extracellular domain of TGFBR2 or variant thereof), and

(d) the fourth polypeptide comprises, e.g., in the N- to C-orientation, a second VL and a second CL. In some embodiments, the first and the second domains (e.g., the first and the second Fc regions) form a homo- or heterodimer. In some embodiments, the first and the second TGF-beta inhibitors (e.g., the first and the second extracellular domains of TGFBR2 or variants thereof) form a homo- or heterodimer.

In some embodiments, the multispecific molecule comprises a first, second, third, and fourth non-contiguous polypeptides, wherein the first, second, third, and fourth non-contiguous polypeptides comprise the amino acid sequences of: SEQ ID NOs: 176, 138, 185, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 176, 138, 186, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 176, 138, 187, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 176, 138, 188, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 176, 138, 189, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 176, 138, 190, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 177, 150, 185, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 177, 150, 186, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 177, 150, 187, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 177, 150, 188, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 177, 150, 189, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 177, 150, 190, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 178, 152, 185, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 178, 152, 186, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 178, 152, 187, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 178, 152, 188, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 178, 152, 189, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 178, 152, 190, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 179, 138, 185, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 179, 138, 186, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 179, 138, 187, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 179, 138, 188, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 179, 138, 189, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 179, 138, 190, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 180, 150, 185, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 180, 150, 186, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 180, 150, 187, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 180, 150, 188, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 180, 150, 189, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 180, 150, 190, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 181, 152, 185, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 181, 152, 186, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 181, 152, 187, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 181, 152, 188, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 181, 152, 189, and 147, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 181, 152, 190, and 148, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 145, 147, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 153, 147, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 154, 147, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 146, 148, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 155, 148, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 156, 148, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 145, 147, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 153, 147, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 154, 147, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 146, 148, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 155, 148, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 156, 148, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 145, 147, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 153, 147, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 154, 147, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 146, 148, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 155, 148, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 156, 148, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 145, 147, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 153, 147, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 154, 147, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 146, 148, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 155, 148, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 156, 148, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 137, 138, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 139, 138, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 149, 150, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 151, 152, 140, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 137, 138, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 139, 138, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 149, 150, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 151, 152, 140, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 137, 138, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 139, 138, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 149, 150, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 151, 152, 162, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 137, 138, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 139, 138, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 149, 150, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 151, 152, 162, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 166, 161, 172, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 167, 161, 172, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 168, 161, 172, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 166, 161, 173, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 167, 161, 173, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 168, 161, 173, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 169, 141, 174, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 170, 141, 174, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 171, 141, 174, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 169, 141, 175, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 170, 141, 175, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 171, 141, 175, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 166, 161, 174, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 167, 161, 174, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 168, 161, 174, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 166, 161, 175, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 167, 161, 175, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 168, 161, 175, and 141, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 166, 141, 174, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 167, 141, 174, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 168, 141, 174, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 166, 141, 175, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 167, 141, 175, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); or SEQ ID NOs: 168, 141, 175, and 161, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto).

In some embodiments, the multispecific molecule comprises a first and a second non-contiguous polypeptides, wherein the first and the second non-contiguous polypeptides comprise the amino acid sequences of: SEQ ID NOs: 142 and 143, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 142 and 144, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 157 and 143, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 157 and 144, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 158 and 143, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 158 and 144, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 163 and 143, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 163 and 144, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 164 and 143, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 164 and 144, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); SEQ ID NOs: 165 and 143, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto); or SEQ ID NOs: 165 and 144, respectively, or a sequence substantially identical thereto (e.g., 85% to 99% identical thereto).

Exemplary multispecific molecules that comprise (i) a CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule), (ii) a PD-L1 binding moiety (e.g., an anti-PD-L1 antibody molecule), and (iii) one or more TGF-beta inhibitors are shown in FIGS. 1A-1J, 2A-2D, 3A-3D, 4A-4D, and 5A-5B.

FIGS. 1A-1J are schematics showing multispecific molecules comprising a Fab against CSF1R and a Fab against PD-L1. The CH1 domain of the anti-CSF1R Fab is linked, e.g., via a linker, to a first Fc region, which is optionally further linked, e.g., via a linker, to a first TGF-beta inhibitor. Similarly, the CH1 domain of the anti-PD-L1 Fab is linked, e.g., via a linker, to a second Fc region, which is optionally further linked, e.g., via a linker, to a second TGF-beta inhibitor.

In some embodiments, the multispecific molecule has the configuration of FIG. 1A. In FIG. 1A, the first TGF-beta inhibitor comprises (TGFBR1 ECD)_a, (TGFBR2 ECD)_b, and (TGFBR3 ECD)_c, or variant thereof, wherein a≥0, b≥0, and c≥0. The various extracellular domains can be linked, e.g., via one or more linkers, in any order. The second TGF-beta inhibitor comprises (TGFBR1 ECD)_d, (TGFBR2 ECD)_e, and (TGFBR3 ECD)_f, or variant thereof, wherein d≥0, e≥0, and f≥0. The various extracellular domains can be linked, e.g., via one or more linkers, in any order. At least one of a, b, c, d, e, or f is not zero. Exemplary arrangements of the extracellular domains include, but are not limited to, in the N- to C-orientation: TGFBR1 ECD and TGFBR2 ECD; TGFBR1 ECD, TGFBR2 ECD, and TGFBR2 ECD; TGFBR1 ECD, TGFBR2 ECD, TGFBR1 ECD, and TGFBR2 ECD; TGFBR1 ECD, TGFBR2 ECD, TGFBR2 ECD, and TGFBR1 ECD; TGFBR1 ECD, TGFBR1 ECD, TGFBR2 ECD, and TGFBR2 ECD; and TGFBR1 ECD, TGFBR2 ECD, TGFBR3 ECD.

In some embodiments, the multispecific molecule has the configuration of FIG. 1B. In FIG. 1B, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof, and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. The first TGF-beta inhibitor and the second TGF-beta inhibitor can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 1C. In FIG. 1C, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof, and the second TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 1D. In FIG. 1D, the first TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof, and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 1E. In FIG. 1E, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. The second TGF-beta inhibitor can be present or absent.

In some embodiments, the multispecific molecule has the configuration of FIG. 1F. In FIG. 1F, the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. The first TGF-beta inhibitor can be present or absent.

In some embodiments, the multispecific molecule has the configuration of FIG. 1G. In FIG. 1G, the first TGF-beta inhibitor comprises (TGFBR2 ECD)₂, or variant thereof. In some embodiments, the two TGFBR2 ECDs are linked, e.g., via a linker. The two TGFBR2 ECDs can be the same or different. The second TGF-beta inhibitor can be present or absent.

In some embodiments, the multispecific molecule has the configuration of FIG. 1H. In FIG. 1H, the second TGF-beta inhibitor comprises (TGFBR2 ECD)₂, or variant thereof. In some embodiments, the two TGFBR2 ECDs are linked, e.g., via a linker. The two TGFBR2 ECDs can be the same or different. The first TGF-beta inhibitor can be present or absent.

In some embodiments, the multispecific molecule has the configuration of FIG. 1I. In FIG. 1I, the first TGF-beta inhibitor comprises TGFBR1 ECD and TGFBR2 ECD, or variant thereof. In some embodiments, the TGFBR1 ECD and TGFBR2 ECD are linked, e.g., via a linker, in either order (e.g., in the N- to C-orientation: TGFBR1 ECD followed by TGFBR2 ECD, or TGFBR2 ECD followed by TGFBR1 ECD). The second TGF-beta inhibitor can be present or absent.

In some embodiments, the multispecific molecule has the configuration of FIG. 1J. In FIG. 1J, the second TGF-beta inhibitor comprises TGFBR1 ECD and TGFBR2 ECD, or variant thereof. In some embodiments, the TGFBR1 ECD and TGFBR2 ECD are linked, e.g., via a linker, in either order (e.g., in the N- to C-orientation: TGFBR1 ECD followed by TGFBR2 ECD, or TGFBR2 ECD followed by TGFBR1 ECD). The first TGF-beta inhibitor can be present or absent.

FIGS. 2A-2D are schematics showing multispecific molecules comprising a Fab against CSF1R, an scFv against PD-L1, a first TGF-beta inhibitor, and a second TGF-beta inhibitor. The CH1 domain of the anti-CSF1R Fab is linked, e.g., via a linker, to a first Fc region, which is optionally further linked, e.g., via a linker, to the anti-PD-L1 scFv. The first TGF-beta inhibitor is linked, e.g., via a linker, to a CH1 domain, which is further linked, e.g., via a linker, to a second Fc region. The second TGF-beta inhibitor is linked, e.g., via a linker, to a CL domain.

In some embodiments, the multispecific molecule has the configuration of FIG. 2A. In FIG. 2A, the first TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof. The first and the second TGF-beta inhibitors can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 2B. In FIG. 2B, the first TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 2C. In FIG. 2C, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 2D. In FIG. 2D, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. The first and the second TGF-beta inhibitors can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer).

FIGS. 3A-3D are schematics showing multispecific molecules comprising a Fab against PD-L1, an scFv against CSF1R, a first TGF-beta inhibitor, and a second TGF-beta inhibitor. The CH1 domain of the anti-PD-L1 Fab is linked, e.g., via a linker, to a first Fc region, which is optionally further linked, e.g., via a linker, to the anti-CSF1R scFv. The first TGF-beta inhibitor is linked, e.g., via a linker, to a CH1 domain, which is further linked, e.g., via a linker, to a second Fc region. The second TGF-beta inhibitor is linked, e.g., via a linker, to a CL domain.

In some embodiments, the multispecific molecule has the configuration of FIG. 3A. In FIG. 3A, the first TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof. The first and the second TGF-beta inhibitors can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 3B. In FIG. 3B, the first TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 3C. In FIG. 3C, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 3D. In FIG. 3D, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. The first and the second TGF-beta inhibitors can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer).

FIGS. 4A-4D are schematics showing multispecific molecules comprising an scFv against PD-L1, an scFv against CSF1R, a first TGF-beta inhibitor, a second TGF-beta inhibitor, a third TGF-beta inhibitor, and a fourth TGF-beta inhibitor. The first TGF-beta inhibitor is linked, e.g., via a linker, to a first CL. The second TGF-beta inhibitor is linked, e.g., via a linker, to a first CH1, which is further linked, e.g., via a linker, to a first Fc region, which is further linked, e.g., via a linker, to the anti-PD-L1 scFv. The third TGF-beta inhibitor is linked, e.g., via a linker, to a second CH1, which is further linked, e.g., via a linker, to a second Fc region, which is further linked, e.g., via a linker, to the anti-CSF1R scFv. The fourth TGF-beta inhibitor is linked, e.g., via a linker, to a second CL.

In some embodiments, the multispecific molecule has the configuration of FIG. 4A. In FIG. 4A, the first, second, third, and fourth TGF-beta inhibitors comprise TGFBR1 ECD, or variant thereof. The first, second, third, and fourth TGF-beta inhibitors can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer). In some embodiments, the third and the fourth TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 4B. In FIG. 4B, the first, second, third, and fourth TGF-beta inhibitors comprise TGFBR2 ECD, or variant thereof. The first, second, third, and fourth TGF-beta inhibitors can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer). In some embodiments, the third and the fourth TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 4C. In FIG. 4C, the first and the second TGF-beta inhibitors comprise TGFBR1 ECD, or variant thereof; and the third and the fourth TGF-beta inhibitors comprise TGFBR2 ECD, or variant thereof. The first and second TGF-beta inhibitors can be the same or different. The third and fourth TGF-beta inhibitors can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer). In some embodiments, the third and the fourth TGF-beta inhibitors form a dimer (e.g., a homo- or heterodimer).

In some embodiments, the multispecific molecule has the configuration of FIG. 4D. In FIG. 4D, the second and the third TGF-beta inhibitors comprise TGFBR1 ECD, or variant thereof; and the first and the fourth TGF-beta inhibitors comprise TGFBR2 ECD, or variant thereof. The second and third TGF-beta inhibitors can be the same or different. The first and fourth TGF-beta inhibitors can be the same or different. In some embodiments, the first and the second TGF-beta inhibitors form a dimer (e.g., a heterodimer). In some embodiments, the third and the fourth TGF-beta inhibitors form a dimer (e.g., a heterodimer).

FIGS. 5A-5B are schematics showing multispecific molecules comprising an scFv against PD-L1, an scFv against CSF1R, a first TGF-beta inhibitor, and a second TGF-beta inhibitor. The first TGF-beta inhibitor is linked, e.g., via a linker, to a first Fc region, which is further linked, e.g., via a linker, to the anti-PD-L1 scFv. The second TGF-beta inhibitor is linked, e.g., via a linker, to a second Fc region, which is further linked, e.g., via a linker, to the anti-CSF1R scFv.

In some embodiments, the multispecific molecule has the configuration of FIG. 5A. In FIG. 5A, the first TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof.

In some embodiments, the multispecific molecule has the configuration of FIG. 5B. In FIG. 5B, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof; and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. The first and second TGF-beta inhibitors can be the same or different.

In one aspect, provided herein is an isolated multispecific, e.g., a bispecific or trispecific, molecule, comprising: (i) a TGF-beta inhibitor; and (ii) an anti-CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule) or an anti-CCR2 binding moiety (e.g., an anti-CCR2 antibody molecule). In one embodiment, the multispecific molecule further comprises a tumor targeting moiety (e.g., a tumor targeting antibody molecule).

In one embodiment, the TGF-beta inhibitor reduces the activity of one, two, or all of: (i) TGF-beta 1, (ii) TGF-beta 2, or (iii) TGF-beta 3, optionally wherein the TGF-beta inhibitor reduces the activity of: (a) TGF-beta 1 and TGF-beta 3, or (b) TGF-beta 1, TGF-beta 2, and TGF-beta 3, e.g., as measured using the methods described in Example 3 with respect to FIG. 7. In one embodiment, the TGF-beta inhibitor comprises a TGF-beta receptor polypeptide (e.g., an extracellular domain of a TGF-beta receptor, or a functional variant thereof). In one embodiment, the TGF-beta inhibitor comprises one, two, or all of: (i) a TGFBR1 polypeptide (e.g., 1, 2, 3, or more of a TGFBR1 polypeptide), (ii) a TGFBR2 polypeptide (e.g., 1, 2, 3, or more of a TGFBR2 polypeptide), or (iii) a TGFBR3 polypeptide (e.g., 1, 2, 3, or more of a TGFBR3 polypeptide).

In one embodiment, the TGF-beta inhibitor comprises a TGFBR1 polypeptide. In one embodiment, the TGF-beta inhibitor comprises an extracellular domain of TGFBR1 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 95, 96, 97, 120, 121, or 122, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 104 or 105, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In one embodiment, the TGF-beta inhibitor comprises a TGFBR2 polypeptide. In one embodiment, the TGF-beta inhibitor comprises an extracellular domain of TGFBR2 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 98, 99, 123, or 124, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the TGF-beta inhibitor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 100, 101, 102, and 103, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In one embodiment, the TGF-beta inhibitor comprises a TGFBR3 polypeptide. In one embodiment, the TGF-beta inhibitor comprises an extracellular domain of TGFBR3 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 106, 107, 125, or 126, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 108, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In one embodiment, the TGF-beta inhibitor comprises two TGF-beta receptor polypeptides that form a homodimer. In one embodiment, the TGF-beta inhibitor comprises two TGFBR1 polypeptides that form a homodimer. In one embodiment, the TGF-beta inhibitor comprises two TGFBR2 polypeptides that form a homodimer. In one embodiment, the TGF-beta inhibitor comprises two TGFBR3 polypeptides that form a homodimer. In one embodiment, the TGF-beta inhibitor comprises two TGF-beta receptor polypeptides that form a heterodimer. In one embodiment, the TGF-beta inhibitor comprises a TGFBR1 polypeptide and a TGFBR2 polypeptide that form a heterodimer. In one embodiment, the TGF-beta inhibitor comprises a TGFBR1 polypeptide and a TGFBR3 polypeptide that form a heterodimer. In one embodiment, the TGF-beta inhibitor comprises a TGFBR2 polypeptide and a TGFBR3 polypeptide that form a heterodimer.

In one embodiment, the TGF-beta inhibitor comprises a first TGF-beta receptor polypeptide and a second TGF-beta receptor polypeptide. In one embodiment, the multispecific molecule comprises a first Fc region (e.g., a first CH1-Fc region) and a second Fc region (e.g., a second CH1-Fc region). In one embodiment, the first TGF-beta receptor polypeptide is linked, e.g., via a linker, to the first Fc region (e.g., a first CH1-Fc region), e.g., the C-terminus of the first Fc region (e.g., a first CH1-Fc region). In one embodiment, the second TGF-beta receptor polypeptide is linked, e.g., via a linker, to the second Fc region (e.g., a second CH1-Fc region), e.g., the C-terminus of the second Fc region (e.g., a second CH1-Fc region). In one embodiment, the first TGF-beta receptor polypeptide and the second TGF-beta receptor polypeptide form a homodimer or heterodimer, e.g., a homodimer. In one embodiment, the first or second TGF-beta receptor polypeptide comprises an extracellular domain of TGFBR1, TGFBR2, or TGFBR3, e.g., an extracellular domain of TGFBR2. In one embodiment, the multispecific molecule has the configuration of FIG. 6A or 6B. In one embodiment, the multispecific molecule comprises the amino acid sequence of SEQ ID NO: 192 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto) and the amino acid sequence of SEQ ID NO: 193 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the multispecific molecule comprises the amino acid sequence of SEQ ID NO: 192 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto) and the amino acid sequence of SEQ ID NO: 195 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the multispecific molecule comprises the amino acid sequence of SEQ ID NO: 194 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto) and the amino acid sequence of SEQ ID NO: 193 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the multispecific molecule comprises the amino acid sequence of SEQ ID NO: 194 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto) and the amino acid sequence of SEQ ID NO: 195 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In one embodiment, the multispecific molecule comprises a heavy chain constant region 1 (CH1) and a light chain constant region (CL). In one embodiment, (i) the first TGF-beta receptor polypeptide is linked, e.g., via a linker, to the CH1, e.g., the N-terminus of the CH1, and (ii) the second TGF-beta receptor polypeptide is linked, e.g., via a linker, to the CL, e.g., the N-terminus of the CL. In one embodiment, the first TGF-beta receptor polypeptide and the second TGF-beta receptor polypeptide form a homodimer or heterodimer, e.g., a homodimer. In one embodiment, the first or second TGF-beta receptor polypeptide comprises an extracellular domain of TGFBR1, TGFBR2, or TGFBR3, e.g., an extracellular domain of TGFBR2. In one embodiment, the multispecific molecule has the configuration of FIG. 6C or 6D. In one embodiment, the multispecific molecule comprises the amino acid sequence of SEQ ID NO: 196 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto) and the amino acid sequence of SEQ ID NO: 198 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the multispecific molecule comprises the amino acid sequence of SEQ ID NO: 196 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto) and the amino acid sequence of SEQ ID NO: 199 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the multispecific molecule comprises the amino acid sequence of SEQ ID NO: 197 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto) and the amino acid sequence of SEQ ID NO: 198 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In one embodiment, the multispecific molecule comprises the amino acid sequence of SEQ ID NO: 197 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto) and the amino acid sequence of SEQ ID NO: 199 (or a sequence substantially identical thereto, e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In one embodiment, the multispecific molecule comprises an anti-CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule). In one embodiment, the multispecific molecule comprises an anti-CCR2 binding moiety (e.g., an anti-CCR2 antibody molecule).

In one embodiment, the tumor targeting moiety (e.g., a tumor targeting antibody molecule) binds to PD-L1, mesothelin, CD47, gangloside 2 (GD2), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron Kinase, c-Met, Immature laminin receptor, TAG-72, BING-4, Calcium-activated chloride channel 2, Cyclin-B1, 9D7, Ep-CAM, EphA3, Her2/neu, Telomerase, SAP-1, Survivin, NY-ESO-1/LAGE-1, PRAME, SSX-2, Melan-A/MART-1, Gp100/pme117, Tyrosinase, TRP-1/-2, MC1R, β-catenin, BRCA1/2, CDK4, CML66, Fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, MUC-1, CA-125, BAGE, GAGE, NY-ESO-1, β-catenin, CDK4, CDCl₂7, CD47, α actinin-4, TRP1/gp75, TRP2, gp100, Melan-A/MART1, gangliosides, WT1, EphA3, Epidermal growth factor receptor (EGFR), CD20, MART-2, MART-1, MUC1, MUC2, MUM1, MUM2, MUMS, NA88-1, NPM, OA1, OGT, RCC, RUI1, RUI2, SAGE, TRG, TRP1, TSTA, Folate receptor alpha, L1-CAM, CAIX, EGFRvIII, gpA33, GD3, GM2, VEGFR, Intergrins (Integrin alphaVbeta3, Integrin alpha5Beta1), Carbohydrates (Le), IGF1R, EPHA3, TRAILR1, TRAILR2, or RANKL.

In one embodiment, the tumor targeting moiety (e.g., a tumor targeting antibody molecule) binds to CD19, CD33, CD47, CD123, CD20, CD99, CD30, BCMA, CD38, CD22, SLAMF7, or NY-ESO1.

In one embodiment, the anti-CSF1R antibody molecule, anti-CCR2 antibody molecule, or tumor targeting antibody molecule is, independently, a full antibody (e.g., an antibody that includes at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g., a Fab, F(ab′)2, Fv, a scFv, a single domain antibody, or a diabody (dAb)). In one embodiment, the anti-CSF1R antibody molecule, anti-CCR2 antibody molecule, or tumor targeting antibody molecule comprises a heavy chain constant region chosen from IgG1, IgG2, IgG3, or IgG4, or a fragment thereof. In one embodiment, the anti-CSF1R antibody molecule, anti-CCR2 antibody molecule, or tumor targeting antibody molecule comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda, or a fragment thereof. In one embodiment, the anti-CSF1R antibody molecule or anti-CCR2 antibody molecule comprises a kappa light chain constant region, or a fragment thereof, and the tumor targeting antibody molecule comprises a lambda light chain constant region, or a fragment thereof. In one embodiment, the anti-CSF1R antibody molecule or anti-CCR2 antibody molecule comprises a lambda light chain constant region, or a fragment thereof, and the tumor targeting antibody molecule comprises a kappa light chain constant region, or a fragment thereof. In one embodiment, the anti-CSF1R antibody molecule or anti-CCR2 antibody molecule and the tumor targeting antibody molecule have a common light chain variable region.

In one embodiment, the multispecific molecule comprises a heavy chain constant region (e.g., an Fc region) chosen from the heavy chain constant regions of IgG1, IgG2, and IgG4, more particularly, the heavy chain constant region of human IgG1, IgG2 or IgG4. In one embodiment, the heavy chain constant region (e.g., an Fc region) is linked to, e.g., covalently linked to, anti-CSF1R antibody molecule, anti-CCR2 antibody molecule, or tumor targeting antibody molecule. In one embodiment, the heavy chain constant region (e.g., an Fc region) comprises one or more mutations that increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function, relative to a naturally-existing heavy chain constant region. In one embodiment, the anti-CSF1R antibody molecule or anti-CCR2 antibody molecule comprises a first heavy chain constant region (e.g., a first Fc region) and the tumor targeting antibody molecule comprises a second heavy chain constant region (e.g., a second Fc region), wherein the first heavy chain constant region comprises one or more mutations that increase heterodimerization of the first heavy chain constant region and the second heavy chain constant region, relative to a naturally-existing heavy chain constant region, and/or wherein the second heavy chain constant region comprises one or more mutations that increase heterodimerization of the second heavy chain constant region and the first heavy chain constant region, relative to a naturally-existing heavy chain constant region. In one embodiment, the first and the second heavy chain constant regions (e.g., first and second Fc regions) comprise one or more of: a paired cavity-protuberance (“knob-in-a hole”), an electrostatic interaction, or a strand-exchange, such that a greater ratio of heteromultimer:homomultimer forms, e.g., relative to naturally-existing heavy chain constant regions. In one embodiment, the first and/or second heavy chain constant region (e.g., a first and/or second Fc region, e.g., a first and/or second IgG1 Fc region) comprises an amino acid substitution at a position chosen from one or more of 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, numbered based on the Eu numbering system. In one embodiment, the first and/or second heavy chain constant region (e.g., a first and/or second Fc region, e.g., a first and/or second IgG1 Fc region) comprises an amino acid substitution chosen from: T366S, L368A, Y407V, or Y349C (e.g., corresponding to a cavity or hole), or T366W or S354C (e.g., corresponding to a protuberance or knob), or a combination thereof, numbered based on the Eu numbering system. In one embodiment, the multispecific molecule comprises a linker, optionally wherein the linker is chosen from: a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker, optionally wherein the linker is a peptide linker, optionally wherein the peptide linker comprises Gly and Ser.

In another aspect, provided herein are isolated nucleic acids encoding the multispecific molecule (e.g., antibody) of any one of the preceding claims.

In another aspect, provided herein are isolated nucleic acid molecules, which comprises the nucleotide sequence encoding any of the multispecific molecules described herein, or a nucleotide sequence substantially homologous thereto (e.g., at least 95% to 99.9% identical thereto).

In another aspect, provided herein are vectors, e.g., expression vectors, comprising one or more of the nucleic acid molecules described herein.

In another aspect, provided herein are host cells comprising the nucleic acid molecule described herein or the vector described herein.

In another aspect, provided herein are methods of making, e.g., producing, the multispecific molecules described herein, comprising culturing the host cell described herein, under suitable conditions, e.g., conditions suitable for gene expression and/or heterodimerization.

In another aspect, provided herein are pharmaceutical compositions comprising the multispecific molecule described herein and a pharmaceutically acceptable carrier, excipient, or stabilizer.

In another aspect, provided herein are method of treating a cancer in a subject, comprising administering to the subject in need thereof the multispecific molecule described herein, wherein the multispecific molecule is administered in an amount effective to reduce the number of TAMs (e.g., the number of TAMs in or near the a tumor in the subject), inhibit the proliferation of TAMs (e.g., the number of TAMs in or near the a tumor in the subject), or reduce or inhibit macrophage infiltration into a tumor in the subject.

In another aspect, provided herein are methods of treating a cancer in a subject by reducing a portion of a population of TAMs, comprising administering to the subject in need thereof the multispecific molecule described herein, wherein the multispecific molecule is administered in an amount effective to inhibit or deplete a portion of a population of TAMs.

In another aspect, provided herein are methods of reducing the proliferation of a portion of a population of TAMs in a subject (e.g., in a subject having cancer, e.g., a solid tumor), comprising, administering to the subject in need thereof the multispecific molecule described herein, wherein the multispecific molecule is administered in an amount effective to reduce the proliferation of a portion of the population of TAMs.

In another aspect, provided herein are methods of inhibiting or depleting a portion of a population of TAMs in a subject having a cancer (e.g., a tumor), comprising administering to the subject the multispecific molecule described herein, wherein the multispecific molecule is administered in an amount effective to reduce the number of tumor infiltrating macrophages, inhibit the proliferation of tumor infiltrating macrophages, or reduce macrophage infiltration into a tumor.

In some embodiments, the cancer is a solid tumor cancer or a metastatic lesion. In some embodiments, the solid tumor cancer is one or more of pancreatic cancer (e.g., pancreatic adenocarcinoma), breast cancer, colorectal cancer, lung cancer (e.g., small or non-small cell lung cancer), skin cancer (e.g., melanoma), ovarian cancer, liver cancer, or brain cancer (e.g., glioma). In some embodiments, the cancer is characterized as containing TAMs, is associated with the presence of TAMs, TAMs are in and/or form part of the cancer (e.g., tumor), or TAMs have been detected in or near the solid tumor. In some embodiments, the cancer is a hematological cancer or a metastatic lesion. In some embodiments, the hematological cancer is one or more of a Hodgkin's lymphoma, Non-Hodgkin's lymphoma, B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome (MDS), multiple myeloma, or acute lymphocytic leukemia.

In some embodiments, the methods further comprise identifying the presence of TAMs in or near the cancer (e.g., tumor) in the subject. In some embodiments, the TAMs express CXCR2 and CCR2, CCR2 and CSF1R, CSF1R and CXCR2, or CCR2, CXCR2, and CSF1R.

In some embodiments, the methods further comprise administering a second therapeutic treatment. In some embodiments, the second therapeutic treatment comprises a therapeutic agent (e.g., a chemotherapeutic agent, a biologic agent, hormonal therapy), radiation, or surgery. In some embodiments, the therapeutic agent is selected from: a chemotherapeutic agent, or a biologic agent. In some embodiments, the therapeutic agent is a checkpoint inhibitor. In some embodiments, the check point inhibitor is selected from the group consisting of an anti-CTLA4 antibody, an anti-PD1 antibody (e.g., Nivolumab, Pembrolizumab or Pidilizumab), an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-TIM3 antibody, an anti-LAG3 antibody, an anti-CD160 antibody, an anti-2B4 antibody, an anti-CD80 antibody, an anti-CD86 antibody, an anti-B7-H3 (CD276) antibody, an anti-B7-H4 (VTCN1) antibody, an anti-HVEM (TNFRSF14 or CD270) antibody, an anti-BTLA antibody, an anti-KIR antibody, an anti-MHC class I antibody, an anti-MHC class II antibody, an anti-GALS antibody, an anti-VISTA antibody, an anti-BTLA antibody, an anti-TIGIT antibody, an anti-LAIR1 antibody, and an anti-A2aR antibody.

In another aspect, provided herein are methods of treating a cancer in a subject, comprising administering to the subject in need thereof the multispecific molecule described herein, wherein the multispecific molecule is administered in an amount effective to reduce the number of MDSCs (e.g., the number of MDSCs in or near the a tumor in the subject), inhibit the proliferation of MDSCs (e.g., the number of MDSCs in or near the a tumor in the subject), or reduce or inhibit MDSC infiltration into a tumor in the subject.

In another aspect, provided herein are methods of reducing the proliferation of a portion of a population of MDSCs in a subject (e.g., in a subject having cancer, e.g., a solid tumor), comprising, administering to the subject in need thereof the multispecific molecule described herein, wherein the multispecific molecule is administered in an amount effective to reduce the proliferation of a portion of the population of MDSCs.

In another aspect, provided herein are methods of inhibiting or depleting a portion of a population of MDSCs in a subject having a cancer (e.g., a tumor), comprising administering to the subject the multispecific molecule described herein, wherein the multispecific molecule is administered in an amount effective to reduce the number of MDSCs, inhibit the proliferation of MDSCs, or reduce MDSC infiltration into a tumor.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1J are schematics showing exemplary multispecific molecules comprising a CSF1R binding moiety, a PD-L1 binding moiety, and one or more TGF-beta inhibitors. Shown in FIGS. 1A-1J are multispecific antibody molecules comprising: a first polypeptide comprising anti-CSF1R VL and CL; a second polypeptide comprising anti-CSF1R VH, CH1, CH2, CH3, and optionally a first TGF-beta inhibitor; a third polypeptide comprising anti-PD-L1 VH, CH1, CH2, CH3, and optionally a second TGF-beta inhibitor; and a fourth polypeptide comprising anti-PD-L1 VL and CL. In FIG. 1A, the first TGF-beta inhibitor comprises (TGFBR1 ECD)_a, (TGFBR2 ECD)_b, and (TGFBR3 ECD)_c, or variant thereof, linked in any order, wherein a≥0, b≥0, and c≥0. The second TGF-beta inhibitor comprises (TGFBR1 ECD)_d, (TGFBR2 ECD)_e, and (TGFBR3 ECD)_f, or variant thereof, linked in any order, wherein d≥0, e≥0, and f≥0. At least one of a, b, c, d, e, or f is not zero. In FIG. 1B, the first and the second TGF-beta inhibitors comprise TGFBR2 ECD or variant thereof. In FIG. 1C, the first TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof, and the second TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof. In FIG. 1D, the first TGF-beta inhibitor comprises TGFBR1 ECD, or variant thereof, and the second TGF-beta inhibitor comprises TGFBR2 ECD, or variant thereof. In FIG. 1E, the first TGF-beta inhibitor comprises TGFBR2 ECD or variant thereof, and the second TGF-beta inhibitor can be present or absent. In FIG. 1F, the second TGF-beta inhibitor comprises TGFBR2 ECD or variant thereof, and the first TGF-beta inhibitor can be present or absent. In FIG. 1G, the first TGF-beta inhibitor comprises two TGFBR2 ECDs or variant thereof, and the second TGF-beta inhibitor can be present or absent. In FIG. 1H, the second TGF-beta inhibitor comprises two TGFBR2 ECDs or variant thereof, and the first TGF-beta inhibitor can be present or absent. In FIG. 1I, the first TGF-beta inhibitor comprises TGFBR1 ECD and TGFBR2 ECD, or variant thereof, and the second TGF-beta inhibitor can be present or absent. In FIG. 1J, the second TGF-beta inhibitor comprises TGFBR1 ECD and TGFBR2 ECD, or variant thereof, and the first TGF-beta inhibitor can be present or absent.

FIGS. 2A-2D are schematics showing additional exemplary multispecific molecules comprising a CSF1R binding moiety, a PD-L1 binding moiety, and one or more TGF-beta receptors. Shown in FIGS. 2A-2D are multispecific antibody molecules comprising: a first polypeptide comprising anti-CSF1R VL and CL; a second polypeptide comprising anti-CSF1R VH, CH1, CH2, CH3, an anti-PDL1 VH, and an anti-PDL1 VL; a third polypeptide comprising a first TGF-beta receptor, CH1, CH2, and CH3; and a fourth polypeptide comprising a second TGF-beta receptor and a CL. In FIG. 2A, the first and the second TGF-beta receptors comprise TGFBR1 ECD or variant thereof. In FIG. 2B, the first TGF-beta receptor comprises TGFBR1 ECD or variant thereof and the second TGF-beta receptor comprises TGFBR2 ECD or variant thereof. In FIG. 2C, the first TGF-beta receptor comprises TGFBR2 ECD or variant thereof and the second TGF-beta receptor comprises TGFBR1 ECD or variant thereof. In FIG. 2D, the first and the second TGF-beta receptors comprise TGFBR2 ECD or variant thereof.

FIGS. 3A-3D are schematics showing additional exemplary multispecific molecules comprising a CSF1R binding moiety, a PD-L1 binding moiety, and one or more TGF-beta receptors. Shown in FIGS. 3A-3D are multispecific antibody molecules comprising: a first polypeptide comprising anti-PDL1 VL and CL; a second polypeptide comprising anti-PDL1 VH, CH1, CH2, CH3, an anti-CSF1R VH, and an anti-CSF1R VL; a third polypeptide comprising a first TGF-beta receptor, CH1, CH2, and CH3; and a fourth polypeptide comprising a second TGF-beta receptor and CL. In FIG. 3A, the first and the second TGF-beta receptors comprise TGFBR1 ECD or variant thereof. In FIG. 3B, the first TGF-beta receptor comprises TGFBR1 ECD or variant thereof and the second TGF-beta receptor comprises TGFBR2 ECD or variant thereof. In FIG. 3C, the first TGF-beta receptor comprises TGFBR2 ECD or variant thereof and the second TGF-beta receptor comprises TGFBR1 ECD or variant thereof. In FIG. 3D, the first and the second TGF-beta receptors comprise TGFBR2 ECD or variant thereof.

FIGS. 4A-4D are schematics showing additional exemplary multispecific molecules comprising a CSF1R binding moiety, a PD-L1 binding moiety, and one or more TGF-beta receptors. Shown in FIGS. 4A-4D are multispecific antibody molecules comprising: a first polypeptide comprising a first TGF-beta receptor and CL; a second polypeptide comprising a second TGF-beta receptor, CH1, CH2, CH3, an anti-PDL1 VH, and an anti-PDL1 VL; a third polypeptide comprising a third TGF-beta receptor, CH1, CH2, CH3, an anti-CSF1R VH, and an anti-CSF1R VL; and a fourth polypeptide comprising a fourth TGF-beta receptor and CL. In FIG. 4A, the first, second, third, and fourth TGF-beta receptors comprise TGFBR1 ECD or variant thereof. In FIG. 4B, the first, second, third, and fourth TGF-beta receptors comprise TGFBR2 ECD or variant thereof. In FIG. 4C, the first and the second TGF-beta receptors comprise TGFBR1 ECD or variant thereof and the third and the fourth TGF-beta receptors comprise TGFBR2 ECD or variant thereof. In FIG. 4D, the second and the third TGF-beta receptors comprise TGFBR1 ECD or variant thereof and the first and the fourth TGF-beta receptors comprise TGFBR2 ECD or variant thereof.

FIGS. 5A-5B are schematics showing additional exemplary multispecific molecules comprising a CSF1R binding moiety, a PD-L1 binding moiety, and one or more TGF-beta receptors. Shown in FIGS. 5A-5B are multispecific antibody molecules comprising: a first polypeptide comprising a first TGF-beta receptor, CH2, CH3, an anti-PDL1 VH, and an anti-PDL1 VL; and a second polypeptide comprising a second TGF-beta receptor, CH2, CH3, an anti-CSF1R VH, and an anti-CSF1R VL. In FIG. 5A, the first TGF-beta receptor comprises a TGFBR1 ECD or variant thereof and the second TGF-beta receptor comprises a TGFBR2 ECD or variant thereof. In FIG. 5B, the first and the second TGF-beta receptors comprise TGFBR2 ECD or variant thereof.

FIGS. 6A-6D are schematics showing exemplary multispecific molecules comprising a TGFβ inhibitor. In some embodiments, the TGFβ inhibitor comprises a TGF-beta receptor ECD homodimer. In some embodiments, the TGFβ inhibitor comprises a TGFBR2 ECD heterodimer. In FIGS. 6A and 6B, the two TGFBR ECD domains are linked to the C-terminus of two Fc regions. In some embodiments, the CH1-Fc-TGFBR ECD region shown in FIG. 6A or 6B comprises the amino acid sequence of SEQ ID NO: 192 or 193. In some embodiments, the Fc-TGFBR ECD region shown in FIG. 6A or 6B comprises the amino acid sequence of SEQ ID NO: 194 or 195. In FIGS. 6C and 6D, the two TGFBR ECD domains are linked to CH1 and CL, respectively. In some embodiments, the TGFBR ECD-CH1-Fc region shown in FIG. 6C or 6D comprises the amino acid sequence of SEQ ID NO: 196 or 197. In some embodiments, the TGFBR ECD-CL region shown in FIG. 6C or 6D comprises the amino acid sequence of SEQ ID NO: 198 or 199. In some embodiments, the multispecific molecule comprises a binding moiety A and a binding moiety B. In some embodiments, the binding moiety A or binding moiety B is an anti-CSF1R binding moiety (e.g., an anti-CSF1R antibody molecule). In some embodiments, the binding moiety A or binding moiety B is an anti-CCR2 binding moiety (e.g., an anti-CCR2 antibody molecule). In some embodiments, the binding moiety A or binding moiety B is a tumor targeting moiety (e.g., a tumor targeting antibody molecule).

FIG. 7 is a graph in which TGFβ/Smad activation is plotted against TGFβ-trap concentrations. Constructs tested in this study included: Single TGFβ Fab-trap, Anti-PDL1×TGFβ-trap, Anti-CCR2×anti-CSF1R, and Anti-CCR2×anti-CSF1R×TGFβ-trap.

DETAILED DESCRIPTION OF THE INVENTION

TAMs originate from circulating monocytes and their recruitment into tumors is driven by tumor-derived chemotactic factors. TAMs can promote tumor cell proliferation and metastasis by causing such responses as inhibition of B and T cell activation, inhibition of tumor-associated antigen presentation, inhibition of cytotoxic granule release, increased angiogenesis, and secretion a wide range of growth and proangiogenic factors (see e.g., Liu et al Cellular & Molecular Immunology (2015) 12, 1-4; and Noy, Roy et al Immunity, Volume 41, Issue 1, 49-61; and Quatromoni et al. Am J Transl Res. 2012; 4(4): 376-389). Consequently, many tumors with a high number of TAMs have an increased tumor growth rate, local proliferation and distant metastasis. Thus, therapies that deplete TAMs or inhibit their activity would be useful.

Definitions

As used herein, the term “transforming growth factor beta-1 (TGF-beta 1)” refers to a protein that in humans is encoded by the gene TGFB1, or its orthologs. Swiss-Prot accession number P01137 provides exemplary human TGF-beta 1 amino acid sequences. An exemplary immature human TGF-beta 1 amino acid sequence is provided in SEQ ID NO: 92. An exemplary mature human TGF-beta 1 amino acid sequence is provided in SEQ ID NO: 117.

As used herein, the term “transforming growth factor beta-2 (TGF-beta 2)” refers to a protein that in humans is encoded by the gene TGFB2, or its orthologs. Swiss-Prot accession number P61812 provides exemplary human TGF-beta 2 amino acid sequences. An exemplary immature human TGF-beta 2 amino acid sequence is provided in SEQ ID NO: 93. An exemplary mature human TGF-beta 2 amino acid sequence is provided in SEQ ID NO: 118.

As used herein, the term “transforming growth factor beta-3 (TGF-beta 3)” refers to a protein that in humans is encoded by the gene TGFB3, or its orthologs. Swiss-Prot accession number P10600 provides exemplary human TGF-beta 3 amino acid sequences. An exemplary immature human TGF-beta 3 amino acid sequence is provided in SEQ ID NO: 94. An exemplary mature human TGF-beta 3 amino acid sequence is provided in SEQ ID NO: 119.

As used herein, a “TGF-beta receptor polypeptide” refers to a TGF-beta receptor (e.g., TGFBR1, TGFBR2, or TGFBR3) or its fragment, or variant thereof.

As used herein, the term “transforming growth factor beta receptor type 1 (TGFBR1)” (also known as ALK-5 or SKR4) refers to a protein that in humans is encoded by the gene TGFBR1, or its orthologs. Swiss-Prot accession number P36897 provides exemplary human TGFBR1 amino acid sequences. Exemplary immature human TGFBR1 amino acid sequences are provided in SEQ ID NOs: 95, 96, and 97. Exemplary mature human TGFBR1 amino acid sequences are provided in SEQ ID NOs: 120, 121, and 122. As used herein, a “TGFBR1 polypeptide” refers to a TGFBR1 or its fragment, or variant thereof.

As used herein, the term “transforming growth factor beta receptor type 2 (TGFBR2)” refers to a protein that in humans is encoded by the gene TGFBR2, or its orthologs. Swiss-Prot accession number P37173 provides exemplary human TGFBR2 amino acid sequences. Exemplary immature human TGFBR2 amino acid sequences are provided in SEQ ID NOs: 98 and 99. Exemplary mature human TGFBR2 amino acid sequences are provided in SEQ ID NOs: 123 and 124. As used herein, a “TGFBR2 polypeptide” refers to a TGFBR2 or its fragment, or variant thereof.

As used herein, the term “transforming growth factor beta receptor type 3 (TGFBR3)” refers to a protein that in humans is encoded by the gene TGFBR3, or its orthologs. Swiss-Prot accession number Q03167 provides exemplary human TGFBR3 amino acid sequences. Exemplary immature human TGFBR3 amino acid sequences are provided in SEQ ID NOs: 106 and 107. Exemplary mature human TGFBR3 amino acid sequences are provided in SEQ ID NOs: 125 and 126. As used herein, a “TGFBR3 polypeptide” refers to a TGFBR3 or its fragment, or variant thereof.

As used herein, the term “variant” of a parent sequence refers to a sequence that has a substantially identical amino acid sequence to the parent sequence, or a fragment thereof. In some embodiments, the variant is a functional variant.

As used herein, an “extracellular domain” or “ECD” of a polypeptide refers to a portion of the polypeptide that lacks the intracellular and transmembrane domains. In some embodiments, an “extracellular domain” or “ECD” of a polypeptide includes the whole portion of the polypeptide that is in the extracellular space when the polypeptide is on the cell surface, a fragment thereof, or a variant thereof.

As used herein, the articles “a” and “an” refer to one or more than one, e.g., to at least one, of the grammatical object of the article. The use of the words “a” or “an” when used in conjunction with the term “comprising” herein may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

As used herein, “about” and “approximately” generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given range of values.

“Antibody molecule” as used herein refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable region sequence. An antibody molecule encompasses antibodies (e.g., full-length antibodies) and antibody fragments. In an embodiment, an antibody molecule comprises an antigen binding or functional fragment of a full length antibody, or a full length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes). In embodiments, an antibody molecule refers to an immunologically active, antigen-binding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody fragment, e.g., functional fragment, is a portion of an antibody, e.g., Fab, Fab′, F(ab′)₂, F(ab)₂, variable fragment (Fv), domain antibody (dAb), or single chain variable fragment (scFv). A functional antibody fragment binds to the same antigen as that recognized by the intact (e.g., full-length) antibody. The terms “antibody fragment” or “functional fragment” also include isolated fragments consisting of the variable regions, such as the “Fv” fragments consisting of the variable regions of the heavy and light chains or recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker (“scFv proteins”). In some embodiments, an antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues. Exemplary antibody molecules include full length antibodies and antibody fragments, e.g., dAb (domain antibody), single chain, Fab, Fab′, and F(ab′)2 fragments, and single chain variable fragments (scFvs).

As used herein, an “immunoglobulin variable region sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable region. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable region. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations that are compatible with formation of the protein structure.

In embodiments, an antibody molecule is monospecific, e.g., it comprises binding specificity for a single epitope. In some embodiments, an antibody molecule is multispecific, e.g., it comprises a plurality of immunoglobulin variable region sequences, where a first immunoglobulin variable region sequence has binding specificity for a first epitope and a second immunoglobulin variable region sequence has binding specificity for a second epitope. In some embodiments, an antibody molecule is a bispecific antibody molecule. “Bispecific antibody molecule” as used herein refers to an antibody molecule that has specificity for more than one (e.g., two, three, four, or more) epitope and/or antigen.

“Antigen” (Ag) as used herein refers to a molecule that can provoke an immune response, e.g., involving activation of certain immune cells and/or antibody generation. Any macromolecule, including almost all proteins or peptides, can be an antigen. Antigens can also be derived from genomic recombinant or DNA. For example, any DNA comprising a nucleotide sequence or a partial nucleotide sequence that encodes a protein capable of eliciting an immune response encodes an “antigen.” In embodiments, an antigen does not need to be encoded solely by a full length nucleotide sequence of a gene, nor does an antigen need to be encoded by a gene at all. In embodiments, an antigen can be synthesized or can be derived from a biological sample, e.g., a tissue sample, a tumor sample, a cell, or a fluid with other biological components. As used, herein a “tumor antigen” or interchangeably, a “cancer antigen” includes any molecule present on, or associated with, a cancer, e.g., a cancer cell or a tumor microenvironment that can provoke an immune response. As used, herein an “immune cell antigen” includes any molecule present on, or associated with, an immune cell that can provoke an immune response.

The “antigen-binding site,” or “binding portion” of an antibody molecule refers to the part of an antibody molecule, e.g., an immunoglobulin (Ig) molecule, that participates in antigen binding. In embodiments, the antigen binding site is formed by amino acid residues of the variable (V) regions of the heavy (H) and light (L) chains. Three highly divergent stretches within the variable regions of the heavy and light chains, referred to as hypervariable regions, are disposed between more conserved flanking stretches called “framework regions,” (FRs). FRs are amino acid sequences that are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In embodiments, in an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface, which is complementary to the three-dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are referred to as “complementarity-determining regions,” or “CDRs.” The framework region and CDRs have been defined and described, e.g., in Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917. Each variable chain (e.g., variable heavy chain and variable light chain) is typically made up of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the amino acid order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

“Cancer” as used herein can encompass all types of oncogenic processes and/or cancerous growths. In embodiments, cancer includes primary tumors as well as metastatic tissues or malignantly transformed cells, tissues, or organs. In embodiments, cancer encompasses all histopathologies and stages, e.g., stages of invasiveness/severity, of a cancer. In embodiments, cancer includes relapsed and/or resistant cancer. The terms “cancer” and “tumor” can be used interchangeably. For example, both terms encompass solid and liquid tumors. As used herein, the term “cancer” or “tumor” includes premalignant, as well as malignant cancers and tumors.

The compositions and methods of the present invention encompass polypeptides and nucleic acids having the sequences specified, or sequences substantially identical or similar thereto, e.g., sequences at least 85%, 90%, 95% identical or higher to the sequence specified. In the context of an amino acid sequence, the term “substantially identical” is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 85%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein.

In the context of nucleotide sequence, the term “substantially identical” is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein.

Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.

To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”).

The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences described herein can be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid (e.g., SEQ ID NO: 1) molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov.

It is understood that the molecules of the present invention may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions.

The term “amino acid” is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids. Exemplary amino acids include naturally-occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing. As used herein the term “amino acid” includes both the D- or L-optical isomers and peptidomimetics.

A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

The terms “polypeptide”, “peptide” and “protein” (if single chain) are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. The polypeptide can be isolated from natural sources, can be a produced by recombinant techniques from a eukaryotic or prokaryotic host, or can be a product of synthetic procedures.

The terms “nucleic acid,” “nucleic acid sequence,” “nucleotide sequence,” or “polynucleotide sequence,” and “polynucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. The polynucleotide may be either single-stranded or double-stranded, and if single-stranded may be the coding strand or non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a non-natural arrangement.

The term “isolated,” as used herein, refers to material that is removed from its original or native environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the co-existing materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of the environment in which it is found in nature.

As used herein, the term “immunosuppressive myeloid cell” or “IMC” generally refers to a cell of myeloid lineage that promotes immunosuppression (e.g., in a tumor microenvironment) (e.g., by inhibiting T cell activation, inhibiting T cell viability, promoting T regulatory cell induction and recruitment). Immunosuppressive myeloid cells include, e.g., tumor associated macrophages (TAMs) and myeloid derived suppressor cells (MDSCs).

As used herein, the term “tumor associated macrophage” or “TAM” generally refers to a macrophage that exists in the microenvironment of a cancer, for example, a tumor.

As used herein, the term “reducing TAMs” generally refers to decreasing the number of TAMs. Reducing includes decreasing the number of TAMs in a tumor or near a tumor (e.g., as compared to the number of TAMs prior to administration of a multispecific molecule described herein (e.g., prior to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more administrations of a multispecific molecule described herein). Reducing includes decreasing any number of TAMs (e.g., 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 100%, all, or substantially) (e.g., as compared to the number of TAMs prior to administration of a multispecific molecule described herein (e.g., prior to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more administrations of a multispecific molecule described herein).

As used herein, the term “myeloid derived suppressor cell” or “MDSC” generally refers to a cell of myeloid origin that is capable of promoting immunosuppression and commonly express CD33, CD11b and CD45. Various subpopulations of MDSCs have been defined, for example monocytic-MDSCs (M-MDSCs) are commonly associated with expression of CD14 and CD124 and low expression of HLA-DR. In some embodiments, the MDSC population is an MO-MDSC population. Polymorphonuclear MDSCs (PMN-MDSCs) are associated with expression of CD15, CD66b, and CD124, and no expression of HLA-DR. Immature MDSCs (I-MDSCs) are associated with expression of CD117 and CD34 and no expression of LIN and HLA-DR. See e.g., Ugel et al. (2015) JCI Vol 125 (9), page 3365.

Various aspects of the invention are described in further detail below. Additional definitions are set out throughout the specification.

Antigens

TAM targeting antigens of the present disclosure include, e.g., CSF1R, CCR2, CXCR2, CD68, CD163, CX3CR1, MARCO, CD204, CD52, and folate receptor beta. Exemplary amino acid sequences of TAM targeting antigens are provided herein.

CSF1R

CSF1R (also known as Macrophage colony-stimulating factor 1 receptor) is a tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. CSF1R promotes the release of pro-inflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Exemplary CSF1R immature amino acid sequences are provided in SEQ ID NOs: 87 and 88.

CSF1R immature amino acid sequence isoform 1

(identifier: P07333-1):

SEQ ID NO: 87

MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEW

DGPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLY

VKDPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMR

HTNYSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIP

GPPALTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQS

DFHNNRYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVESAY

LNLSSEQNLIQEVTVGEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPEPK

LANATTKDTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWRALTFELTLRY

PPEVSVIWTFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVLQVW

DDPYPEVLSQEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIP

ISAGAHTHPPDEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRW

KIIESYEGNSYTFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEAT

AFGLGKEDAVLKVAVKMLKSTAHADEKEALMSELKIMSHLGQHENIVNLL

GACTHGGPVLVITEYCCYGDLLNFLRRKAEAMLGPSLSPGQDPEGGVDYK

NIHLEKKYVRRDSGFSSQGVDTYVEMRPVSTSSNDSFSEQDLDKEDGRPL

ELRDLLHFSSQVAQGMAFLASKNCIHRDVAARNVLLTNGHVAKIGDFGLA

RDIMNDSNYIVKGNARLPVKWMAPESIFDCVYTVQSDVWSYGILLWEIFS

LGLNPYPGILVNSKFYKLVKDGYQMAQPAFAPKNIYSIMQACWALEPTHR

PTFQQICSFLQEQAQEDRRERDYTNLPSSSRSGGSGSSSSELEEESSSEH

LTCCEQGDIAQPLLQPNNYQFC

CSF1R immature amino acid sequence isoform 2

(identifier: P07333-2):

SEQ ID NO: 88

MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEW

DGPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLY

VKDPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMR

HTNYSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIP

GPPALTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQS

DFHNNRYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVGTPS

PSLCPA

CCR2

CCR2 (also known as C-C chemokine receptor type 2) is a G protein coupled receptor for the CCL2, CCL7 and CCL13 chemokines. CCR2 is known to function in the recruitment of monocytes/macrophages and T cells. CCR2 is expressed is expressed on monocytes and a small subpopulation of T cells and exhibits an almost identical expression pattern in mice and humans (Mack et al. J Immunol 2001; 166:4697-4704). Exemplary CCR2 amino acid sequences are provided in SEQ ID NOs: 89 and 90.

CCR2 amino acid sequence isoform A (Identifier:

P41597-1):

SEQ ID NO: 89

MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYS

LVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAH

SAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALK

ARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNN

FHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVIFTIMI

VYFLFWTPYNIVILLNTFQEFFGLSNCESTSQLDQATQVTETLGMTHCCI

NPIIYAFVGEKFRSLFHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGL

LDGRGKGKSIGRAPEASLQDKEGA

CCR2 amino acid sequence isoform B (Identifier:

P41597-2):

SEQ ID NO: 90

MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYS

LVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAH

SAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALK

ARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNN

FHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVIFTIMI

VYFLFWTPYNIVILLNTFQEFFGLSNCESTSQLDQATQVTETLGMTHCCI

NPIIYAFVGEKFRRYLSVFFRKHITKRFCKQCPVFYRETVDGVTSTNTPS

TGEQEVSAGL

CXCR2

CXCR2 (also known as interleukin-8 receptor) is the G protein coupled receptor for IL8 which is a neutrophil chemotactic factor. Binding of IL8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. CXCR2 binds to IL-8 with high affinity, and also binds with high affinity to CXCL3, GRO/MGSA and NAP-2. CXCR2 is expressed at high levels on circulating neutrophils and is critical for directing their migration to sites of inflammation (J Clin Invest. 2012; 122(9):3127-3144). An exemplary CXCR2 amino acid sequence is provided in SEQ ID NO: 91.

CXCR2 amino acid sequence (Identifier: P25025-1):

SEQ ID NO: 91

MEDFNMESDSFEDFWKGEDLSNYSYSSTLPPFLLDAAPCEPESLEINKYF

VVIIYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALT

LPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVH

ATRTLTQKRYLVKFICLSIWGLSLLLALPVLLFRRTVYSSNVSPACYEDM

GNNTANWRMLLRILPQSFGFIVPLLIMLFCYGFTLRTLFKAHMGQKHRAM

RVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQETCERRNHIDRALDATE

ILGILHSCLNPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVG

SSSGHTSTTL

Exemplary Antibodies

Exemplary antibodies binding TAM antigens are provided throughout the specification and below. Exemplary anti-CSF1R antibodies are described herein as well as in WO2009026303A1; WO2011123381A1; WO2016207312A1; WO2016106180A1; US20160220669A1; US20160326254A1; WO2013169264A1; WO2013087699A1; WO2011140249A2; WO2011131407A1; WO2011123381A1; WO2011107553A1; and WO2011070024A1, all of which are herein incorporated by reference in their entirety. Exemplary CCR2 antibodies are described herein as well as in WO2013192596A2; WO2010021697A2; WO2001057226A1; and WO1997031949A1, all of which are herein incorporated by reference in their entirety. Exemplary CXCR2 antibodies are described in WO2014170317A1 and US20160060347 (see e.g., a) SEQ ID NO: 14 (light chain) and SEQ ID NO: 15 (heavy chain); b) SEQ ID NO: 24 (light chain) and SEQ ID NO: 25 (heavy chain); c) SEQ ID NO: 34 (light chain) and SEQ ID NO: 35 (heavy chain); d) SEQ ID NO: 44 (light chain) and SEQ ID NO: 45 (heavy chain); e) SEQ ID NO: 54 (light chain) and SEQ ID NO: 55 (heavy chain); f) SEQ ID NO: 64 (light chain) and SEQ ID NO: 65 (heavy chain); g) SEQ ID NO: 74 (light chain) and SEQ ID NO: 75 (heavy chain); h) SEQ ID NO: 84 (light chain) and SEQ ID NO: 85 (heavy chain)), all of which are herein incorporated by reference in their entirety. Exemplary anti-CD163 antibodies are provided in US20120258107 (see e.g., MAC2158, MAC2-48), herein incorporated by reference in its entirety. Exemplary anti-CD52 antibodies are described in US20050152898, herein incorporated by reference in its entirety. Exemplary anti-folate antibodies are described in U.S. Pat. No. 9,522,196, herein incorporated by reference in its entirety. Exemplary anti-CD52 antibodies are described in US20050152898, herein incorporated by reference in its entirety. Exemplary anti-MARCO antibodies are described in WO2016196612, herein incorporated by reference in its entirety.

Antibody Molecules

In one embodiment, the multispecific molecule comprises an antibody molecule that binds to a first tumor associated macrophage (TAM) antigen; and an antibody molecule that binds to a second TAM antigen. In some embodiments, the first and/or second TAM antigen is, e.g., a mammalian, e.g., a human. For example, the antibody molecule binds specifically to an epitope, e.g., linear or conformational epitope, on the TAM antigen.

In one embodiment, the multispecific molecule comprises an antibody molecule that binds to a first myeloid derived suppressor cell (MDSC) antigen; and an antibody molecule that binds to a second MDSC antigen. In some embodiments, the first and/or second MDSC antigen is, e.g., a mammalian, e.g., a human. For example, the antibody molecule binds specifically to an epitope, e.g., linear or conformational epitope, on the MDSC antigen.

In an embodiment, an antibody molecule is a monospecific antibody molecule and binds a single epitope. E.g., a monospecific antibody molecule having a plurality of immunoglobulin variable region sequences, each of which binds the same epitope.

In an embodiment an antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable region sequences, wherein a first immunoglobulin variable region sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable region sequence of the plurality has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In an embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g., the different proteins (or different subunits of a multimeric protein). In an embodiment a multispecific antibody molecule comprises a third, fourth or fifth immunoglobulin variable region. In an embodiment, a multispecific antibody molecule is a bispecific antibody molecule, a trispecific antibody molecule, or a tetraspecific antibody molecule.

In an embodiment a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable region sequence which has binding specificity for a first epitope and a second immunoglobulin variable region sequence that has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In an embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g., the different proteins (or different subunits of a multimeric protein). In an embodiment a bispecific antibody molecule comprises a heavy chain variable region sequence and a light chain variable region sequence which have binding specificity for a first epitope and a heavy chain variable region sequence and a light chain variable region sequence which have binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a scFv or a Fab, or fragment thereof, have binding specificity for a first epitope and a scFv or a Fab, or fragment thereof, have binding specificity for a second epitope.

In an embodiment, an antibody molecule comprises a diabody, and a single-chain molecule, as well as an antigen-binding fragment of an antibody (e.g., Fab, F(ab′)₂, and Fv). For example, an antibody molecule can include a heavy (H) chain variable region sequence (abbreviated herein as VH), and a light (L) chain variable region sequence (abbreviated herein as VL). In an embodiment an antibody molecule comprises or consists of a heavy chain and a light chain (referred to herein as a half antibody. In another example, an antibody molecule includes two heavy (H) chain variable region sequences and two light (L) chain variable region sequence, thereby forming two antigen binding sites, such as Fab, Fab′, F(ab′)₂, Fc, Fd, Fd′, Fv, single chain antibodies (scFv for example), single variable region antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which may be produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. These functional antibody fragments retain the ability to selectively bind with their respective antigen or receptor. Antibodies and antibody fragments can be from any class of antibodies including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and from any subclass (e.g., IgG1, IgG2, IgG3, and IgG4) of antibodies. The a preparation of antibody molecules can be monoclonal or polyclonal. An antibody molecule can also be a human, humanized, CDR-grafted, or in vitro generated antibody. The antibody can have a heavy chain constant region chosen from, e.g., IgG1, IgG2, IgG3, or IgG4. The antibody can also have a light chain chosen from, e.g., kappa or lambda. The term “immunoglobulin” (Ig) is used interchangeably with the term “antibody” herein.

Examples of antigen-binding fragments of an antibody molecule include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a diabody (dAb) fragment, which consists of a VH domain; (vi) a camelid or camelized variable region; (vii) a single chain Fv (scFv), see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883); (viii) a single domain antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

Antibody molecules include intact molecules as well as functional fragments thereof. Constant regions of the antibody molecules can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function).

Antibody molecules can also be single domain antibodies. Single domain antibodies can include antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. Single domain antibodies may be any of the art, or any future single domain antibodies. Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, fish, shark, goat, rabbit, and bovine. According to another aspect of the invention, a single domain antibody is a naturally occurring single domain antibody known as heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed in WO 9404678, for example. For clarity reasons, this variable region derived from a heavy chain antibody naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain antibodies naturally devoid of light chain; such VHHs are within the scope of the invention.

The VH and VL regions can be subdivided into regions of hypervariability, termed “complementarity determining regions” (CDR), interspersed with regions that are more conserved, termed “framework regions” (FR or FW).

The extent of the framework region and CDRs has been precisely defined by a number of methods (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917; and the AbM definition used by Oxford Molecular's AbM antibody modeling software. See, generally, e.g., Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg).

The terms “complementarity determining region,” and “CDR,” as used herein refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, LCDR3).

The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 (“Chothia” numbering scheme). As used herein, the CDRs defined according the “Chothia” number scheme are also sometimes referred to as “hypervariable loops.”

For example, under Kabat, the CDR amino acid residues in the heavy chain variable region (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable region (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia, the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3).

Each VH and VL typically includes three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The antibody molecule can be a polyclonal or a monoclonal antibody.

The terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. A monoclonal antibody can be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods).

The antibody can be recombinantly produced, e.g., produced by phage display or by combinatorial methods.

Phage display and combinatorial methods for generating antibodies are known in the art (as described in, e.g., Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. International Publication No. WO 92/18619; Dower et al. International Publication No. WO 91/17271; Winter et al. International Publication WO 92/20791; Markland et al. International Publication No. WO 92/15679; Breitling et al. International Publication WO 93/01288; McCafferty et al. International Publication No. WO 92/01047; Garrard et al. International Publication No. WO 92/09690; Ladner et al. International Publication No. WO 90/02809; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J Mol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991) Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982, the contents of all of which are incorporated by reference herein).

In one embodiment, the antibody is a fully human antibody (e.g., an antibody made in a mouse which has been genetically engineered to produce an antibody from a human immunoglobulin sequence), or a non-human antibody, e.g., a rodent (mouse or rat), goat, primate (e.g., monkey), camel antibody. Preferably, the non-human antibody is a rodent (mouse or rat antibody). Methods of producing rodent antibodies are known in the art.

Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. International Application WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. International Application WO 92/03918; Kay et al. International Application 92/03917; Lonberg, N. et al. 1994 Nature 368:856-859; Green, L. L. et al. 1994 Nature Genet. 7:13-21; Morrison, S. L. et al. 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al. 1993 Year Immunol 7:33-40; Tuaillon et al. 1993 PNAS 90:3720-3724; Bruggeman et al. 1991 Eur J Immunol 21:1323-1326).

An antibody molecule can be one in which the variable region, or a portion thereof, e.g., the CDRs, are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibody molecules generated in a non-human organism, e.g., a rat or mouse, and then modified, e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention.

An “effectively human” protein is a protein that does substantially not evoke a neutralizing antibody response, e.g., the human anti-murine antibody (HAMA) response. HAMA can be problematic in a number of circumstances, e.g., if the antibody molecule is administered repeatedly, e.g., in treatment of a chronic or recurrent disease condition. A HAMA response can make repeated antibody administration potentially ineffective because of an increased antibody clearance from the serum (see, e.g., Saleh et al., Cancer Immunol. Immunother., 32:180-190 (1990)) and also because of potential allergic reactions (see, e.g., LoBuglio et al., Hybridoma, 5:5117-5123 (1986)).

Chimeric antibodies can be produced by recombinant DNA techniques known in the art (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86/01533; Cabilly et al. U.S. Pat. No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 Science 240:1041-1043); Liu et al. (1987) PNAS 84:3439-3443; Liu et al., 1987, J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al., 1987, Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al., 1988, J. Natl Cancer Inst. 80:1553-1559).

A humanized or CDR-grafted antibody will have at least one or two but generally all three recipient CDRs (of heavy and or light immuoglobulin chains) replaced with a donor CDR. The antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding to the antigen. Preferably, the donor will be a rodent antibody, e.g., a rat or mouse antibody, and the recipient will be a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDRs is called the “donor” and the immunoglobulin providing the framework is called the “acceptor.” In one embodiment, the donor immunoglobulin is a non-human (e.g., rodent). The acceptor framework is a naturally-occurring (e.g., a human) framework or a consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.

As used herein, the term “consensus sequence” refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A “consensus framework” refers to the framework region in the consensus immunoglobulin sequence.

An antibody molecule can be humanized by methods known in the art (see e.g., Morrison, S. L., 1985, Science 229:1202-1207, by Oi et al., 1986, BioTechniques 4:214, and by Queen et al. U.S. Pat. Nos. 5,585,089, 5,693,761 and 5,693,762, the contents of all of which are hereby incorporated by reference).

Humanized or CDR-grafted antibody molecules can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced. See e.g., U.S. Pat. No. 5,225,539; Jones et al. 1986 Nature 321:552-525; Verhoeyan et al. 1988 Science 239:1534; Beidler et al. 1988 J. Immunol. 141:4053-4060; Winter U.S. Pat. No. 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on Mar. 26, 1987; Winter U.S. Pat. No. 5,225,539), the contents of which is expressly incorporated by reference.

Also within the scope of the invention are humanized antibody molecules in which specific amino acids have been substituted, deleted or added. Criteria for selecting amino acids from the donor are described in U.S. Pat. No. 5,585,089, e.g., columns 12-16 of U.S. Pat. No. 5,585,089, e.g., columns 12-16 of U.S. Pat. No. 5,585,089, the contents of which are hereby incorporated by reference. Other techniques for humanizing antibodies are described in Padlan et al. EP 519596 A1, published on Dec. 23, 1992.

The antibody molecule can be a single chain antibody. A single-chain antibody (scFV) may be engineered (see, for example, Colcher, D. et al. (1999) Ann N Y Acad Sci 880:263-80; and Reiter, Y. (1996) Clin Cancer Res 2:245-52). The single chain antibody can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target protein.

In yet other embodiments, the antibody molecule has a heavy chain constant region chosen from, e.g., the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; particularly, chosen from, e.g., the (e.g., human) heavy chain constant regions of IgG1, IgG2, IgG3, and IgG4. In another embodiment, the antibody molecule has a light chain constant region chosen from, e.g., the (e.g., human) light chain constant regions of kappa or lambda. The constant region can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, and/or complement function). In one embodiment the antibody has: effector function; and can fix complement. In other embodiments the antibody does not; recruit effector cells; or fix complement. In another embodiment, the antibody has reduced or no ability to bind an Fc receptor. For example, it is a isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.

Methods for altering an antibody constant region are known in the art. Antibodies with altered function, e.g. altered affinity for an effector ligand, such as FcR on a cell, or the C1 component of complement can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 A1, U.S. Pat. Nos. 5,624,821 and 5,648,260, the contents of all of which are hereby incorporated by reference). Similar type of alterations could be described which if applied to the murine, or other species immunoglobulin would reduce or eliminate these functions.

An antibody molecule can be derivatized or linked to another functional molecule (e.g., another peptide or protein). As used herein, a “derivatized” antibody molecule is one that has been modified. Methods of derivatization include but are not limited to the addition of a fluorescent moiety, a radionucleotide, a toxin, an enzyme or an affinity ligand such as biotin. Accordingly, the antibody molecules of the invention are intended to include derivatized and otherwise modified forms of the antibodies described herein, including immunoadhesion molecules. For example, an antibody molecule can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).

One type of derivatized antibody molecule is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies). Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate). Such linkers are available from Pierce Chemical Company, Rockford, Ill.

Multispecific Antibody Molecules

In embodiments, multispecific antibody molecules can comprise more than one antigen-binding site, where different sites are specific for different antigens. In embodiments, multispecific antibody molecules can bind more than one (e.g., two or more) epitopes on the same antigen. In embodiments, multispecific antibody molecules comprise an antigen-binding site specific for a target cell (e.g., cancer cell) and a different antigen-binding site specific for an immune effector cell. In one embodiment, the multispecific antibody molecule is a bispecific antibody molecule. Bispecific antibody molecules can be classified into five different structural groups: (i) bispecific immunoglobulin G (BsIgG); (ii) IgG appended with an additional antigen-binding moiety; (iii) bispecific antibody fragments; (iv) bispecific fusion proteins; and (v) bispecific antibody conjugates.

BsIgG is a format that is monovalent for each antigen. Exemplary BsIgG formats include but are not limited to crossMab, DAF (two-in-one), DAF (four-in-one), DutaMab, DT-IgG, knobs-in-holes common LC, knobs-in-holes assembly, charge pair, Fab-arm exchange, SEEDbody, triomab, LUZ-Y, Fcab, κλ-body, orthogonal Fab. See Spiess et al. Mol. Immunol. 67(2015):95-106. Exemplary BslgGs include catumaxomab (Fresenius Biotech, Trion Pharma, Neopharm), which contains an anti-CD3 arm and an anti-EpCAM arm; and ertumaxomab (Neovii Biotech, Fresenius Biotech), which targets CD3 and HER2. In some embodiments, BsIgG comprises heavy chains that are engineered for heterodimerization. For example, heavy chains can be engineered for heterodimerization using a “knobs-into-holes” strategy, a SEED platform, a common heavy chain (e.g., in κλ-bodies), and use of heterodimeric Fc regions. See Spiess et al. Mol. Immunol. 67(2015):95-106. Strategies that have been used to avoid heavy chain pairing of homodimers in BsIgG include knobs-in-holes, duobody, azymetric, charge pair, HA-TF, SEEDbody, and differential protein A affinity. See Id. BsIgG can be produced by separate expression of the component antibodies in different host cells and subsequent purification/assembly into a BsIgG. BsIgG can also be produced by expression of the component antibodies in a single host cell. BsIgG can be purified using affinity chromatography, e.g., using protein A and sequential pH elution.

IgG appended with an additional antigen-binding moiety is another format of bispecific antibody molecules. For example, monospecific IgG can be engineered to have bispecificity by appending an additional antigen-binding unit onto the monospecific IgG, e.g., at the N- or C-terminus of either the heavy or light chain. Exemplary additional antigen-binding units include single domain antibodies (e.g., variable heavy chain or variable light chain), engineered protein scaffolds, and paired antibody variable regions (e.g., single chain variable fragments or variable fragments). See Id. Examples of appended IgG formats include dual variable domain IgG (DVD-Ig), IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)—IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, zybody, and DVI-IgG (four-in-one). See Spiess et al. Mol. Immunol. 67(2015):95-106. An example of an IgG-scFv is MM-141 (Merrimack Pharmaceuticals), which binds IGF-1R and HERS. Examples of DVD-Ig include ABT-981 (AbbVie), which binds IL-1α and IL-1β; and ABT-122 (AbbVie), which binds TNF and IL-17A.

Bispecific antibody fragments (BsAb) are a format of bispecific antibody molecules that lack some or all of the antibody constant regions. For example, some BsAb lack an Fc region.

In embodiments, bispecific antibody fragments include heavy and light chain regions that are connected by a peptide linker that permits efficient expression of the BsAb in a single host cell. Exemplary bispecific antibody fragments include but are not limited to nanobody, nanobody-HAS, BiTE, Diabody, DART, TandAb, scDiabody, scDiabody-CH3, Diabody-CH3, triple body, miniantibody, minibody, TriBi minibody, scFv-CH3 KIH, Fab-scFv, scFv-CH-CL-scFv, F(ab′)2, F(ab′)2-scFv2, scFv-KIH, Fab-scFv-Fc, tetravalent HCAb, scDiabody-Fc, Diabody-Fc, tandem scFv-Fc, and intrabody. See Id. For example, the BiTE format comprises tandem scFvs, where the component scFvs bind to CD3 on T cells and a surface antigen on cancer cells

Bispecific fusion proteins include antibody fragments linked to other proteins, e.g., to add additional specificity and/or functionality. An example of a bispecific fusion protein is an immTAC, which comprises an anti-CD3 scFv linked to an affinity-matured T-cell receptor that recognizes HLA-presented peptides. In embodiments, the dock-and-lock (DNL) method can be used to generate bispecific antibody molecules with higher valency. Also, fusions to albumin binding proteins or human serum albumin can be extend the serum half-life of antibody fragments. See Id.

In embodiments, chemical conjugation, e.g., chemical conjugation of antibodies and/or antibody fragments, can be used to create BsAb molecules. See Id. An exemplary bispecific antibody conjugate includes the CovX-body format, in which a low molecular weight drug is conjugated site-specifically to a single reactive lysine in each Fab arm or an antibody or fragment thereof. In embodiments, the conjugation improves the serum half-life of the low molecular weight drug. An exemplary CovX-body is CVX-241 (NCT01004822), which comprises an antibody conjugated to two short peptides inhibiting either VEGF or Ang2. See Id.

The antibody molecules can be produced by recombinant expression, e.g., of at least one or more component, in a host system. Exemplary host systems include eukaryotic cells (e.g., mammalian cells, e.g., CHO cells, or insect cells, e.g., SF9 or S2 cells) and prokaryotic cells (e.g., E. coli). Bispecific antibody molecules can be produced by separate expression of the components in different host cells and subsequent purification/assembly. Alternatively, the antibody molecules can be produced by expression of the components in a single host cell. Purification of bispecific antibody molecules can be performed by various methods such as affinity chromatography, e.g., using protein A and sequential pH elution. In other embodiments, affinity tags can be used for purification, e.g., histidine-containing tag, myc tag, or streptavidin tag.

Multispecific Antibody Molecules Targeting CSF1R

In one aspect, disclosed herein is a multispecific antibody molecule comprising a CSF1R binding moiety. In some embodiments, the CSF1R binding moiety comprises an anti-CSF1R antibody molecule. Exemplary anti-CSF1R antibody molecule sequences are described in WO2009026303A1; WO2011123381A1; WO2016207312A1; WO2016106180A1; US20160220669A1; US20160326254A1; WO2013169264A1; WO2013087699A1; WO2011140249A2; WO2011131407A1; WO2011123381A1; WO2011107553A1; and WO2011070024A1, all of which are herein incorporated by reference in their entirety. In some embodiments, the CSF1R binding moiety comprises the CDR (e.g., one, two, three, four, five, or all six CDRs), VH, VL, heavy chain, or light chain sequences of emactuzumab, or a sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the CSF1R binding moiety comprises the CDR (e.g., one, two, three, four, five, or all six CDRs), VH, VL, heavy chain, or light chain sequences of cabiralizumab, or a sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the CSF1R binding moiety comprises the CDR (e.g., one, two, three, four, five, or all six CDRs), VH, VL, heavy chain, or light chain sequences of AMG820, or a sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the CSF1R binding moiety comprises the CDR (e.g., one, two, three, four, five, or all six CDRs), VH, VL, heavy chain, or light chain sequences of IMC-CS4, or a sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the CSF1R binding moiety comprises a VH or VL amino acid sequence disclosed in Table 1, a CDR of a VH or VL amino acid sequence disclosed in Table 1, or a sequence substantially identical thereto.

TABLE 1

Exemplary anti-CSF1R antibody molecule sequences

SEQ ID

NO
Description
Sequence

SEQ ID
αmCSF1R VH
QVQLQQSGAELVKPGSSVKISCKASGYTFTSNFMHWIKQQPGNG

NO: 48

LEWIGWIYPGDGDTEYNQKFNGKATLTADKSSSTAYMQLSSLTS

EDSAVYFCAVNYGGYVLDAWGQGASVTVSS

SEQ ID
αmCSF1R VL
EIVLTQSPTTMAASPGEKVTITCRASSSTNYMSWYQQKSGASPKP

NO: 50

WIYETSKLASGVPDRFSGSGSGTSYSFTISSMETEDAATYYCHQW

SSTPLTFGSGTKLEIK

SEQ ID
αhCSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQG

NO: 66
emactuzumab
LEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRS

VH
DDTAVYYCARDQRLYFDVWGQGTTVTVSS

SEQ ID
αhCSF1R
DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAP

NO: 67
emactuzumab
KLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ

VL
SFSYPTFGQGTKLEIK

SEQ ID
αhCSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQ

NO: 69
cabiralizumab
GLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLR

VH
SEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS

SEQ ID
αhCSF1R
EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKP

NO: 70
cabiralizumab
GQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYY

VL
CHLSNEDLSTFGGGTKVEIK

Multispecific Antibody Molecules Targeting CCR2

In one aspect, disclosed herein is a multispecific antibody molecule comprising a CCR2 binding moiety. Exemplary CCR2 antibodies are described herein as well as in WO2013192596A2; WO2010021697A2; WO2001057226A1; and WO1997031949A1, all of which are herein incorporated by reference in their entirety. In some embodiments, the CCR2 binding moiety comprises the CDR (e.g., one, two, three, four, five, or all six CDRs), VH, VL, heavy chain, or light chain sequences of plozalizumab, or a sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the CCR2 binding moiety comprises a VH or VL amino acid sequence disclosed in Table 2, a CDR of a VH or VL amino acid sequence disclosed in Table 2, or a sequence substantially identical thereto.

TABLE 2

Exemplary anti-CCR2 antibody molecule sequences

SEQ ID

NO
Description
Sequence

SEQ ID
αCCR2 MC12
QVQLQESGPGLVQPSQTLSLTCTVSGFSLTDFSVHWVRQPPGKG

NO: 44
VH
LEWMGRIRSEGNTDYNSALKSRLSISRDTSKSQVFLKMNSLQTE

DTAIYFCTRGDILGFGYWGQGVMVTVSS

SEQ ID
αCCR2 MC12
DIVMTQSPLSVSVTPGESASISCRSSKSLLHFKGITFVYWYLQKPG

NO: 45
VL
QSPQLLIFRMSSLASGVPDRFSGSGSETDFTLKISRVEAEDVGTYY

CGQLLENPYTFGAGTKLELK

SEQ ID
αhCCR2
EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGK

NO: 54
plozalizumab
GLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMN

VH
SLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS

SEQ ID
αhCCR2
DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRP

NO: 57
plozalizumab
GQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGV

VL
YYCWQGTHFPYTFGQGTRLEIK

SEQ ID
αhCCR2 D1
EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYHMHWVRQAPG

NO: 59
VH
QGLEWMGWINPNSGVTKYAQKFQGRVTMTRDTSINTAYMELS

RLRFDDTDVYYCATGGFGYWGEGTLVTVSS

SEQ ID
αhCCR2 D1
LPVLTQPPSVSKGLRQTATLTCTGNSNNVGNQGAAWLQQHQGQ

NO: 60
VL
PPKLLSYRNHNRPSGVSERFSPSRSGDTSSLTITGLQPEDEADYYC

LAWDSSLRAFVFGTGTKLTVL

SEQ ID
αhCCR2
QVQLVQSGAEVKKPGASVKVSCKASGYTFSSYYMHWVRQAPG

NO: 62
42G7 VH
QGLEWMGIINPSGGNTSYAQKFQGRVTMTRDTSTSTVYMELSSL

RSEDTAVYYCARGGYQLPHGRARAFDMWGQGTMVTVSS

SEQ ID
αhCCR2
AIRMTQSPLSLPVTLGQPASISCTSSQSLVYRDGTTYLNWFQQRP

NO: 63
42G7 VL
GQSPRRLIYKVSNRDSGVPDRFTGSGSGTTFTLTISRVEAEDVGIY

YCMQGTHWPLTFGQGTKVEIK

SEQ ID
αhCCR2
EVQLVESGGGLVQPGGSLRLSCVASGFTFSDYWMSWVRQAPGK

NO: 64
43G12 VH
GLEWVANIKKDGSVNYYVDSVKGRFTISRDNAKNSLYLQMNSL

RAEDTAVYYCTRFDYWGQGTLVTVSS

SEQ ID
αhCCR2
QAGLTQPPSVSKGLRQTATLTCTGNSNNVGNQGAAWLQQHQG

NO: 65
43G12 VL
HPPKLLFYRNNNRASGISERLSASRSGNTASLTITGLQPEDEADY

YCLTWDSSLSVVVFGGGTKLTVL

Multispecific Antibody Molecules Targeting PD-L1

In one aspect, disclosed herein is a multispecific antibody molecule comprising a PD-L1 binding moiety. In some embodiments, the PD-L1 binding moiety comprises an anti-PD-L1 antibody molecule. Exemplary anti-PD-L1 antibody molecule sequences are described in WO2013079174, WO 2010077634, WO2007/005874, and US20120039906, all of which are herein incorporated by reference in their entirety. In some embodiments, the PD-L1 binding moiety comprises the CDR (e.g., one, two, three, four, five, or all six CDRs), VH, VL, heavy chain, or light chain sequences of durvalumab, or a sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the PD-L1 binding moiety comprises the CDR (e.g., one, two, three, four, five, or all six CDRs), VH, VL, heavy chain, or light chain sequences of atezolizumab, or a sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the PD-L1 binding moiety comprises the CDR (e.g., one, two, three, four, five, or all six CDRs), VH, VL, heavy chain, or light chain sequences of avelumab, or a sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the PD-L1 binding moiety comprises a VH or VL amino acid sequence disclosed in Table 3, a CDR of a VH or VL amino acid sequence disclosed in Table 3, or a sequence substantially identical thereto.

TABLE 3

Exemplary anti-PD-L1 antibody molecule sequences

SEQ ID

NO
Description
Sequence

SEQ ID
αPD-L1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGK

NO: 109
durvalumab
GLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSL

VH
RAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS

SEQ ID
αPD-L1
EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAP

NO: 110
durvalumab
RLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQ

VL
YGSLPWTFGQGTKVEIK

SEQ ID
αPD-L1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGK

NO: 111
atezolizumab
GLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSL

VH
RAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS

SEQ ID
αPD-L1
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAP

NO: 112
atezolizumab
KLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ

VL
YLYHPATFGQGTKVEIK

SEQ ID
αPD-L1
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGK

NO: 113
avelumab VH
GLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRA

EDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS

SEQ ID
αPD-L1
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGK

NO: 114
avelumab VL
APKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYY

CSSYTSSSTRVFGTGTKVTVL

CDR-Grafted Scaffolds

In embodiments, the antibody molecule is a CDR-grafted scaffold domain. In embodiments, the scaffold domain is based on a fibronectin domain, e.g., fibronectin type III domain. The overall fold of the fibronectin type III (Fn3) domain is closely related to that of the smallest functional antibody fragment, the variable region of the antibody heavy chain. There are three loops at the end of Fn3; the positions of BC, DE and FG loops approximately correspond to those of CDR1, 2 and 3 of the VH domain of an antibody. Fn3 does not have disulfide bonds; and therefore Fn3 is stable under reducing conditions, unlike antibodies and their fragments (see, e.g., WO 98/56915; WO 01/64942; WO 00/34784). An Fn3 domain can be modified (e.g., using CDRs or hypervariable loops described herein) or varied, e.g., to select domains that bind to an antigen/marker/cell described herein.

In embodiments, a scaffold domain, e.g., a folded domain, is based on an antibody, e.g., a “minibody” scaffold created by deleting three beta strands from a heavy chain variable region of a monoclonal antibody (see, e.g., Tramontano et al., 1994, J Mol. Recognit. 7:9; and Martin et al., 1994, EMBO J. 13:5303-5309). The “minibody” can be used to present two hypervariable loops. In embodiments, the scaffold domain is a V-like domain (see, e.g., Coia et al. WO 99/45110) or a domain derived from tendamistatin, which is a 74 residue, six-strand beta sheet sandwich held together by two disulfide bonds (see, e.g., McConnell and Hoess, 1995, J Mol. Biol. 250:460). For example, the loops of tendamistatin can be modified (e.g., using CDRs or hypervariable loops) or varied, e.g., to select domains that bind to a marker/antigen/cell described herein. Another exemplary scaffold domain is a beta-sandwich structure derived from the extracellular domain of CTLA-4 (see, e.g., WO 00/60070).

Other exemplary scaffold domains include but are not limited to T-cell receptors; MHC proteins; extracellular domains (e.g., fibronectin Type III repeats, EGF repeats); protease inhibitors (e.g., Kunitz domains, ecotin, BPTI, and so forth); TPR repeats; trifoil structures; zinc finger domains; DNA-binding proteins; particularly monomeric DNA binding proteins; RNA binding proteins; enzymes, e.g., proteases (particularly inactivated proteases), RNase; chaperones, e.g., thioredoxin, and heat shock proteins; and intracellular signaling domains (such as SH2 and SH3 domains). See, e.g., US 20040009530 and U.S. Pat. No. 7,501,121, incorporated herein by reference.

In embodiments, a scaffold domain is evaluated and chosen, e.g., by one or more of the following criteria: (1) amino acid sequence, (2) sequences of several homologous domains, (3) 3-dimensional structure, and/or (4) stability data over a range of pH, temperature, salinity, organic solvent, oxidant concentration. In embodiments, the scaffold domain is a small, stable protein domain, e.g., a protein of less than 100, 70, 50, 40 or 30 amino acids. The domain may include one or more disulfide bonds or may chelate a metal, e.g., zinc.

Exemplary structures of the multifunctional molecules defined herein are described below. Exemplary structures are further described in: Weidle U et al. (2013) The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer. Cancer Genomics & Proteomics 10: 1-18 (2013); and Spiess C et al. (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular Immunology 67: 95-106; the full contents of each of which is incorporated by reference herein).

Heterodimerized Antibody Molecules

Heterodimerized bispecific antibodies are based on the natural IgG structure, wherein the two binding arms recognize different antigens. IgG derived formats that enable defined monovalent (and simultaneous) antigen binding are generated by forced heavy chain heterodimerization, combined with technologies that minimize light chain mispairing (e.g., common light chain). Forced heavy chain heterodimerization can be obtained using, e.g., knob-in-hole OR strand exchange engineered domains (SEED).

Knob-In-Hole

Knob-in-Hole as described in U.S. Pat. Nos. 5,731,116, 7,476,724 and Ridgway, J. et al. (1996) Prot. Engineering 9(7): 617-621, broadly involves: (1) mutating the CH3 domain of one or both antibodies to promote heterodimerization; and (2) combining the mutated antibodies under conditions that promote heterodimerization. “Knobs” or “protuberances” are typically created by replacing a small amino acid in a parental antibody with a larger amino acid (e.g., T366Y or T366W); “Holes” or “cavities” are created by replacing a larger residue in a parental antibody with a smaller amino acid (e.g., Y407T, T366S, I368A and/or Y407V), numbered based on the Eu numbering system.

Strand Exchange Engineered Domains (SEED)

SEED is based on sequence exchanges between IgG1 and IgA to create non-identical chains which heterodimerize preferentially. Alternating sequences from human IgA and IgG in the SEED CH3 domains generate two asymmetric but complementary domains, designated AG and GA. The SEED design allows efficient generation of AG/GA heterodimers, while disfavoring homodimerization of AG and GA SEED CH3 domains.

Common Light Chain & CrossMab

Light chain mispairing must be avoided to generate homogenous preparations of bispecific IgGs. One way to achieve this is through the use of the common light chain principle, i.e. combining two binders that share one light chain but still have separate specificities. Another option is the CrossMab technology which avoids non-specific L chain mispairing by exchanging CH1 and CL domains in the Fab of one half of the bispecific antibody. Such crossover variants retain binding specificity and affinity, but make the two arms so different that L chain mispairing is prevented.

Antibody-Based Fusions

A variety of formats can be generated which contain additional binding entities attached to the N or C terminus of antibodies. These fusions with single chain or disulfide stabilized Fvs or Fabs result in the generation of tetravalent molecules with bivalent binding specificity for each antigen. Combinations of scFvs and scFabs with IgGs enable the production of molecules which can recognize three or more different antigens.

Antibody-Fab Fusion

Antibody-Fab fusions are bispecific antibodies comprising a traditional antibody to a first target and a Fab to a second target fused to the C terminus of the antibody heavy chain. Commonly the antibody and the Fab will have a common light chain. Antibody fusions can be produced by (1) engineering the DNA sequence of the target fusion, and (2) transfecting the target DNA into a suitable host cell to express the fusion protein. It seems like the antibody-scFv fusion may be linked by a (Gly)-Ser linker between the C-terminus of the CH3 domain and the N-terminus of the scFv, as described by Coloma, J. et al. (1997) Nature Biotech 15:159.

Antibody-scFv Fusion

Antibody-scFv Fusions are bispecific antibodies comprising a traditional antibody and a scFv of unique specificity fused to the C terminus of the antibody heavy chain. The scFv can be fused to the C terminus through the Heavy Chain of the scFv either directly or through a linker peptide. Antibody fusions can be produced by (1) engineering the DNA sequence of the target fusion, and (2) transfecting the target DNA into a suitable host cell to express the fusion protein. It seems like the antibody-scFv fusion may be linked by a (Gly)-Ser linker between the C-terminus of the CH3 domain and the N-terminus of the scFv, as described by Coloma, J. et al. (1997) Nature Biotech 15:159.

Variable Domain Immunoglobulin DVD

A related format is the dual variable domain immunoglobulin (DVD), which are composed of VH and VL domains of a second specificity place upon the N termini of the V domains by shorter linker sequences.

Fc-Containing Entities (Mini-Antibodies)

Fc-containing entities, also known as mini-antibodies, can be generated by fusing scFv to the C-termini of constant heavy region domain 3 (CH3-scFv) and/or to the hinge region (scFv-hinge-Fc) of an antibody with a different specificity. Trivalent entities can also be made which have disulfide stabilized variable regions (without peptide linker) fused to the C-terminus of CH3 domains of IgGs.

Fc-Less Bispecifics

Fc-less bispecifics are characterized by generally having smaller size than Fc-containing entities. Common bispecific of this class include Fab-scFv2 and Fab-scFv molecules. This class also includes, e.g., BiTEs (bispecific T-cell engagers), diabodies, TandAbs (tetravalent tandem antibodies), and DARTs (dual affinity retargeting molecules). BiTEs are created by fusing two scFvs via a flexible linker peptide. Diabodies consist of two VH and two VL domains from two different antibodies. Interaction only with complementary domains on another chain is achieved by attaching domains with short linker peptides which permits pairing only with VH and VL domains. VH of the first binder linked to the VL of the second binder is co-expressed with the VH of the second antibody linked to VL of the first antibody. TandAbs molecules are generated by functional dimerization of a protein consisting of four antibody variable H- and L-chains in an orientation that prevents intramolecular pairing. DARTs are entities that are stabilized by disulfide bonds which apply a similar design concept to that of diabodies.

Kappa/Lambda Formats

Multispecific molecules (e.g., multispecific antibody molecules) that include the lambda light chain polypeptide and a kappa light chain polypeptides, can be used to allow for heterodimerization. Methods for generating bispecific antibody molecules comprising the lambda light chain polypeptide and a kappa light chain polypeptides are disclosed in PCT/US2017/53053 filed on Sep. 22, 2017, incorporated herein by reference in its entirety.

In embodiments, the multispecific molecules include a multispecific antibody molecule, e.g., an antibody molecule comprising two binding specificities, e.g., a bispecific antibody molecule. The multispecific antibody molecule includes:

a lambda light chain polypeptide 1 (LLCP1) specific for a first epitope;

a heavy chain polypeptide 1 (HCP1) specific for the first epitope;

a kappa light chain polypeptide 2 (KLCP2) specific for a second epitope; and

a heavy chain polypeptide 2 (HCP2) specific for the second epitope.

“Lambda light chain polypeptide 1 (LLCP1)”, as that term is used herein, refers to a polypeptide comprising sufficient light chain (LC) sequence, such that when combined with a cognate heavy chain variable region, can mediate specific binding to its epitope and complex with an HCP1. In an embodiment it comprises all or a fragment of a CH1 region. In an embodiment, an LLCP1 comprises LC-CDR1, LC-CDR2, LC-CDR3, FR1, FR2, FR3, FR4, and CH1, or sufficient sequence therefrom to mediate specific binding of its epitope and complex with an HCP1. LLCP1, together with its HCP1, provide specificity for a first epitope (while KLCP2, together with its HCP2, provide specificity for a second epitope). As described elsewhere herein, LLCP1 has a higher affinity for HCP1 than for HCP2.

“Kappa light chain polypeptide 2 (KLCP2)”, as that term is used herein, refers to a polypeptide comprising sufficient light chain (LC) sequence, such that when combined with a cognate heavy chain variable region, can mediate specific binding to its epitope and complex with an HCP2. In an embodiments it comprises all or a fragment of a CH1 region. In an embodiment, a KLCP2 comprises LC-CDR1, LC-CDR2, LC-CDR3, FR1, FR2, FR3, FR4, and CH1, or sufficient sequence therefrom to mediate specific binding of its epitope and complex with an HCP2. KLCP2, together with its HCP2, provide specificity for a second epitope (while LLCP1, together with its HCP1, provide specificity for a first epitope).

“Heavy chain polypeptide 1 (HCP1)”, as that term is used herein, refers to a polypeptide comprising sufficient heavy chain (HC) sequence, e.g., HC variable region sequence, such that when combined with a cognate LLCP1, can mediate specific binding to its epitope and complex with an HCP1. In an embodiments it comprises all or a fragment of a CH1region. In an embodiment, it comprises all or a fragment of a CH2 and/or CH3 region. In an embodiment an HCP1 comprises HC-CDR1, HC-CDR2, HC-CDR3, FR1, FR2, FR3, FR4, CH1, CH2, and CH3, or sufficient sequence therefrom to: (i) mediate specific binding of its epitope and complex with an LLCP1, (ii) to complex preferentially, as described herein to LLCP1 as opposed to KLCP2; and (iii) to complex preferentially, as described herein, to an HCP2, as opposed to another molecule of HCP1. HCP1, together with its LLCP1, provide specificity for a first epitope (while KLCP2, together with its HCP2, provide specificity for a second epitope).

“Heavy chain polypeptide 2 (HCP2)”, as that term is used herein, refers to a polypeptide comprising sufficient heavy chain (HC) sequence, e.g., HC variable region sequence, such that when combined with a cognate LLCP1, can mediate specific binding to its epitope and complex with an HCP1. In an embodiments it comprises all or a fragment of a CH1region. In an embodiments it comprises all or a fragment of a CH2 and/or CH3 region. In an embodiment an HCP1 comprises HC-CDR1, HC-CDR2, HC-CDR3, FR1, FR2, FR3, FR4, CH1, CH2, and CH3, or sufficient sequence therefrom to: (i) mediate specific binding of its epitope and complex with an KLCP2, (ii) to complex preferentially, as described herein to KLCP2 as opposed to LLCP1; and (iii) to complex preferentially, as described herein, to an HCP1, as opposed to another molecule of HCP2. HCP2, together with its KLCP2, provide specificity for a second epitope (while LLCP1, together with its HCP1, provide specificity for a first epitope).

In some embodiments of the multispecific antibody molecule disclosed herein:

LLCP1 has a higher affinity for HCP1 than for HCP2; and/or

KLCP2 has a higher affinity for HCP2 than for HCP1.

In embodiments, the affinity of LLCP1 for HCP1 is sufficiently greater than its affinity for HCP2, such that under preselected conditions, e.g., in aqueous buffer, e.g., at pH 7, in saline, e.g., at pH 7, or under physiological conditions, at least 75%, 80, 90, 95, 98, 99, 99.5, or 99.9% of the multispecific antibody molecule molecules have a LLCP1complexed, or interfaced with, a HCP1.

In some embodiments of the multispecific antibody molecule disclosed herein:

the HCP1 has a greater affinity for HCP2, than for a second molecule of HCP1; and/or

the HCP2 has a greater affinity for HCP1, than for a second molecule of HCP2.

In embodiments, the affinity of HCP1 for HCP2 is sufficiently greater than its affinity for a second molecule of HCP1, such that under preselected conditions, e.g., in aqueous buffer, e.g., at pH 7, in saline, e.g., at pH 7, or under physiological conditions, at least 75%, 80, 90, 95, 98, 99 99.5 or 99.9% of the multispecific antibody molecule molecules have a HCP1complexed, or interfaced with, a HCP2.

In another aspect, disclosed herein is a method for making, or producing, a multispecific antibody molecule. The method includes:

(i) providing a first heavy chain polypeptide (e.g., a heavy chain polypeptide comprising one, two, three or all of a first heavy chain variable region (first VH), a first CH1, a first heavy chain constant region (e.g., a first CH2, a first CH3, or both));

(ii) providing a second heavy chain polypeptide (e.g., a heavy chain polypeptide comprising one, two, three or all of a second heavy chain variable region (second VH), a second CH1, a second heavy chain constant region (e.g., a second CH2, a second CH3, or both));

(iii) providing a lambda chain polypeptide (e.g., a lambda light variable region (VLλ), a lambda light constant chain (VLλ), or both) that preferentially associates with the first heavy chain polypeptide (e.g., the first VH); and

(iv) providing a kappa chain polypeptide (e.g., a lambda light variable region (VLκ), a lambda light constant chain (VLκ), or both) that preferentially associates with the second heavy chain polypeptide (e.g., the second VH),

under conditions where (i)-(iv) associate.

In embodiments, the first and second heavy chain polypeptides form an Fc interface that enhances heterodimerization.

In embodiments, (i)-(iv) (e.g., nucleic acid encoding (i)-(iv)) are introduced in a single cell, e.g., a single mammalian cell, e.g., a CHO cell. In embodiments, (i)-(iv) are expressed in the cell.

In embodiments, (i)-(iv) (e.g., nucleic acid encoding (i)-(iv)) are introduced in different cells, e.g., different mammalian cells, e.g., two or more CHO cell. In embodiments, (i)-(iv) are expressed in the cells.

In one embodiments, the method further comprises purifying a cell-expressed antibody molecule, e.g., using a lambda- and/or- kappa-specific purification, e.g., affinity chromatography.

In embodiments, the method further comprises evaluating the cell-expressed multispecific antibody molecule. For example, the purified cell-expressed multispecific antibody molecule can be analyzed by techniques known in the art, include mass spectrometry. In one embodiment, the purified cell-expressed antibody molecule is cleaved, e.g., digested with papain to yield the Fab moieties and evaluated using mass spectrometry.

In embodiments, the method produces correctly paired kappa/lambda multispecific, e.g., bispecific, antibody molecules in a high yield, e.g., at least 75%, 80, 90, 95, 98, 99 99.5 or 99.9%.

In other embodiments, the multispecific, e.g., a bispecific, antibody molecule that includes:

(i) a first heavy chain polypeptide (HCP1) (e.g., a heavy chain polypeptide comprising one, two, three or all of a first heavy chain variable region (first VH), a first CH1, a first heavy chain constant region (e.g., a first CH2, a first CH3, or both)), e.g., wherein the HCP1 binds to a first epitope;

(ii) a second heavy chain polypeptide (HCP2) (e.g., a heavy chain polypeptide comprising one, two, three or all of a second heavy chain variable region (second VH), a second CH1, a second heavy chain constant region (e.g., a second CH2, a second CH3, or both)), e.g., wherein the HCP2 binds to a second epitope;

(iii) a lambda light chain polypeptide (LLCP1) (e.g., a lambda light variable region (VL1), a lambda light constant chain (VL1), or both) that preferentially associates with the first heavy chain polypeptide (e.g., the first VH), e.g., wherein the LLCP1 binds to a first epitope; and

(iv) a kappa light chain polypeptide (KLCP2) (e.g., a lambda light variable region (VLk), a lambda light constant chain (VLk), or both) that preferentially associates with the second heavy chain polypeptide (e.g., the second VH), e.g., wherein the KLCP2 binds to a second epitope.

In embodiments, the first and second heavy chain polypeptides form an Fc interface that enhances heterodimerization. In embodiments, the multispecific antibody molecule has a first binding specificity that includes a hybrid VL1-CL1 heterodimerized to a first heavy chain variable region connected to the Fc constant, CH2-CH3 domain (having a knob modification) and a second binding specificity that includes a hybrid VLk-CLk heterodimerized to a second heavy chain variable region connected to the Fc constant, CH2-CH3 domain (having a hole modification).

Multispecific Molecules Comprising Non-Contiguous Polypeptides

In one embodiment, the multispecific molecule is not a single polypeptide chain.

In one embodiment, the antibody molecule includes two, complete heavy chains and two, complete light chains. In one embodiment, the multispecific molecules having at least two or at least three non-contiguous polypeptide chains include a first and second heavy chain constant regions (e.g., a first and second Fc region) in at least two non-contiguous polypeptide chains, e.g., as described herein.

In embodiments, the multispecific molecule is a bispecific or bifunctional molecule, wherein the first and second polypeptides (i) and (ii) are non-contiguous, e.g., are two separate polypeptide chains. In some embodiments, the first and second polypeptides (i) and (ii) include a paired amino acid substitution at a position chosen from one or more of 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, e.g., of the Fc region of human IgG1, numbered based on the Eu numbering system. For example, the first heavy chain constant region (e.g., the first Fc region) can include an amino acid substitution chosen from: T366S, L368A, or Y407V (e.g., corresponding to a cavity or hole), and the second heavy chain constant region (e.g., the second Fc region) includes a T366W (e.g., corresponding to a protuberance or knob), numbered based on the Eu numbering system. In some embodiments, the first and second polypeptides are a first and second member of a heterodimeric first and second Fc region.

In some embodiments, the first polypeptide has the following configuration from N-to-C:

(a) a first portion of a first antigen domain, e.g., a first VH-CH1 of a Fab molecule, that binds to a first antigen, e.g., CSF1R, connected, optionally via a linker to, the first heavy chain constant region (e.g., the CH2 connected to the CH3 region) (e.g., a first Fc region); (b) a first portion of a second antigen domain, e.g., a second VH-CH1 of a Fab molecule, that binds to a second antigen, e.g., CCR2 or CXCR2, connected, optionally via a linker to, the second heavy chain constant region (e.g., the CH2 connected to the CH3 region) (e.g., a first Fc region); (c) the third polypeptide has the following configuration from N-to-C: a second portion of the first antigen domain, e.g., a first VL-CL of the Fab, where the VL is of kappa subtype and binds to the first antigen, e.g., CSF1R (e.g., the same antigen bound by the first VH-CH1); (d) the fourth polypeptide has the following configuration from N-to-C: a second portion of the second antigen domain, e.g. a second VL-CL of the Fab, where the VL is of lambda subtype and binds to a second antigen, e.g., a cancer antigen, e.g., CCR2 or CXCR2 (e.g., the same antigen bound by the second VH-CH1).

In embodiments, the first heavy chain constant region (e.g., the first CH2-CH3 region) includes a protuberance or knob, e.g., as described herein. In embodiments, the second heavy chain constant region (e.g., the second CH2-CH3 region) includes a cavity or hole. In embodiments, the first and second heavy chain constant regions promote heterodimerization of the bispecific molecule.

TGF-Beta Inhibitor

In one aspect, provided herein is a multispecific antibody molecule comprising a TGF-beta inhibitor. In some embodiments, the TGF-beta inhibitor binds to and inhibits TGF-beta, e.g., reduces the activity of TGF-beta. In some embodiments, the TGF-beta inhibitor inhibits (e.g., reduces the activity of) TGF-beta 1. In some embodiments, the TGF-beta inhibitor inhibits (e.g., reduces the activity of) TGF-beta 2. In some embodiments, the TGF-beta inhibitor inhibits (e.g., reduces the activity of) TGF-beta 3. In some embodiments, the TGF-beta inhibitor inhibits (e.g., reduces the activity of) TGF-beta 1 and TGF-beta 3. In some embodiments, the TGF-beta inhibitor inhibits (e.g., reduces the activity of) TGF-beta 1, TGF-beta 2, and TGF-beta 3.

In some embodiments, the TGF-beta inhibitor comprises a portion of a TGF-beta receptor (e.g., an extracellular domain of a TGF-beta receptor) that is capable of inhibiting (e.g., reducing the activity of) TGF-beta, or functional fragment or variant thereof. In some embodiments, the TGF-beta inhibitor comprises a TGFBR1 polypeptide (e.g., an extracellular domain of TGFBR1 or functional variant thereof). In some embodiments, the TGF-beta inhibitor comprises a TGFBR2 polypeptide (e.g., an extracellular domain of TGFBR2 or functional variant thereof). In some embodiments, the TGF-beta inhibitor comprises a TGFBR3 polypeptide (e.g., an extracellular domain of TGFBR3 or functional variant thereof). In some embodiments, the TGF-beta inhibitor comprises a TGFBR1 polypeptide (e.g., an extracellular domain of TGFBR1 or functional variant thereof) and a TGFBR2 polypeptide (e.g., an extracellular domain of TGFBR2 or functional variant thereof). In some embodiments, the TGF-beta inhibitor comprises a TGFBR1 polypeptide (e.g., an extracellular domain of TGFBR1 or functional variant thereof) and a TGFBR3 polypeptide (e.g., an extracellular domain of TGFBR3 or functional variant thereof). In some embodiments, the TGF-beta inhibitor comprises a TGFBR2 polypeptide (e.g., an extracellular domain of TGFBR2 or functional variant thereof) and a TGFBR3 polypeptide (e.g., an extracellular domain of TGFBR3 or functional variant thereof).

Exemplary TGF-beta receptor polypeptides that can be used as TGF-beta inhibitors have been disclosed in U.S. Pat. Nos. 8,993,524, 9,676,863, 8,658,135, US20150056199, US20070184052, and WO2017037634, all of which are herein incorporated by reference in their entirety.

In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of TGFBR1 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 95, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 96, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 97, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 104, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 105, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of TGFBR2 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 98, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 99, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 100, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 101, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 102, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 103, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of TGFBR3 or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 106, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises an extracellular domain of SEQ ID NO: 107, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-beta inhibitor comprises the amino acid sequence of SEQ ID NO: 108, or a sequence substantially identical thereto (e.g., a sequence that is at least 80%, 85%, 90%, or 95% identical thereto).

In some embodiments, the TGF-beta inhibitor comprises no more than one TGF-beta receptor extracellular domain. In some embodiments, the TGF-beta inhibitor comprises two or more (e.g., two, three, four, five, or more) TGF-beta receptor extracellular domains, linked together, e.g., via a linker.

TABLE 4

Exemplary amino acid sequences of TGF-beta polypeptides

or TGF-beta receptor polypeptides

SEQ ID

NO
Description
Amino acid sequence

SEQ ID
Immature
MPPSGLRLLLLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIE

NO: 92
human
AIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEP

TGF-beta 1
EPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELRE

(P01137-1)
AVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLA

PSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQV

DINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRAL

DTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGP

CPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVG

RKPKVEQLSNMIVRSCKCS

SEQ ID
Human
LSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAV

NO: 117
TGF-beta 1
LALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDK

(P01137-1)
FKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVEL

YQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIE

GFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLM

ATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLG

WKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASA

APCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS

SEQ ID
Immature
MHYCVLSAFLILHLVTVALSLSTCSTLDMDQFMRKRIEAIRGQILSK

NO: 93
human
LKLTSPPEDYPEPEEVPPEVISIYNSTRDLLQEKASRRAAACERERSD

TGF-beta 2
EEYYAKEVYKIDMPPFFPSENAIPPTFYRPYFRIVRFDVSAMEKNAS

(P61812-1)
NLVKAEFRVFRLQNPKARVPEQRIELYQILKSKDLTSPTQRYIDSKV

VKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPS

NNYIIPNKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLL

LMLLPSYRLESQQTNRRKKRALDAAYCFRNVQDNCCLRPLYIDFKR

DLGWKWIHEPKGYNANFCAGACPYLWSSDTQHSRVLSLYNTINPE

ASASPCCVSQDLEPLTILYYIGKTPKIEQLSNMIVKSCKCS

SEQ ID
Human
LSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEPEEVPPEVIS

NO: 118
TGF-beta 2
IYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPPFFPSEN

(P61812-1)
AIPPTFYRPYFRIVRFDVSAMEKNASNLVKAEFRVFRLQNPKARVPE

QRIELYQILKSKDLTSPTQRYIDSKVVKTRAEGEWLSFDVTDAVHE

WLHHKDRNLGFKISLHCPCCTFVPSNNYIIPNKSEELEARFAGIDGTS

TYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQTNRRKKRA

LDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAG

ACPYLWSSDTQHSRVLSLYNTINPEASASPCCVSQDLEPLTILYYIGK

TPKIEQLSNMIVKSCKCS

SEQ ID
Immature
MKMHLQRALVVLALLNFATVSLSLSTCTTLDFGHIKKKRVEAIRGQ

NO: 94
human
ILSKLRLTSPPEPTVMTHVPYQVLALYNSTRELLEEMHGEREEGCTQ

TGF-beta 3
ENTESEYYAKEIHKFDMIQGLAEHNELAVCPKGITSKVFRFNVSSVE

(P10600-1)
KNRTNLFRAEFRVLRVPNPSSKRNEQRIELFQILRPDEHIAKQRYIGG

KNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPN

GDILENIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHNPHLIL

MMIPPHRLDNPGQGGQRKKRALDTNYCFRNLEENCCVRPLYIDFRQ

DLGWKWVHEPKGYYANFCSGPCPYLRSADTTHSTVLGLYNTLNPE

ASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKCS

SEQ ID
Human
LSTCTTLDFGHIKKKRVEAIRGQILSKLRLTSPPEPTVMTHVPYQVL

NO: 119
TGF-beta 3
ALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGLAE

(P10600-1)
HNELAVCPKGITSKVFRFNVSSVEKNRTNLFRAEFRVLRVPNPSSKR

NEQRIELFQILRPDEHIAKQRYIGGKNLPTRGTAEWLSFDVTDTVRE

WLLRRESNLGLEISIHCPCHTFQPNGDILENIHEVMEIKFKGVDNED

DHGRGDLGRLKKQKDHHNPHLILMMIPPHRLDNPGQGGQRKKRAL

DTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGP

CPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGR

TPKVEQLSNMVVKSCKCS

SEQ ID
Immature
MEAAVAAPRPRLLLLVLAAAAAAAAALLPGATALQCFCHLCTKDN

NO: 95
human
FTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTG

TGFBR1
SVTTTYCCNQDHCNKIELPTTVKSSPGLGPVELAAVIAGPVCFVCISL

isoform 1
MLMVYICHNRTVIHHRVPNEEDPSLDRPFISEGTTLKDLIYDMTTSG

(P36897-1)
SGSGLPLLVQRTIARTIVLQESIGKGRFGEVWRGKWRGEEVAVKIFS

SREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSD

YHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKP

AIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVG

TKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGI

HEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALR

VMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM

SEQ ID
Human
LQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPR

NO: 120
TGFBR1
DRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVELA

isoform 1
AVIAGPVCFVCISLMLMVYICHNRTVIHHRVPNEEDPSLDRPFISEGT

(P36897-1)
TLKDLIYDMTTSGSGSGLPLLVQRTIARTIVLQESIGKGRFGEVWRG

KWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNK

DNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGL

AHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHD

SATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMG

LVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRP

NIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQ

QEGIKM

SEQ ID
Immature
MEAAVAAPRPRLLLLVLAAAAAAAAALLPGATALQCFCHLCTKDN

NO: 96
human
FTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTG

TGFBR1
SVTTTYCCNQDHCNKIELPTTGPFSVKSSPGLGPVELAAVIAGPVCF

isoform 2
VCISLMLMVYICHNRTVIHHRVPNEEDPSLDRPFISEGTTLKDLIYD

(P36897-2)
MTTSGSGSGLPLLVQRTIARTIVLQESIGKGRFGEVWRGKWRGEEV

AVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQ

LWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEI

VGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDI

APNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIA

RRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRW

QSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM

SEQ ID
Human
LQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPR

NO: 121
TGFBR1
DRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTGPFSVKSSPGLGP

isoform 2
VELAAVIAGPVCFVCISLMLMVYICHNRTVIHHRVPNEEDPSLDRPFI

(P36897-2)
SEGTTLKDLIYDMTTSGSGSGLPLLVQRTIARTIVLQESIGKGRFGEV

WRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAA

DNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALST

ASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLA

VRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADI

YAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCE

QKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTL

SQLSQQEGIKM

SEQ ID
Immature
MEAAVAAPRPRLLLLVLAAAAAAAAALLPGATALQCFCHLCTKDN

NO: 97
human
FTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTG

TGFBR1
SVTTTYCCNQDHCNKIELPTTGLPLLVQRTIARTIVLQESIGKGRFGE

isoform 3
VWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIA

(P36897-3)
ADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALS

TASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGL

AVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRAD

IYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVC

EQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKT

LSQLSQQEGIKM

SEQ ID
Human
LQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPR

NO: 122
TGFBR1
DRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTGLPLLVQRTIARTI

isoform 3
VLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQT

(P36897-3)
VMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYT

VTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVK

KNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSI

NMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPS

DPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYAN

GAARLTALRIKKTLSQLSQQEGIKM

SEQ ID
Human
LQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPR

NO: 104
TGFBR1
DRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVEL

fragment 1

SEQ ID
Human
ALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIP

NO: 105
TGFBR1
RDRPFVCAPSSKTGSVTTTYCCNQDHCNKIEL

fragment 2

SEQ ID
Immature
MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAV

NO: 98
human
KFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN

TGFBR2
DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSC

isoform B
SSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYCY

(short
RVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNIN

isoform)
HNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEE

(P37173-1)
YASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAK

GNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIV

HRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTA

RYMAPEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVGE

VKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQM

VCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKIPE

DGSLNTTK

SEQ ID
Human
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC

NO: 123
TGFBR2
MSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE

isoform B
DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL

(short
VIFQVTGISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLM

isoform)
EFSEHCAIILEDDRSDISSTCANNINHNTELLPIELDTLVGKGRFAEVY

(P37173-1)
KAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQ

FLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGS

SLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFG

LSLRLDPTLSVDDLANSGQVGTARYMAPEVLESRMNLENVESFKQT

DVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKD

NVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCV

AERFSELEHLDRLSGRSCSEEKIPEDGSLNTTK

SEQ ID
Immature
MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSDVEMEAQKDEIICPSC

NO: 99
human
NRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC

TGFBR2
MSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE

isoform A
DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL

(long
VIFQVTGISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLM

isoform)
EFSEHCAIILEDDRSDISSTCANNINHNTELLPIELDTLVGKGRFAEVY

(P37173-2)
KAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQ

FLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGS

SLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFG

LSLRLDPTLSVDDLANSGQVGTARYMAPEVLESRMNLENVESFKQT

DVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKD

NVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCV

AERFSELEHLDRLSGRSCSEEKIPEDGSLNTTK

SEQ ID
Human
TIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGA

NO: 124
TGFBR2
VKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRK

isoform A
NDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCS

(long
CSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYC

isoform)
YRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNI

(P37173-2)
NHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYE

EYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHA

KGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPI

VHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGT

ARYMAPEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVG

EVKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQ

MVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKI

PEDGSLNTTK

SEQ ID
Human
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC

NO: 100
TGFBR2
MSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE

fragment 1
DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD

(ECD of

human

TGFBR2

isoform B)

SEQ ID
Human
IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMS

NO: 101
TGFBR2
NCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDA

fragment 2
ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD

SEQ ID
Human
TIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGA

NO: 102
TGFBR2
VKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRK

fragment 3
NDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCS

(ECD of
CSSDECNDNIIFSEEYNTSNPD

human

TGFBR2

isoform A)

SEQ ID
Human
QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDEN

NO: 103
TGFBR2
ITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSD

fragment 4
ECNDNIIF

SEQ ID
Immature
MTSHYVIAIFALMSSCLATAGPEPGALCELSPVSASHPVQALMESFT

NO: 106
human
VLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQREVTLHLNPISSV

TGFBR3
HIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLVSEGSVVQFSSA

isoform 1
NFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELKIARNIYIKV

(Q03167-1)
GEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSSQPQNEEVH

IIELITPNSNPYSAFQVDITIDIRPSQEDLEVVKNLILILKCKKSVNWVI

KSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDIPSTQGNLVKW

ALDNGYSPITSYTMAPVANRFHLRLENNAEEMGDEEVHTIPPELRIL

LDPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGEDGLPRP

KDPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAVEKDSFQ

ASGYSGMDVTLLDPTCKAKMNGTHFVLESPLNGCGTRPRWSALDG

VVYYNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDASLF

TRPEIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQG

VFSVPENGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIE

NICPKDESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQ

CELTLCTKMEKHPQKLPKCVPPDEACTSLDASIIWAMMQNKKTFTK

PLAVIHHEAESKEKGPSMKEPNPISPPIFHGLDTLTVMGIAFAAFVIG

ALLTGALWYIYSHTGETAGRQQVPTSPPASENSSAAHSIGSTQSTPC

SSSSTA

SEQ ID
Human
GPEPGALCELSPVSASHPVQALMESFTVLSGCASRGTTGLPQEVHVL

NO: 125
TGFBR3
NLRTAGQGPGQLQREVTLHLNPISSVHIHHKSVVFLLNSPHPLVWH

isoform 1
LKTERLATGVSRLFLVSEGSVVQFSSANFSLTAETEERNFPHGNEHL

(Q03167-1)
LNWARKEYGAVTSFTELKIARNIYIKVGEDQVFPPKCNIGKNFLSLN

YLAEYLQPKAAEGCVMSSQPQNEEVHIIELITPNSNPYSAFQVDITID

IRPSQEDLEVVKNLILILKCKKSVNWVIKSFDVKGSLKIIAPNSIGFGK

ESERSMTMTKSIRDDIPSTQGNLVKWALDNGYSPITSYTMAPVANR

FHLRLENNAEEMGDEEVHTIPPELRILLDPGALPALQNPPIRGGEGQ

NGGLPFPFPDISRRVWNEEGEDGLPRPKDPVIPSIQLFPGLREPEEVQ

GSVDIALSVKCDNEKMIVAVEKDSFQASGYSGMDVTLLDPTCKAK

MNGTHFVLESPLNGCGTRPRWSALDGVVYYNSIVIQVPALGDSSG

WPDGYEDLESGDNGFPGDMDEGDASLFTRPEIVVFNCSLQQVRNPS

SFQEQPHGNITFNMELYNTDLFLVPSQGVFSVPENGHVYVEVSVTK

AEQELGFAIQTCFISPYSNPDRMSHYTIIENICPKDESVKFYSPKRVHF

PIPQADMDKKRFSFVFKPVFNTSLLFLQCELTLCTKMEKHPQKLPKC

VPPDEACTSLDASIIWAMMQNKKTFTKPLAVIHHEAESKEKGPSMK

EPNPISPPIFHGLDTLTVMGIAFAAFVIGALLTGALWYIYSHTGETAG

RQQVPTSPPASENSSAAHSIGSTQSTPCSSSSTA

SEQ ID
Immature
MTSHYVIAIFALMSSCLATAGPEPGALCELSPVSASHPVQALMESFT

NO: 107
human
VLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQREVTLHLNPISSV

TGFBR3
HIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLVSEGSVVQFSSA

isoform 2
NFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELKIARNIYIKV

(Q03167-2)
GEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSSQPQNEEVH

IIELITPNSNPYSAFQVDITIDIRPSQEDLEVVKNLILILKCKKSVNWVI

KSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDIPSTQGNLVKW

ALDNGYSPITSYTMAPVANRFHLRLENNEEMGDEEVHTIPPELRILL

DPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGEDGLPRPK

DPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAVEKDSFQAS

GYSGMDVTLLDPTCKAKMNGTHFVLESPLNGCGTRPRWSALDGV

VYYNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDASLFT

RPEIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQGV

FSVPENGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIEN

ICPKDESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQCE

LTLCTKMEKHPQKLPKCVPPDEACTSLDASIIWAMMQNKKTFTKPL

AVIHHEAESKEKGPSMKEPNPISPPIFHGLDTLTVMGIAFAAFVIGAL

LTGALWYIYSHTGETAGRQQVPTSPPASENSSAAHSIGSTQSTPCSSS

STA

SEQ ID
Human
GPEPGALCELSPVSASHPVQALMESFTVLSGCASRGTTGLPQEVHVL

NO: 126
TGFB R3
NLRTAGQGPGQLQREVTLHLNPISSVHIHHKSVVFLLNSPHPLVWH

isoform 2
LKTERLATGVSRLFLVSEGSVVQFSSANFSLTAETEERNFPHGNEHL

(Q03167-2)
LNWARKEYGAVTSFTELKIARNIYIKVGEDQVFPPKCNIGKNFLSLN

YLAEYLQPKAAEGCVMSSQPQNEEVHIIELITPNSNPYSAFQVDITID

IRPSQEDLEVVKNLILILKCKKSVNWVIKSFDVKGSLKIIAPNSIGFGK

ESERSMTMTKSIRDDIPSTQGNLVKWALDNGYSPITSYTMAPVANR

FHLRLENNEEMGDEEVHTIPPELRILLDPGALPALQNPPIRGGEGQN

GGLPFPFPDISRRVWNEEGEDGLPRPKDPVIPSIQLFPGLREPEEVQG

SVDIALSVKCDNEKMIVAVEKDSFQASGYSGMDVTLLDPTCKAKM

NGTHFVLESPLNGCGTRPRWSALDGVVYYNSIVIQVPALGDSSGWP

DGYEDLESGDNGFPGDMDEGDASLFTRPEIVVFNCSLQQVRNPSSF

QEQPHGNITFNMELYNTDLFLVPSQGVFSVPENGHVYVEVSVTKAE

QELGFAIQTCFISPYSNPDRMSHYTIIENICPKDESVKFYSPKRVHFPI

PQADMDKKRFSFVFKPVFNTSLLFLQCELTLCTKMEKHPQKLPKCV

PPDEACTSLDASIIWAMMQNKKTFTKPLAVIHHEAESKEKGPSMKE

PNPISPPIFHGLDTLTVMGIAFAAFVIGALLTGALWYIYSHTGETAGR

QQVPTSPPASENSSAAHSIGSTQSTPCSSSSTA

SEQ ID
Human
GPEPGALCELSPVSASHPVQALMESFTVLSGCASRGTTGLPQEVHVL

NO: 108
TGFB R3
NLRTAGQGPGQLQREVTLHLNPISSVHIHHKSVVFLLNSPHPLVWH

fragment 1
LKTERLATGVSRLFLVSEGSVVQFSSANFSLTAETEERNFPHGNEHL

LNWARKEYGAVTSFTELKIARNIYIKVGEDQVFPPKCNIGKNFLSLN

YLAEYLQPKAAEGCVMSSQPQNEEVHIIELITPNSNPYSAFQVDITID

IRPSQEDLEVVKNLILILKCKKSVNWVIKSFDVKGSLKIIAPNSIGFGK

ESERSMTMTKSIRDDIPSTQGNLVKWALDNGYSPITSYTMAPVANR

FHLRLENNAEEMGDEEVHTIPPELRILLDPGALPALQNPPIRGGEGQ

NGGLPFPFPDISRRVWNEEGEDGLPRPKDPVIPSIQLFPGLREPEEVQ

GSVDIALSVKCDNEKMIVAVEKDSFQASGYSGMDVTLLDPTCKAK

MNGTHFVLESPLNGCGTRPRWSALDGVVYYNSIVIQVPALGDSSG

WPDGYEDLESGDNGFPGDMDEGDASLFTRPEIVVFNCSLQQVRNPS

SFQEQPHGNITFNMELYNTDLFLVPSQGVFSVPENGHVYVEVSVTK

AEQELGFAIQTCFISPYSNPDRMSHYTIIENICPKDESVKFYSPKRVHF

PIPQADMDKKRFSFVFKPVFNTSLLFLQCELTLCTKMEKHPQKLPKC

VPPDEACTSLDASIIWAMMQNKKTFTKPLAVIHHEAESKEKGPSMK

EPNPISPPIFHGLDTLTV

SEQ ID
hCH1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT

NO: 192
hFc_Hole-
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV

3x4GS-
DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV

TGFbR2
TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVC

TLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS

LSLSPGXGGGGSGGGGSGGGGSIPPHVQKSVNNDMIVTDNNGAVK

FPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKND

ENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCS

SDECNDNIIFSEEYNTSNPD, wherein X is K or absent

SEQ ID
hCH1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT

NO: 193
hFc_Knob-
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV

3x4GS-
DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV

TGFbR2
TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY

TLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS

LSLSPGXGGGGSGGGGSGGGGSIPPHVQKSVNNDMIVTDNNGAVK

FPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKND

ENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCS

SDECNDNIIFSEEYNTSNPD, wherein X is K or absent

SEQ ID
hFc_Hole-
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS

NO: 194
3x4GS-
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

TGFbR2
DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREE

MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS

FFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGXG

GGGSGGGGSGGGGSIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFC

DVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV

CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNI

IFSEEYNTSNPD, wherein X is K or absent

SEQ ID
hFc_Knob-
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS

NO: 195
3x4GS-
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

TGFbR2
DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREE

MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG

SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX

GGGGSGGGGSGGGGSIPPHVQKSVNNDMIVTDNNGAVKFPQLCKF

CDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLET

VCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECND

NIIFSEEYNTSNPD, wherein X is K or absent

SEQ ID
TGFbR2-
IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMS

NO: 196
3x4GS-
NCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDA

hCH1-
ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGG

hFc_Hole
SGGGGSGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP

VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC

NVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP

KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR

EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK

AKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGX, wherein X is K or absent

SEQ ID
TGFbR2-
IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMS

NO: 197
3x4GS-
NCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDA

hCH1-
ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGG

hFc_Knob
SGGGGSGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP

VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC

NVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP

KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR

EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM

HEALHNHYTQKSLSLSPGX, wherein X is K or absent

SEQ ID
TGFbR2-
IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMS

NO: 198
3x4GS-
NCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDA

hCLIg_vl
ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGG

SGGGGSGGGGSGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPG

AVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKS

HRSYSCQVTHEGSTVEKTVAPTECS

SEQ ID
TGFβR2-
IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMS

NO: 199
3x4GS-
NCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDA

hCLIg_vk
ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGG

SGGGGSGGGGSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRE

AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEK

HKVYACEVTHQGLSSPVTKSFNRGEC

Nucleic Acids

The invention also features nucleic acids comprising nucleotide sequences that encode heavy and light chain variable regions and CDRs or hypervariable loops of the antibody molecules, as described herein. For example, the invention features a first and second nucleic acid encoding heavy and light chain variable regions, respectively, of an antibody molecule chosen from one or more of the antibody molecules disclosed herein. The nucleic acid can comprise a nucleotide sequence as set forth in the tables herein, or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, or which differs by no more than 3, 6, 15, 30, or 45 nucleotides from the sequences shown in the tables herein.

In certain embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g., conserved substitutions). In other embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g., conserved substitutions). In yet another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g., conserved substitutions).

In certain embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having the nucleotide sequence as set forth in the tables herein, a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having the nucleotide sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In yet another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having the nucleotide sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein).

Vectors

Further provided herein are vectors comprising the nucleotide sequences encoding an antibody molecule described herein. In one embodiment, the vectors comprise nucleotides encoding an antibody molecule described herein. In one embodiment, the vectors comprise the nucleotide sequences described herein. The vectors include, but are not limited to, a virus, plasmid, cosmid, lambda phage or a yeast artificial chromosome (YAC).

Numerous vector systems can be employed. For example, one class of vectors utilizes DNA elements which are derived from animal viruses such as, for example, bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (Rous Sarcoma Virus, MMTV or MOMLV) or SV40 virus. Another class of vectors utilizes RNA elements derived from RNA viruses such as Semliki Forest virus, Eastern Equine Encephalitis virus and Flaviviruses.

Additionally, cells which have stably integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow for the selection of transfected host cells. The marker may provide, for example, prototropy to an auxotrophic host, biocide resistance (e.g., antibiotics), or resistance to heavy metals such as copper, or the like. The selectable marker gene can be either directly linked to the DNA sequences to be expressed, or introduced into the same cell by cotransformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcriptional promoters, enhancers, and termination signals.

Once the expression vector or DNA sequence containing the constructs has been prepared for expression, the expression vectors may be transfected or introduced into an appropriate host cell. Various techniques may be employed to achieve this, such as, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, lipid based transfection or other conventional techniques. In the case of protoplast fusion, the cells are grown in media and screened for the appropriate activity.

Methods and conditions for culturing the resulting transfected cells and for recovering the antibody molecule produced are known to those skilled in the art, and may be varied or optimized depending upon the specific expression vector and mammalian host cell employed, based upon the present description.

Cells

In another aspect, the application features host cells and vectors containing the nucleic acids described herein. The nucleic acids may be present in a single vector or separate vectors present in the same host cell or separate host cell. The host cell can be a eukaryotic cell, e.g., a mammalian cell, an insect cell, a yeast cell, or a prokaryotic cell, e.g., E. coli. For example, the mammalian cell can be a cultured cell or a cell line. Exemplary mammalian cells include lymphocytic cell lines (e.g., NSO), Chinese hamster ovary cells (CHO), COS cells, oocyte cells, and cells from a transgenic animal, e.g., mammary epithelial cell. The invention also provides host cells comprising a nucleic acid encoding an antibody molecule as described herein.

In one embodiment, the host cells are genetically engineered to comprise nucleic acids encoding the antibody molecule.

In one embodiment, the host cells are genetically engineered by using an expression cassette. The phrase “expression cassette,” refers to nucleotide sequences, which are capable of affecting expression of a gene in hosts compatible with such sequences. Such cassettes may include a promoter, an open reading frame with or without introns, and a termination signal. Additional factors necessary or helpful in effecting expression may also be used, such as, for example, an inducible promoter.

The invention also provides host cells comprising the vectors described herein.

The cell can be, but is not limited to, a eukaryotic cell, a bacterial cell, an insect cell, or a human cell. Suitable eukaryotic cells include, but are not limited to, Vero cells, HeLa cells, COS cells, CHO cells, HEK293 cells, BHK cells and MDCKII cells. Suitable insect cells include, but are not limited to, Sf9 cells.

Uses and Combination Therapies

Methods described herein include treating a cancer in a subject by using a multispecific molecule described herein, e.g., using a pharmaceutical composition described herein. Also provided are methods for reducing or ameliorating a symptom of a cancer in a subject, as well as methods for inhibiting the growth of a cancer and/or killing one or more cancer cells. In embodiments, the methods described herein decrease the size of a tumor and/or decrease the number of cancer cells in a subject administered with a described herein or a pharmaceutical composition described herein.

In embodiments, the cancer is a hematological cancer. In embodiments, the hematological cancer is a leukemia or a lymphoma. As used herein, a “hematologic cancer” refers to a tumor of the hematopoietic or lymphoid tissues, e.g., a tumor that affects blood, bone marrow, or lymph nodes. Exemplary hematologic malignancies include, but are not limited to, leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, acute monocytic leukemia (AMoL), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), or large granular lymphocytic leukemia), lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma (e.g., classical Hodgkin lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma), mycosis fungoides, non-Hodgkin lymphoma (e.g., B-cell non-Hodgkin lymphoma (e.g., Burkitt lymphoma, small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma) or T-cell non-Hodgkin lymphoma (mycosis fungoides, anaplastic large cell lymphoma, or precursor T-lymphoblastic lymphoma)), primary central nervous system lymphoma, Sézary syndrome, Waldenström macroglobulinemia), chronic myeloproliferative neoplasm, Langerhans cell histiocytosis, multiple myeloma/plasma cell neoplasm, myelodysplastic syndrome, or myelodysplastic/myeloproliferative neoplasm.

In embodiments, the cancer is a solid cancer. Exemplary solid cancers include, but are not limited to, ovarian cancer, rectal cancer, stomach cancer, testicular cancer, cancer of the anal region, uterine cancer, colon cancer, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine, cancer of the esophagus, melanoma, Kaposi's sarcoma, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, brain stem glioma, pituitary adenoma, epidermoid cancer, carcinoma of the cervix squamous cell cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the vagina, sarcoma of soft tissue, cancer of the urethra, carcinoma of the vulva, cancer of the penis, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, spinal axis tumor, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, metastatic lesions of said cancers, or combinations thereof.

In some embodiments, the cancer is a hematological cancer or a metastatic lesion. In some embodiments, the hematological cancer is one or more of a Hodgkin's lymphoma, Non-Hodgkin's lymphoma, B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome (MDS), multiple myeloma, or acute lymphocytic leukemia.

In embodiments, the multispecific molecules (or pharmaceutical composition) are administered in a manner appropriate to the disease to be treated or prevented. The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease. Appropriate dosages may be determined by clinical trials. For example, when “an effective amount” or “a therapeutic amount” is indicated, the precise amount of the pharmaceutical composition (or multispecific molecules) to be administered can be determined by a physician with consideration of individual differences in tumor size, extent of infection or metastasis, age, weight, and condition of the subject. In embodiments, the pharmaceutical composition described herein can be administered at a dosage of 10⁴to 10⁹cells/kg body weight, e.g., 10⁵to 10⁶cells/kg body weight, including all integer values within those ranges. In embodiments, the pharmaceutical composition described herein can be administered multiple times at these dosages. In embodiments, the pharmaceutical composition described herein can be administered using infusion techniques described in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988).

In embodiments, the multispecific molecules or pharmaceutical composition is administered to the subject parenterally. In embodiments, the cells are administered to the subject intravenously, subcutaneously, intratumorally, intranodally, intramuscularly, intradermally, or intraperitoneally. In embodiments, the cells are administered, e.g., injected, directly into a tumor or lymph node. In embodiments, the cells are administered as an infusion (e.g., as described in Rosenberg et al., New Eng. J. of Med. 319:1676, 1988) or an intravenous push. In embodiments, the cells are administered as an injectable depot formulation. In embodiments, the subject is a mammal. In embodiments, the subject is a human, monkey, pig, dog, cat, cow, sheep, goat, rabbit, rat, or mouse. In embodiments, the subject is a human. In embodiments, the subject is a pediatric subject, e.g., less than 18 years of age, e.g., less than 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or less years of age. In embodiments, the subject is an adult, e.g., at least 18 years of age, e.g., at least 19, 20, 21, 22, 23, 24, 25, 25-30, 30-35, 35-40, 40-50, 50-60, 60-70, 70-80, or 80-90 years of age.

Combination Therapies

The multispecific molecules disclosed herein can be used in combination with a second therapeutic agent or procedure.

In embodiments, the multispecific molecule and the second therapeutic agent or procedure are administered/performed after a subject has been diagnosed with a cancer, e.g., before the cancer has been eliminated from the subject. In embodiments, the multispecific molecule and the second therapeutic agent or procedure are administered/performed simultaneously or concurrently. For example, the delivery of one treatment is still occurring when the delivery of the second commences, e.g., there is an overlap in administration of the treatments. In other embodiments, the multispecific molecule and the second therapeutic agent or procedure are administered/performed sequentially. For example, the delivery of one treatment ceases before the delivery of the other treatment begins.

In embodiments, combination therapy can lead to more effective treatment than monotherapy with either agent alone. In embodiments, the combination of the first and second treatment is more effective (e.g., leads to a greater reduction in symptoms and/or cancer cells) than the first or second treatment alone. In embodiments, the combination therapy permits use of a lower dose of the first or the second treatment compared to the dose of the first or second treatment normally required to achieve similar effects when administered as a monotherapy. In embodiments, the combination therapy has a partially additive effect, wholly additive effect, or greater than additive effect.

In one embodiment, the multispecific molecule is administered in combination with a therapy, e.g., a cancer therapy (e.g., one or more of anti-cancer agents, immunotherapy, photodynamic therapy (PDT), surgery and/or radiation). The terms “chemotherapeutic,” “chemotherapeutic agent,” and “anti-cancer agent” are used interchangeably herein. The administration of the multispecific molecule and the therapy, e.g., the cancer therapy, can be sequential (with or without overlap) or simultaneous. Administration of the multispecific molecule can be continuous or intermittent during the course of therapy (e.g., cancer therapy). Certain therapies described herein can be used to treat cancers and non-cancerous diseases. For example, PDT efficacy can be enhanced in cancerous and non-cancerous conditions (e.g., tuberculosis) using the methods and compositions described herein (reviewed in, e.g., Agostinis, P. et al. (2011) CA Cancer J. Clin. 61:250-281).

Anti-Cancer Therapies

In other embodiments, the multispecific molecule is administered in combination with a low or small molecular weight chemotherapeutic agent. Exemplary low or small molecular weight chemotherapeutic agents include, but not limited to, 13-cis-retinoic acid (isotretinoin, ACCUTANE®), 2-CdA (2-chlorodeoxyadenosine, cladribine, LEUSTATIN™), 5-azacitidine (azacitidine, VIDAZA®), 5-fluorouracil (5-FU, fluorouracil, ADRUCIL®), 6-mercaptopurine (6-MP, mercaptopurine, PURINETHOL®), 6-TG (6-thioguanine, thioguanine, THIOGUANINE TABLOID®), abraxane (paclitaxel protein-bound), actinomycin-D (dactinomycin, COSMEGEN®), alitretinoin (PANRETIN®), all-transretinoic acid (ATRA, tretinoin, VESANOID®), altretamine (hexamethylmelamine, HMM, HEXALEN®), amethopterin (methotrexate, methotrexate sodium, MTX, TREXALL™, RHEUMATREX®), amifostine (ETHYOL®), arabinosylcytosine (Ara-C, cytarabine, CYTOSAR-U®), arsenic trioxide (TRISENOX®), asparaginase (Erwinia L-asparaginase, L-asparaginase, ELSPAR®, KIDROLASE®), BCNU (carmustine, BiCNU®), bendamustine (TREANDA®), bexarotene (TARGRETIN®), bleomycin (BLENOXANE®), busulfan (BUSULFEX®, MYLERAN®), calcium leucovorin (Citrovorum Factor, folinic acid, leucovorin), camptothecin-11 (CPT-11, irinotecan, CAMPTOSAR®), capecitabine (XELODA®), carboplatin (PARAPLATIN®), carmustine wafer (prolifeprospan 20 with carmustine implant, GLIADEL® wafer), CCI-779 (temsirolimus, TORISEL®), CCNU (lomustine, CeeNU), CDDP (cisplatin, PLATINOL®, PLATINOL-AQ®), chlorambucil (leukeran), cyclophosphamide (CYTOXAN®, NEOSAR®), dacarbazine (DIC, DTIC, imidazole carboxamide, DTIC-DOME®), daunomycin (daunorubicin, daunorubicin hydrochloride, rubidomycin hydrochloride, CERUBIDINE®), decitabine (DACOGEN®), dexrazoxane (ZINECARD®), DHAD (mitoxantrone, NOVANTRONE®), docetaxel (TAXOTERE®), doxorubicin (ADRIAMYCIN®, RUBEX®), epirubicin (ELLENCE™), estramustine (EMCYT®), etoposide (VP-16, etoposide phosphate, TOPOSAR®, VEPESID®, ETOPOPHOS®), floxuridine (FUDR®), fludarabine (FLUDARA®), fluorouracil (cream) (CARAC™, EFUDEX®, FLUOROPLEX®), gemcitabine (GEMZAR®), hydroxyurea (HYDREA®, DROXIA™, MYLOCEL™), idarubicin (IDAMYCIN®), ifosfamide (IFEX®), ixabepilone (IXEMPRA™), LCR (leurocristine, vincristine, VCR, ONCOVIN®, VINCASAR PFS®), L-PAM (L-sarcolysin, melphalan, phenylalanine mustard, ALKERAN®), mechlorethamine (mechlorethamine hydrochloride, mustine, nitrogen mustard, MUSTARGEN®), mesna (MESNEX™), mitomycin (mitomycin-C, MTC, MUTAMYCIN®), nelarabine (ARRANON®), oxaliplatin (ELOXATIN™), paclitaxel (TAXOL®, ONXAL™), pegaspargase (PEG-L-asparaginase, ONCOSPAR®), PEMETREXED (ALIMTA®), pentostatin (NIPENT®), procarbazine (MATULANE®), streptozocin (ZANOSAR®), temozolomide (TEMODAR®), teniposide (VM-26, VUMON®), TESPA (thiophosphoamide, thiotepa, TSPA, THIOPLEX®), topotecan (HYCAMTIN®), vinblastine (vinblastine sulfate, vincaleukoblastine, VLB, ALKABAN-AQ®, VELBAN®), vinorelbine (vinorelbine tartrate, NAVELBINE®), and vorinostat (ZOLINZA®).

In another embodiment, the multispecific molecule is administered in conjunction with a biologic. Biologics useful in the treatment of cancers are known in the art and a binding molecule of the invention may be administered, for example, in conjunction with such known biologics. For example, the FDA has approved the following biologics for the treatment of breast cancer: HERCEPTIN® (trastuzumab, Genentech Inc., South San Francisco, Calif.; a humanized monoclonal antibody that has anti-tumor activity in HER2-positive breast cancer); FASLODEX® (fulvestrant, Astra7eneca Pharmaceuticals, LP, Wilmington, Del.; an estrogen-receptor antagonist used to treat breast cancer); ARIMIDEX® (anastrozole, Astra7eneca Pharmaceuticals, LP; a nonsteroidal aromatase inhibitor which blocks aromatase, an enzyme needed to make estrogen); Aromasin® (exemestane, Pfizer Inc., New York, N.Y.; an irreversible, steroidal aromatase inactivator used in the treatment of breast cancer); FEMARA® (letrozole, Novartis Pharmaceuticals, East Hanover, N.J.; a nonsteroidal aromatase inhibitor approved by the FDA to treat breast cancer); and NOLVADEX® (tamoxifen, AstraZeneca Pharmaceuticals, LP; a nonsteroidal antiestrogen approved by the FDA to treat breast cancer). Other biologics with which the binding molecules of the invention may be combined include: AVASTIN® (bevacizumab, Genentech Inc.; the first FDA-approved therapy designed to inhibit angiogenesis); and ZEVALIN® (ibritumomab tiuxetan, Biogen Idec, Cambridge, Mass.; a radiolabeled monoclonal antibody currently approved for the treatment of B-cell lymphomas).

In addition, the FDA has approved the following biologics for the treatment of colorectal cancer: AVASTIN®; ERBITUX® (cetuximab, ImClone Systems Inc., New York, N.Y., and Bristol-Myers Squibb, New York, N.Y.; is a monoclonal antibody directed against the epidermal growth factor receptor (EGFR)); GLEEVEC® (imatinib mesylate; a protein kinase inhibitor); and ERGAMISOL® (levamisole hydrochloride, Janssen Pharmaceutica Products, LP, Titusville, N.J.; an immunomodulator approved by the FDA in 1990 as an adjuvant treatment in combination with 5-fluorouracil after surgical resection in patients with Dukes' Stage C colon cancer).

For the treatment of lung cancer, exemplary biologics include TARCEVA® (erlotinib HCL, OSI Pharmaceuticals Inc., Melville, N.Y.; a small molecule designed to target the human epidermal growth factor receptor 1 (HER1) pathway).

For the treatment of multiple myeloma, exemplary biologics include VELCADE® Velcade (bortezomib, Millennium Pharmaceuticals, Cambridge Mass.; a proteasome inhibitor). Additional biologics include THALIDOMID® (thalidomide, Clegene Corporation, Warren, N.J.; an immunomodulatory agent and appears to have multiple actions, including the ability to inhibit the growth and survival of myeloma cells and anti-angiogenesis).

Additional exemplary cancer therapeutic antibodies include, but are not limited to, 3F8, abagovomab, adecatumumab, afutuzumab, alacizumab pegol, alemtuzumab (CAMPATH®, MABCAMPATH®), altumomab pentetate (HYBRI-CEAKER®), anatumomab mafenatox, anrukinzumab (IMA-638), apolizumab, arcitumomab (CEA-SCAN®), bavituximab, bectumomab (LYMPHOSCAN®), belimumab (BENLYSTA®, LYMPHOSTAT-B®), besilesomab (SCINTIMUN®), bevacizumab (AVASTIN®), bivatuzumab mertansine, blinatumomab, brentuximab vedotin, cantuzumab mertansine, capromab pendetide (PROSTASCINT®), catumaxomab (REMOVAB®), CC49, cetuximab (C225, ERBITUX®), citatuzumab bogatox, cixutumumab, clivatuzumab tetraxetan, conatumumab, dacetuzumab, denosumab (PROLIA®), detumomab, ecromeximab, edrecolomab (PANOREX®), elotuzumab, epitumomab cituxetan, epratuzumab, ertumaxomab (REXOMUN®), etaracizumab, farletuzumab, figitumumab, fresolimumab, galiximab, gemtuzumab ozogamicin (MYLOTARG®), girentuximab, glembatumumab vedotin, ibritumomab (ibritumomab tiuxetan, ZEVALIN®), igovomab (INDIMACIS-125®), intetumumab, inotuzumab ozogamicin, ipilimumab, iratumumab, labetuzumab (CEA-CIDE®), lexatumumab, lintuzumab, lucatumumab, lumiliximab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, nacolomab tafenatox, naptumomab estafenatox, necitumumab, nimotuzumab (THERACIM®, THERALOC®), nofetumomab merpentan (VERLUMA®), ofatumumab (ARZERRA®), olaratumab, oportuzumab monatox, oregovomab (OVAREX®), panitumumab (VECTIBIX®), pemtumomab (THERAGYN®), pertuzumab (OMNITARG®), pintumomab, pritumumab, ramucirumab, ranibizumab (LUCENTIS®), rilotumumab, rituximab (MABTHERA®, RITUXAN®), robatumumab, satumomab pendetide, sibrotuzumab, siltuximab, sontuzumab, tacatuzumab tetraxetan (AFP-CIDE®), taplitumomab paptox, tenatumomab, TGN1412, ticilimumab (tremelimumab), tigatuzumab, TNX-650, tositumomab (BEXXAR®), trastuzumab (HERCEPTIN®), tremelimumab, tucotuzumab celmoleukin, veltuzumab, volociximab, votumumab (HUMASPECT®), zalutumumab (HUMAX-EGFR®), and zanolimumab (HUMAX-CD4®).

In other embodiments, the multispecific molecule is administered in combination with a viral cancer therapeutic agent. Exemplary viral cancer therapeutic agents include, but not limited to, vaccinia virus (vvDD-CDSR), carcinoembryonic antigen-expressing measles virus, recombinant vaccinia virus (TK-deletion plus GM-CSF), Seneca Valley virus-001, Newcastle virus, coxsackie virus A21, GL-ONC1, EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine, carcinoembryonic antigen-expressing measles virus, G207 oncolytic virus, modified vaccinia virus Ankara vaccine expressing p53, OncoVEX GM-CSF modified herpes-simplex 1 virus, fowlpox virus vaccine vector, recombinant vaccinia prostate-specific antigen vaccine, human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, MVA-EBNA1/LMP2 Inj. vaccine, quadrivalent HPV vaccine, quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (GARDASIL®), recombinant fowlpox-CEA(6D)/TRICOM vaccine; recombinant vaccinia-CEA(6D)-TRICOM vaccine, recombinant modified vaccinia Ankara-5T4 vaccine, recombinant fowlpox-TRICOM vaccine, oncolytic herpes virus NV1020, HPV L1 VLP vaccine V504, human papillomavirus bivalent (types 16 and 18) vaccine (CERVARIX®), herpes simplex virus HF10, Ad5CMV-p53 gene, recombinant vaccinia DF3/MUC1 vaccine, recombinant vaccinia-MUC-1 vaccine, recombinant vaccinia-TRICOM vaccine, ALVAC MART-1 vaccine, replication-defective herpes simplex virus type I (HSV-1) vector expressing human Preproenkephalin (NP2), wild-type reovirus, reovirus type 3 Dearing (REOLYSIN®), oncolytic virus HSV1716, recombinant modified vaccinia Ankara (MVA)-based vaccine encoding Epstein-Barr virus target antigens, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, rAd-p53 gene, Ad5-delta24RGD, HPV vaccine 580299, JX-594 (thymidine kinase-deleted vaccinia virus plus GM-CSF), HPV-16/18 L1/AS04, fowlpox virus vaccine vector, vaccinia-tyrosinase vaccine, MEDI-517 HPV-16/18 VLP ASO4 vaccine, adenoviral vector containing the thymidine kinase of herpes simplex virus TK99UN, HspE7, FP253/Fludarabine, ALVAC(2) melanoma multi-antigen therapeutic vaccine, ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine, Ad-REIC/Dkk-3, rAd-IFN SCH 721015, TIL-Ad-INFg, Ad-ISF35, and coxsackievirus A21 (CVA21, CAVATAK®).

In other embodiments, the multispecific molecule is administered in combination with a nanopharmaceutical. Exemplary cancer nanopharmaceuticals include, but not limited to, ABRAXANE® (paclitaxel bound albumin nanoparticles), CRLX101 (CPT conjugated to a linear cyclodextrin-based polymer), CRLX288 (conjugating docetaxel to the biodegradable polymer poly (lactic-co-glycolic acid)), cytarabine liposomal (liposomal Ara-C, DEPOCYT™), daunorubicin liposomal (DAUNOXOME®), doxorubicin liposomal (DOXIL®, CAELYX®), encapsulated-daunorubicin citrate liposome (DAUNOXOME®), and PEG anti-VEGF aptamer (MACUGEN®).

In some embodiments, the multispecific molecule is administered in combination with paclitaxel or a paclitaxel formulation, e.g., TAXOL®, protein-bound paclitaxel (e.g., ABRAXANE®). Exemplary paclitaxel formulations include, but are not limited to, nanoparticle albumin-bound paclitaxel (ABRAXANE®, marketed by Abraxis Bioscience), docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel, Taxoprexin, marketed by Protarga), polyglutamate bound-paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX, marketed by Cell Therapeutic), the tumor-activated prodrug (TAP), ANG105 (Angiopep-2 bound to three molecules of paclitaxel, marketed by ImmunoGen), paclitaxel-EC-1 (paclitaxel bound to the erbB2-recognizing peptide EC-1; see Li et al., Biopolymers (2007) 87:225-230), and glucose-conjugated paclitaxel (e.g., 2′-paclitaxel methyl 2-glucopyranosyl succinate, see Liu et al., Bioorganic & Medicinal Chemistry Letters (2007) 17:617-620).

Exemplary RNAi and antisense RNA agents for treating cancer include, but not limited to, CALAA-01, siG12D LODER (Local Drug EluteR), and ALN-VSP02.

Other cancer therapeutic agents include, but not limited to, cytokines (e.g., aldesleukin (IL-2, Interleukin-2, PROLEUKIN®), alpha Interferon (IFN-alpha, Interferon alfa, INTRON® A (Interferon alfa-2b), ROFERON-A® (Interferon alfa-2a)), Epoetin alfa (PROCRIT®), filgrastim (G-CSF, Granulocyte-Colony Stimulating Factor, NEUPOGEN®), GM-CSF (Granulocyte Macrophage Colony Stimulating Factor, sargramostim, LEUKINE™), IL-11 (Interleukin-11, oprelvekin, NEUMEGA®), Interferon alfa-2b (PEG conjugate) (PEG interferon, PEG-INTRON™), and pegfilgrastim (NEULASTA™)), hormone therapy agents (e.g., aminoglutethimide (CYTADREN®), anastrozole (ARIMIDEX®), bicalutamide (CASODEX®), exemestane (AROMASIN®), fluoxymesterone (HALOTESTIN®), flutamide (EULEXIN®), fulvestrant (FASLODEX®), goserelin (ZOLADEX®), letrozole (FEMARA®), leuprolide (ELIGARD™, LUPRON®, LUPRON DEPOT®, VIADUR™), megestrol (megestrol acetate, MEGACE®), nilutamide (ANANDRON®, NILANDRON®), octreotide (octreotide acetate, SANDOSTATIN®, SANDOSTATIN LAR®), raloxifene (EVISTA®), romiplostim (NPLATE®), tamoxifen (NOVALDEX®), and toremifene (FARESTON®)), phospholipase A2 inhibitors (e.g., anagrelide (AGRYLIN®)), biologic response modifiers (e.g., BCG (THERACYS®, TICE®), and Darbepoetin alfa (ARANESP®)), target therapy agents (e.g., bortezomib (VELCADE®), dasatinib (SPRYCEL™), denileukin diftitox (ONTAK®), erlotinib (TARCEVA®), everolimus (AFINITOR®), gefitinib (IRESSA®), imatinib mesylate (STI-571, GLEEVEC™), lapatinib (TYKERB®), sorafenib (NEXAVAR®), and SU11248 (sunitinib, SUTENT®)), immunomodulatory and antiangiogenic agents (e.g., CC-5013 (lenalidomide, REVLIMID®), and thalidomide (THALOMID®)), glucocorticosteroids (e.g., cortisone (hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, ALA-CORT®, HYDROCORT ACETATE®, hydrocortone phosphate LANACORT®, SOLU-CORTEF®), decadron (dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®), methylprednisolone (6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, DURALONE®, MEDRALONE®, MEDROL®, M-PREDNISOL®, SOLU-MEDROL®), prednisolone (DELTA-CORTEF®, ORAPRED®, PEDIAPRED®, PRELONE®), and prednisone (DELTASONE®, LIQUID PRED®, METICORTEN®, ORASONE®)), and bisphosphonates (e.g., pamidronate (AREDIA®), and zoledronic acid (ZOMETA®))

In some embodiments, the multispecific molecule is used in combination with a tyrosine kinase inhibitor (e.g., a receptor tyrosine kinase (RTK) inhibitor). Exemplary tyrosine kinase inhibitor include, but are not limited to, an epidermal growth factor (EGF) pathway inhibitor (e.g., an epidermal growth factor receptor (EGFR) inhibitor), a vascular endothelial growth factor (VEGF) pathway inhibitor (e.g., an antibody against VEGF, a VEGF trap, a vascular endothelial growth factor receptor (VEGFR) inhibitor (e.g., a VEGFR-1 inhibitor, a VEGFR-2 inhibitor, a VEGFR-3 inhibitor)), a platelet derived growth factor (PDGF) pathway inhibitor (e.g., a platelet derived growth factor receptor (PDGFR) inhibitor (e.g., a PDGFR-ß inhibitor)), a RAF-1 inhibitor, a KIT inhibitor and a RET inhibitor. In some embodiments, the anti-cancer agent used in combination with the AHCM agent is selected from the group consisting of: axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN™, AZD2171), dasatinib (SPRYCEL®, BMS-354825), erlotinib (TARCEVA®), gefitinib (IRESSA®), imatinib (Gleevec®, CGP57148B, STI-571), lapatinib (TYKERB®, TYVERB®), lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib (TASIGNA®), semaxanib (semaxinib, SU5416), sunitinib (SUTENT®, SU11248), toceranib (PALLADIA®), vandetanib (ZACTIMA®, ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab (HERCEPTIN®), bevacizumab (AVASTIN®), rituximab (RITUXAN®), cetuximab (ERBITUX®), panitumumab (VECTIBIX®), ranibizumab (Lucentis®), nilotinib (TASIGNA®), sorafenib (NEXAVAR®), alemtuzumab (CAMPATH®), gemtuzumab ozogamicin (MYLOTARG®), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK™), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF®), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, XL228, AEE788, AG-490, AST-6, BMS-599626, CUDC-101, PD153035, pelitinib (EKB-569), vandetanib (zactima), WZ3146, WZ4002, WZ8040, ABT-869 (linifanib), AEE788, AP24534 (ponatinib), AV-951 (tivozanib), axitinib, BAY 73-4506 (regorafenib), brivanib alaninate (BMS-582664), brivanib (BMS-540215), cediranib (AZD2171), CHIR-258 (dovitinib), CP 673451, CYC116, E7080, Ki8751, masitinib (AB1010), MGCD-265, motesanib diphosphate (AMG-706), MP-470, OSI-930, Pazopanib Hydrochloride, PD173074, nSorafenib Tosylate (Bay 43-9006), SU 5402, TSU-68 (SU6668), vatalanib, XL880 (GSK1363089, EXEL-2880). Selected tyrosine kinase inhibitors are chosen from sunitinib, erlotinib, gefitinib, or sorafenib. In one embodiment, the tyrosine kinase inhibitor is sunitinib.

In one embodiment, the multispecific molecule is administered in combination with one of more of: an anti-angiogenic agent, or a vascular targeting agent or a vascular disrupting agent. Exemplary anti-angiogenic agents include, but are not limited to, VEGF inhibitors (e.g., anti-VEGF antibodies (e.g., bevacizumab); VEGF receptor inhibitors (e.g., itraconazole); inhibitors of cell proliferatin and/or migration of endothelial cells (e.g., carboxyamidotriazole, TNP-470); inhibitors of angiogenesis stimulators (e.g., suramin), among others. A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis (reviewed in, e.g., Thorpe, P. E. (2004) Clin. Cancer Res. Vol. 10:415-427). VTAs can be small-molecule. Exemplary small-molecule VTAs include, but are not limited to, microtubule destabilizing drugs (e.g., combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503); and vadimezan (ASA404).

Immune Checkpoint Inhibitors

In other embodiments, methods described herein comprise use of an immune checkpoint inhibitor in combination with the multispecific molecule. The methods can be used in a therapeutic protocol in vivo.

In embodiments, an immune checkpoint inhibitor inhibits a checkpoint molecule.

Exemplary checkpoint molecules include but are not limited to CTLA4, PD1, PD-L1, PD-L2, TIM3, LAG3, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), BTLA, KIR, MHC class I, MHC class II, GALS, VISTA, BTLA, TIGIT, LAIR1, and A2aR. See, e.g., Pardoll. Nat. Rev. Cancer 12.4(2012):252-64, incorporated herein by reference.

In embodiments, the immune checkpoint inhibitor is a PD-1 inhibitor, e.g., an anti-PD-1 antibody such as Nivolumab, Pembrolizumab or Pidilizumab. Nivolumab (also called MDX-1106, MDX-1106-04, ONO-4538, or BMS-936558) is a fully human IgG4 monoclonal antibody that specifically inhibits PD1. See, e.g., U.S. Pat. No. 8,008,449 and WO2006/121168. Pembrolizumab (also called Lambrolizumab, MK-3475, MK03475, SCH-900475 or KEYTRUDA®; Merck) is a humanized IgG4 monoclonal antibody that binds to PD-1. See, e.g., Hamid, O. et al. (2013) New England Journal of Medicine 369 (2): 134-44, U.S. Pat. No. 8,354,509 and WO2009/114335. Pidilizumab (also called CT-011 or Cure Tech) is a humanized IgGlk monoclonal antibody that binds to PD1. See, e.g., WO2009/101611. In one embodiment, the inhibitor of PD-1 is an antibody molecule having a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence of Nivolumab, Pembrolizumab or Pidilizumab. Additional anti-PD1 antibodies, e.g., AMP 514 (Amplimmune), are described, e.g., in U.S. Pat. No. 8,609,089, US 2010028330, and/or US 20120114649.

In some embodiments, the PD-1 inhibitor is an immunoadhesin, e.g., an immunoadhesin comprising an extracellular/PD-1 binding portion of a PD-1 ligand (e.g., PD-L1 or PD-L2) that is fused to a constant region (e.g., an Fc region of a heavy chain). In embodiments, the PD-1 inhibitor is AMP-224 (B7-DCIg, e.g., described in WO2011/066342and WO2010/027827), a PD-L2 Fc fusion soluble receptor that blocks the interaction between B7-H1 and PD-1.

In embodiments, the immune checkpoint inhibitor is a PD-L1 inhibitor, e.g., an antibody molecule. In some embodiments, the PD-L1 inhibitor is YW243.55.570, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105. In some embodiments, the anti-PD-L1 antibody is MSB0010718C (also called A09-246-2; Merck Serono), which is a monoclonal antibody that binds to PD-L1. Exemplary humanized anti-PD-L1 antibodies are described, e.g., in WO2013/079174. In one embodiment, the PD-L1 inhibitor is an anti-PD-L1 antibody, e.g., YW243.55.570. The YW243.55.570 antibody is described, e.g., in WO 2010/077634. In one embodiment, the PD-L1 inhibitor is MDX-1105 (also called BMS-936559), which is described, e.g., in WO2007/005874. In one embodiment, the PD-L1 inhibitor is MDPL3280A (Genentech/Roche), which is a human Fc-optimized IgG1 monoclonal antibody against PD-L1. See, e.g., U.S. Pat. No. 7,943,743 and U.S. Publication No.: 20120039906. In one embodiment, the inhibitor of PD-L1 is an antibody molecule having a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence of YW243.55.570, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105.

In embodiments, the immune checkpoint inhibitor is a PD-L2 inhibitor, e.g., AMP-224 (which is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD1 and B7-H1. See, e.g., WO2010/027827 and WO2011/066342.

In one embodiment, the immune checkpoint inhibitor is a LAG-3 inhibitor, e.g., an anti LAG-3 antibody molecule. In embodiments, the anti-LAG-3 antibody is BMS-986016 (also called BMS986016; Bristol-Myers Squibb). BMS-986016 and other humanized anti-LAG-3 antibodies are described, e.g., in US 2011/0150892, WO2010/019570, and WO2014/008218.

In embodiments, the immune checkpoint inhibitor is a TIM-3 inhibitor, e.g., anti-TIM3 antibody molecule, e.g., described in U.S. Pat. No. 8,552,156, WO 2011/155607, EP 2581113 and U.S. Publication No.: 2014/044728.

In embodiments, the immune checkpoint inhibitor is a CTLA-4 inhibitor, e.g., anti-CTLA-4 antibody molecule. Exemplary anti-CTLA4 antibodies include Tremelimumab (IgG2 monoclonal antibody from Pfizer, formerly known as ticilimumab, CP-675,206); and Ipilimumab (also called MDX-010, CAS No. 477202-00-9). Other exemplary anti-CTLA-4 antibodies are described, e.g., in U.S. Pat. No. 5,811,097.

EXAMPLES

The following examples are intended to be illustrative, and are not meant in any way to be limiting.

Example 1. Generation of Multiple αCCR2/αCSF1R Bispecific Antibody Molecules
1. Construction of the Plasmids.

The DNA encoding the protein sequences was optimized for expression in Cricetulus griseus, synthesized, and cloned into the pcDNA3.4-TOPO (Life Technologies A14697) using Gateway cloning. All constructs contained an Ig Kappa leader sequence (ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTAC AGGA (SEQ ID NO: 115), SEQ ID NO: METDTLLLWVLLLWVPGSTG (SEQ ID NO: 116)). The nucleic acid sequences used are shown in Table 5.

TABLE 5

Exemplary nucleic acid sequences of antibodies

SEQ ID

NO
Description
Nucleic Acid Sequence

SEQ ID
αCCR2
CAGGTCCAGCTGCAAGAGTCTGGCCCTGGACTGGTTCAGCCCTC

NO: 1
MC12 VH
TCAGACCCTGTCTCTGACCTGTACCGTGTCCGGCTTCTCCCTGAC

CGACTTCTCTGTGCACTGGGTCCGACAGCCTCCAGGCAAAGGAC

TGGAATGGATGGGCAGAATCAGATCCGAGGGCAACACCGACTA

CAACAGCGCCCTGAAGTCCCGGCTGTCTATCAGCAGAGACACC

TCCAAGAGCCAGGTGTTCCTGAAGATGAACTCCCTGCAGACCG

AGGACACCGCCATCTATTTCTGCACCAGAGGCGACATCCTCGGC

TTCGGCTATTGGGGACAGGGCGTGATGGTCACCGTTAGCTCT

SEQ ID
αCCR2
GACATCGTGATGACCCAGTCTCCACTGTCCGTGTCTGTGACCCC

NO: 2
MC12 VL
TGGCGAGTCTGCCTCCATCTCCTGCAGATCCTCCAAGAGCCTGC

TGCACTTCAAGGGCATCACCTTCGTGTACTGGTATCTGCAGAAG

CCCGGCCAGTCTCCTCAGCTGCTGATCTTCAGAATGTCCAGCCT

GGCCTCTGGCGTGCCCGATAGATTTTCTGGCTCCGGCTCCGAGA

CAGACTTCACCCTGAAGATCTCCAGAGTGGAAGCCGAGGACGT

GGGCACCTACTATTGTGGCCAGCTGCTGGAAAACCCCTACACCT

TTGGCGCTGGCACCAAGCTGGAACTGAAG

SEQ ID
R2b CH1
GCTCAGACCACCGCTCCTAGCGTGTACCCTTTGGCTCCTGGCTG

NO: 3

TGGCGACACCACCTCTTCTACAGTGACCCTGGGCTGTCTGGTCA

AGGGCTACTTTCCTGAGCCTGTGACCGTGACCTGGAACTCTGGT

GCCCTGTCCTCCGACGTGCACACCTTTCCAGCTGTGCTGCAGTC

CGGCCTGTACACCCTGACATCCTCCGTGACCTCTTCCACCTGGC

CTAGCCAGACCGTGACATGCAATGTGGCTCACCCTGCCTCCAGC

ACCAAGGTGGACAAGAAGGTGGAACGGCGG

SEQ ID
R2b CL
AGAGCTGACGCTGCCCCTACCGTGTCTATCTTCCCTCCATCCAT

NO: 4

GGAACAGCTGACCTCTGGCGGAGCTACCGTCGTGTGCTTCGTGA

ACAACTTCTACCCTCGGGACATCTCCGTGAAGTGGAAGATCGAC

GGCTCTGAGCAGCGAGATGGCGTGCTGGATTCTGTGACCGACC

AGGACTCCAAGGACAGCACCTACTCCATGTCTAGCACCCTGAG

CCTGACCAAGGTGGAATACGAGCGGCACAACCTGTATACCTGC

GAGGTGGTGCACAAGACCTCCAGCTCTCCCGTGGTCAAGTCCTT

CAACCGGAACGAGTGC

SEQ ID
αmCSF1R
CAGGTCCAGTTGCAGCAGTCTGGCGCTGAGCTGGTCAAGCCTG

NO: 5
VH
GATCCTCCGTGAAGATCTCCTGCAAGGCCTCCGGCTACACCTTC

ACCTCCAACTTCATGCACTGGATCAAGCAGCAGCCCGGCAACG

GCCTGGAATGGATCGGATGGATCTATCCTGGCGACGGCGACAC

CGAGTACAACCAGAAGTTCAACGGCAAGGCTACCCTGACCGCC

GACAAGTCCTCTTCCACCGCTTACATGCAGCTGTCCAGCCTGAC

CTCTGAGGACTCCGCCGTGTACTTCTGCGCCGTGAATTATGGCG

GCTACGTGCTGGATGCTTGGGGCCAAGGCGCTTCTGTGACAGTG

TCCTCT

SEQ ID
R2a CH1
GCCGAGACAACCGCTCCTAGCGTTTACCCTCTGGCTCCTGGCAC

NO: 6

AGCCCTGAAGTCCAACTCTATGGTCACCCTGGGCTGCCTGGTCA

AGGGCTACTTTCCTGAGCCTGTGACCGTGACCTGGAACTCTGGT

GCTCTGTCTAGCGGCGTGCACACCTTTCCAGCTGTGCTGCAGAG

CGGCCTGTACACCCTGACATCTAGCGTGACCGTGCCTTCCAGCA

CCTGGTCTAGTCAGGCTGTGACCTGCAACGTGGCCCATCCTGCC

TCTTCTACCAAGGTGGACAAGAAAATCGTGCCCAGAGAGTGCA

AC

SEQ ID
αmCSF1R
GAGATCGTGCTGACCCAGTCTCCTACCACCATGGCTGCTAGCCC

NO: 7
VL
TGGCGAGAAAGTGACAATTACCTGCCGGGCCTCCTCCTCCACCA

ACTACATGTCCTGGTATCAGCAGAAGTCCGGCGCCTCTCCTAAG

CCTTGGATCTACGAGACATCCAAGCTGGCCTCTGGCGTGCCCGA

TAGATTTTCCGGCTCTGGCTCCGGCACCTCCTACAGCTTCACCA

TCTCCAGCATGGAAACAGAGGACGCCGCCACCTACTACTGCCA

CCAGTGGTCATCTACCCCTCTGACCTTTGGCAGCGGCACCAAGC

TGGAAATCAAG

SEQ ID
R2a CL
AGAGCTGACGCCGCTCCTACCGTGTCTATCTTCCCTCCATCCAT

NO: 8

GGAACAGCTGACCTCCGGCGGAGCTACCGTCGTGTGTTTCGTGA

ACAACTTCTACCCTCGGGACATCTCCGTGAAGTGGAAGATCGAC

GGCTCTGAGCAGCGAGATGGCGTGCTGGATTCTGTGACCGACC

AGGACTCCAAGGACAGCACCTACTCCATGTCTAGCACCCTGAG

CCTGACCAAGGTGGAATACGAGCGGCACAACCTGTATACCTGC

GAGGTGGTGCACAAGACCTCCAGCTCTCCCGTGGTCAAGTCCTT

CAACCGGAACGAGTGC

SEQ ID
mFc Knob
ACCATTAAGCCTTGTCCTCCATGCAAGTGCCCCGCTCCTAATCT

NO: 9

GCTCGGAGGCCCTTCCGTGTTCATCTTTCCACCTAAGATCAAGG

ACGTGCTGATGATCTCCCTGTCTCCTATCGTGACCTGCGTGGTG

GTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGTTGGTT

CGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACAC

AGAGAGGACTACAACTCTACCCTGAGAGTGGTGTCTGCCCTGCC

TATCCAGCATCAGGACTGGATGTCCGGCAAAGAATTCAAGTGC

AAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAGCGGACCA

TCTCTAAGCCTAAGGGCTCTGTCAGGGCCCCTCAGGTGTACGTT

CTGCCTCCTTGCGAGGAAGAGATGACCAAGAAACAAGTGACAC

TGTGGTGCATGGTCACAGACTTCATGCCCGAGGACATCTACGTG

GAATGGACCAACAACGGCAAGACCGAGCTGAACTACAAGAAC

ACCGAGCCTGTGCTGGACTCCGACGGCTCCTACTTCATGTACTC

CAAGCTGCGCGTCGAGAAGAAGAACTGGGTCGAGAGAAACTCC

TACTCCTGCTCCGTGGTGCACGAGGGCCTGCACAATCACCACAC

CACCAAGTCCTTCTCTCGGACCCCTGGCAAG

SEQ ID
mFc Hole
ACCATCAAGCCCTGTCCTCCATGCAAGTGCCCCGCTCCTAATCT

NO: 10

GCTCGGAGGCCCTTCCGTGTTCATCTTCCCACCTAAGATCAAGG

ACGTGCTGATGATCTCCCTGTCTCCTATCGTGACCTGCGTGGTG

GTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGTTGGTT

CGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACAC

AGAGAGGACTACAACAGCACCCTGAGAGTGGTGTCTGCCCTGC

CAATCCAGCACCAGGATTGGATGTCCGGCAAAGAATTCAAGTG

CAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAGCGGACC

ATCTCTAAGCCTAAGGGCTCTGTGCGGGCTCCCCAAGTTTGTGT

TCTGCCTCCACCTGAGGAAGAGATGACCAAGAAACAAGTGACC

CTGTCTTGTGCCGTGACCGACTTCATGCCCGAGGACATCTACGT

GGAATGGACCAACAATGGCAAGACCGAGCTGAACTACAAGAAC

ACCGAGCCTGTGCTGGACTCCGACGGCTCCTACTTCATGGTGTC

TAAGCTGCGCGTCGAGAAGAAGAACTGGGTCGAGAGAAACTCC

TACTCCTGCTCCGTGGTGCACGAGGGCCTGCACAATCACCACAC

CACCAAGTCCTTCTCTCGGACCCCTGGCAAG

SEQ ID
αhCCR2
GAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTAAGCCTG

NO: 11
plozalizumab
GCGGCTCTCTGAGACTGTCTTGTGCCGCTTCTGGCTTCACCTTCT

VH
CCGCCTACGCCATGAACTGGGTCCGACAGGCTCCTGGCAAAGG

CCTGGAATGGGTCGGAAGAATCCGGACCAAGAACAACAACTAC

GCCACCTACTACGCCGACTCCGTGAAGGACCGGTTCACCATCTC

TCGGGACGACTCCAAGAACACCCTGTACCTGCAGATGAACTCC

CTGAAAACCGAGGACACCGCCGTGTACTACTGCACCACCTTCTA

CGGCAATGGCGTGTGGGGACAGGGCACACTGGTTACCGTTTCTT

CCGCCTCCACCAAGGGACCCTCTGTGTTTCCTCTGGCTCCCTCC

AGCAAGTCTACCTCTGGTGGAACAGCTGCCCTGGGCTGCCTGGT

CAAGGATTACTTTCCTGAGCCTGTGACCGTGTCCTGG

SEQ ID
hCH1
GCTTCTACCAAGGGACCCAGCGTGTTCCCTCTGGCTCCTTCCAG

NO: 12

CAAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCA

AGGACTACTTTCCTGAGCCTGTGACCGTGTCTTGGAACTCTGGC

GCTCTGACATCCGGCGTGCACACATTTCCAGCTGTGCTGCAGTC

CTCCGGCCTGTACTCTCTGTCCTCTGTCGTGACCGTGCCTTCCAG

CTCTCTGGGAACCCAGACCTACATCTGCAATGTGAACCACAAGC

CTTCCAACACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTG

C

SEQ ID
hFc Knob
GATAAGACCCACACATGTCCTCCATGCCCTGCCCCTGAGCTGCT

NO: 13

GGGCGGACCTTCCGTGTTCCTGTTCCCTCCAAAGCCCAAGGACA

CCCTGATGATCAGCCGGACCCCTGAAGTGACCTGCGTGGTGGTG

GATGTGTCCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGT

GGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGA

GGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCATCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCA

AGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCAT

CAGCAAGGCCAAGGGCCAGCCCCGCGAACCTCAGGTGTACACA

CTGCCTCCCTGCCGGGAAGAGATGACCAAGAACCAGGTGTCCC

TGTGGTGCCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTG

GAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACC

ACCCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACTC

CAAACTGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAATGTG

TTCAGCTGTAGCGTGATGCACGAGGCCCTGCACAACCACTACAC

CCAGAAGTCCCTGAGCCTGTCTCCTGGCAAA

SEQ ID
αhCCR2
GACGTGGTCATGACACAGAGCCCTCTGTCTCTGCCCGTGACATT

NO: 14
plozalizumab
GGGACAGCCTGCCTCCATCTCCTGCAAGTCCTCTCAGTCCCTGC

VL
TGGACTCTGACGGCAAGACCTTCCTGAACTGGTTCCAGCAGCGG

CCTGGCCAGTCTCCTAGAAGGCTGATCTACCTGGTGTCCAAGCT

GGATTCTGGCGTGCCCGACAGATTCTCCGGCTCTGGCTCTGGCA

CCGACTTCACCCTGAAGATCTCCAGAGTGGAAGCCGAGGACGT

GGGCGTGTACTACTGTTGGCAGGGCACCCACTTTCCATACACCT

TCGGCCAGGGCACCAGACTGGAAATCAAG

SEQ ID
hCL (kappa)
AGAACAGTGGCCGCTCCTTCCGTGTTCATCTTCCCACCCTCCGA

NO: 15

CGAGCAGCTGAAGTCCGGCACCGCTTCTGTCGTGTGCCTGCTCA

ACAACTTCTACCCTCGGGAAGCCAAGGTGCAGTGGAAGGTGGA

CAACGCCCTGCAGTCCGGCAACTCCCAGGAATCCGTCACCGAG

CAGGACTCCAAGGACAGCACCTACTCCCTGTCCTCCACCCTGAC

CCTGTCCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGC

GAAGTGACCCACCAGGGCCTGAGCAGCCCCGTGACCAAGTCCT

TCAACCGGGGCGAGTGC

SEQ ID
αhCCR2 D1
GAAGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTG

NO: 16
VH
GCGCCTCTGTGAAGGTGTCCTGCAAGGCTTCTGGCTACACCTTT

ACCGGCTACCACATGCACTGGGTCCGACAGGCTCCAGGACAAG

GCTTGGAATGGATGGGCTGGATCAACCCCAACTCCGGCGTGAC

CAAATACGCCCAGAAATTCCAGGGCAGAGTGACCATGACCAGA

GACACCTCCATCAACACCGCCTACATGGAACTGTCCCGGCTGAG

ATTCGACGACACCGACGTGTACTACTGTGCCACCGGCGGCTTTG

GCTATTGGGGAGAGGGAACACTGGTCACCGTGTCCTCC

SEQ ID
αhCCR2 D1
CTGCCCGTGTTGACCCAGCCTCCTAGCGTTTCCAAGGGCCTGAG

NO: 17
VL
ACAGACCGCCACACTGACCTGTACCGGCAACTCTAACAACGTG

GGCAATCAGGGCGCTGCCTGGTTGCAGCAGCATCAGGGACAGC

CTCCAAAGCTGCTGTCCTACCGGAACCACAACAGACCTAGCGG

CGTGTCCGAGCGGTTCAGCCCTTCTAGATCTGGCGACACCTCCA

GCCTGACCATCACTGGACTGCAGCCTGAGGACGAGGCCGACTA

CTATTGTCTGGCCTGGGACAGCTCCCTGCGGGCCTTTGTTTTTGG

CACCGGCACCAAGCTGACCGTGCTG

SEQ ID
hCL
GGACAACCTAAGGCCAATCCTACCGTGACACTGTTCCCTCCATC

NO: 18
(lambda)
CTCCGAGGAACTGCAGGCCAACAAGGCTACCCTCGTGTGCCTG

ATCTCCGACTTTTACCCTGGCGCTGTGACCGTGGCCTGGAAGGC

TGATGGATCTCCTGTGAAGGCTGGCGTGGAAACCACCAAGCCTT

CCAAGCAGTCCAACAACAAATACGCCGCCTCCTCCTACCTGTCT

CTGACCCCTGAACAGTGGAAGTCCCACCGGTCCTACAGCTGCCA

AGTGACCCATGAGGGCTCCACCGTGGAAAAGACCGTGGCTCCT

ACCGAGTGCTCC

SEQ ID
αhCCR2
CAGGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTG

NO: 19
42G7 VH
GCGCCTCTGTGAAGGTGTCCTGCAAGGCTTCCGGCTACACCTTC

TCCAGCTACTACATGCACTGGGTCCGACAGGCCCCTGGACAAG

GATTGGAGTGGATGGGCATCATCAACCCCTCTGGCGGCAACAC

CTCTTACGCCCAGAAATTCCAGGGCAGAGTGACCATGACCAGA

GACACCTCCACCAGCACCGTGTACATGGAACTGTCCAGCCTGA

GATCCGAGGACACCGCCGTGTACTACTGTGCCAGAGGCGGATA

CCAGCTGCCTCACGGTAGAGCCAGAGCCTTCGATATGTGGGGC

CAGGGCACAATGGTCACCGTGTCCTCT

SEQ ID
αhCCR2
GCCATCAGAATGACCCAGTCTCCACTGAGCCTGCCTGTGACATT

NO: 20
42G7 VL
GGGCCAGCCTGCCTCTATCTCCTGCACCTCCTCTCAGTCTCTGGT

GTACAGAGATGGCACCACCTACCTGAACTGGTTCCAGCAGAGG

CCTGGCCAGTCTCCTAGACGGCTGATCTACAAGGTGTCCAACAG

AGACTCTGGCGTGCCCGACAGATTCACCGGCTCTGGCTCTGGCA

CCACATTCACCCTGACCATCTCCAGAGTGGAAGCCGAGGACGT

GGGCATCTACTACTGTATGCAGGGCACCCACTGGCCTCTGACCT

TTGGCCAGGGAACAAAGGTGGAAATCAAG

SEQ ID
αhCCR2
GAGGTGCAGCTGGTTGAATCTGGCGGAGGATTGGTTCAGCCTG

NO: 21
43G12 VH
GCGGCTCTCTGAGACTGTCTTGTGTGGCCTCTGGCTTCACCTTCT

CCGACTACTGGATGTCCTGGGTCCGACAGGCTCCTGGCAAAGG

ACTGGAATGGGTCGCCAACATCAAGAAAGACGGCTCCGTGAAC

TACTACGTGGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGA

CAACGCCAAGAACTCCCTGTACCTGCAGATGAACAGCCTGAGA

GCCGAGGACACCGCCGTGTACTACTGCACCAGATTCGATTACTG

GGGCCAGGGCACCCTGGTCACAGTGTCCTCT

SEQ ID
αhCCR2
CAGGCTGGCTTGACCCAGCCTCCTAGCGTTTCCAAGGGCCTGAG

NO: 22
43G12 VL
ACAGACCGCCACACTGACCTGTACCGGCAACTCTAACAACGTG

GGCAATCAGGGCGCTGCCTGGTTGCAGCAGCATCAGGGACATC

CTCCAAAGCTGCTGTTCTACCGGAACAACAACAGAGCCTCCGG

CATCTCCGAGCGGCTGTCTGCTTCTAGATCCGGCAATACCGCCA

GCCTGACCATCACTGGACTGCAGCCTGAGGACGAGGCCGACTA

CTATTGCCTGACCTGGGACTCCTCTCTGTCCGTGGTGGTTTTTGG

CGGAGGCACCAAGCTGACAGTGCTG

SEQ ID
αhCSF1R
CAGGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTG

NO: 23
emactuzumab
GCGCCTCTGTGAAGGTGTCCTGCAAGGCTTCCGGCTACACCTTT

VH
ACCAGCTACGACATCTCCTGGGTCCGACAGGCTCCTGGACAAG

GCTTGGAATGGATGGGCGTGATCTGGACCGATGGCGGCACCAA

TTACGCCCAGAAACTGCAGGGCAGAGTGACCATGACCACCGAC

ACCTCTACCTCCACCGCCTACATGGAACTGCGGTCCCTGAGATC

TGACGACACCGCCGTGTACTACTGCGCCAGAGATCAGCGGCTG

TACTTCGATGTGTGGGGCCAGGGCACAACCGTGACAGTGTCCTC

T

SEQ ID
αhCSF1R
GACATCCAGATGACCCAGTCTCCATCCTCTCTGTCCGCCTCTGT

NO: 24
emactuzumab
GGGCGACAGAGTGACCATCACCTGTAGAGCCTCCGAGGACGTG

VL
AACACCTACGTGTCCTGGTATCAGCAGAAGCCCGGCAAGGCTC

CCAAGCTGCTGATCTACGCCGCCTCTAACAGATACACCGGCGTG

CCCTCTAGATTCTCCGGCTCTGGCTCTGGCACCGACTTTACCCTG

ACAATCTCCAGCCTGCAGCCTGAGGACTTCGCCACCTACTACTG

CCAGCAGTCCTTCAGCTACCCCACCTTTGGCCAGGGCACCAAGC

TGGAAATCAAG

SEQ ID
hFc Hole
GATAAGACCCACACCTGTCCTCCCTGCCCTGCCCCTGAACTGCT

NO: 25

GGGCGGACCTAGCGTGTTCCTGTTCCCTCCAAAGCCCAAGGACA

CCCTGATGATCAGCCGGACCCCTGAAGTGACCTGCGTGGTGGTG

GATGTGTCCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGT

GGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGA

GGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCA

AGGTGTCCAACAAGGCCCTGCCAGCCCCTATCGAGAAAACCAT

CAGCAAGGCCAAGGGCCAGCCTAGAGAGCCTCAGGTCTGCACC

CTGCCTCCCAGCCGGGAAGAGATGACCAAGAACCAGGTGTCCC

TGAGCTGCGCCGTGAAGGGCTTCTACCCCTCCGATATCGCCGTG

GAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACC

ACCCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGGTGTC

CAAACTGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAATGTG

TTCAGCTGTAGCGTGATGCACGAGGCCCTGCACAACCACTACAC

CCAGAAGTCTCTGAGCCTGAGCCCTGGCAAA

SEQ ID
αhCSF1R
CAGGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTG

NO: 26
cabiralizumab
GCTCCTCCGTGAAGGTGTCCTGCAAGGCTTCTGGCTACACCTTT

VH
ACCGACAACTACATGATCTGGGTCCGACAGGCTCCTGGACAGG

GACTTGAGTGGATGGGCGACATCAACCCTTACAACGGCGGCAC

CACCTTCAACCAGAAATTCAAGGGCAGAGTGACCATCACCGCC

GACAAGTCTACCTCCACCGCCTACATGGAACTGTCCAGCCTGAG

ATCTGAGGACACCGCCGTGTACTACTGCGCCAGAGAGTCCCCTT

ACTTCTCCAACCTGTACGTGATGGACTACTGGGGCCAGGGCACA

CTGGTCACAGTGTCCTCT

SEQ ID
αhCSF1R
GAGATCGTGCTGACCCAGTCTCCTGCCACACTGTCACTGTCTCC

NO: 27
cabiralizumab
AGGCGAGAGAGCTACCCTGTCCTGCAAGGCTTCTCAGTCCGTGG

VL
ACTACGACGGCGACAACTACATGAACTGGTATCAGCAGAAGCC

CGGCCAGGCTCCTAGACTGCTGATCTACGCCGCCTCCAACCTGG

AATCTGGCATCCCCGCTAGATTCTCCGGCTCTGGCTCTGGCACA

GACTTTACCCTGACCATCTCCAGCCTGGAACCTGAGGACTTCGC

CGTGTACTACTGCCACCTGTCCAACGAGGACCTGTCCACATTTG

GCGGAGGCACCAAGGTGGAAATCAAG

TABLE 6

Sequences used to construct ORFs.

Sequence ID
Variable
Constant
Fc

SEQ ID NO: 28
SEQ ID NO: 1
SEQ ID NO: 3
SEQ ID NO: 9

SEQ ID NO: 29
SEQ ID NO: 2
SEQ ID NO: 4

SEQ ID NO: 30
SEQ ID NO: 5
SEQ ID NO: 6
SEQ ID NO: 10

SEQ ID NO: 31
SEQ ID NO: 7
SEQ ID NO: 8

SEQ ID NO: 32
SEQ ID NO: 11
SEQ ID NO: 12
SEQ ID NO: 13

SEQ ID NO: 33
SEQ ID NO: 14
SEQ ID NO: 15

SEQ ID NO: 34
SEQ ID NO: 16
SEQ ID NO: 12
SEQ ID NO: 13

SEQ ID NO: 35
SEQ ID NO: 17
SEQ ID NO: 18

SEQ ID NO: 36
SEQ ID NO: 19
SEQ ID NO: 12
SEQ ID NO: 13

SEQ ID NO: 37
SEQ ID NO: 20
SEQ ID NO: 15

SEQ ID NO: 38
SEQ ID NO: 21
SEQ ID NO: 12
SEQ ID NO: 13

SEQ ID NO: 39
SEQ ID NO: 22
SEQ ID NO: 18

SEQ ID NO: 40
SEQ ID NO: 23
SEQ ID NO: 12
SEQ ID NO: 25

SEQ ID NO: 41
SEQ ID NO: 24
SEQ ID NO: 15

SEQ ID NO: 42
SEQ ID NO: 26
SEQ ID NO: 12
SEQ ID NO: 25

SEQ ID NO: 43
SEQ ID NO: 27
SEQ ID NO: 15

TABLE 7

Nucleic acid sequences of ORFs.

SEQ ID

NO
Nucleic Acid Sequence

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 28
ACAGGTCCAGCTGCAAGAGTCTGGCCCTGGACTGGTTCAGCCCTCTCAGACCCTGTCTC

TGACCTGTACCGTGTCCGGCTTCTCCCTGACCGACTTCTCTGTGCACTGGGTCCGACAG

CCTCCAGGCAAAGGACTGGAATGGATGGGCAGAATCAGATCCGAGGGCAACACCGACT

ACAACAGCGCCCTGAAGTCCCGGCTGTCTATCAGCAGAGACACCTCCAAGAGCCAGGT

GTTCCTGAAGATGAACTCCCTGCAGACCGAGGACACCGCCATCTATTTCTGCACCAGAG

GCGACATCCTCGGCTTCGGCTATTGGGGACAGGGCGTGATGGTCACCGTTAGCTCTGCT

CAGACCACCGCTCCTAGCGTGTACCCTTTGGCTCCTGGCTGTGGCGACACCACCTCTTC

TACAGTGACCCTGGGCTGTCTGGTCAAGGGCTACTTTCCTGAGCCTGTGACCGTGACCT

GGAACTCTGGTGCCCTGTCCTCCGACGTGCACACCTTTCCAGCTGTGCTGCAGTCCGGC

CTGTACACCCTGACATCCTCCGTGACCTCTTCCACCTGGCCTAGCCAGACCGTGACATG

CAATGTGGCTCACCCTGCCTCCAGCACCAAGGTGGACAAGAAGGTGGAACGGCGGACC

ATTAAGCCTTGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCTTCCGT

GTTCATCTTTCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCTATCGTGAC

CTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGTTGGTTCGTGA

ACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGACTACAACTCTAC

CCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCATCAGGACTGGATGTCCGGCAAAGAAT

TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAGCGGACCATCTCTAA

GCCTAAGGGCTCTGTCAGGGCCCCTCAGGTGTACGTTCTGCCTCCTTGCGAGGAAGAGA

TGACCAAGAAACAAGTGACACTGTGGTGCATGGTCACAGACTTCATGCCCGAGGACAT

CTACGTGGAATGGACCAACAACGGCAAGACCGAGCTGAACTACAAGAACACCGAGCCT

GTGCTGGACTCCGACGGCTCCTACTTCATGTACTCCAAGCTGCGCGTCGAGAAGAAGA

ACTGGGTCGAGAGAAACTCCTACTCCTGCTCCGTGGTGCACGAGGGCCTGCACAATCA

CCACACCACCAAGTCCTTCTCTCGGACCCCTGGCAAGTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACCGG

NO: 29
CGACATCGTGATGACCCAGTCTCCACTGTCCGTGTCTGTGACCCCTGGCGAGTCTGCCT

CCATCTCCTGCAGATCCTCCAAGAGCCTGCTGCACTTCAAGGGCATCACCTTCGTGTAC

TGGTATCTGCAGAAGCCCGGCCAGTCTCCTCAGCTGCTGATCTTCAGAATGTCCAGCCT

GGCCTCTGGCGTGCCCGATAGATTTTCTGGCTCCGGCTCCGAGACAGACTTCACCCTGA

AGATCTCCAGAGTGGAAGCCGAGGACGTGGGCACCTACTATTGTGGCCAGCTGCTGGA

AAACCCCTACACCTTTGGCGCTGGCACCAAGCTGGAACTGAAGAGAGCTGACGCTGCC

CCTACCGTGTCTATCTTCCCTCCATCCATGGAACAGCTGACCTCTGGCGGAGCTACCGT

CGTGTGCTTCGTGAACAACTTCTACCCTCGGGACATCTCCGTGAAGTGGAAGATCGACG

GCTCTGAGCAGCGAGATGGCGTGCTGGATTCTGTGACCGACCAGGACTCCAAGGACAG

CACCTACTCCATGTCTAGCACCCTGAGCCTGACCAAGGTGGAATACGAGCGGCACAAC

CTGTATACCTGCGAGGTGGTGCACAAGACCTCCAGCTCTCCCGTGGTCAAGTCCTTCAA

CCGGAACGAGTGCTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 30
ACAGGTCCAGTTGCAGCAGTCTGGCGCTGAGCTGGTCAAGCCTGGATCCTCCGTGAAG

ATCTCCTGCAAGGCCTCCGGCTACACCTTCACCTCCAACTTCATGCACTGGATCAAGCA

GCAGCCCGGCAACGGCCTGGAATGGATCGGATGGATCTATCCTGGCGACGGCGACACC

GAGTACAACCAGAAGTTCAACGGCAAGGCTACCCTGACCGCCGACAAGTCCTCTTCCA

CCGCTTACATGCAGCTGTCCAGCCTGACCTCTGAGGACTCCGCCGTGTACTTCTGCGCC

GTGAATTATGGCGGCTACGTGCTGGATGCTTGGGGCCAAGGCGCTTCTGTGACAGTGTC

CTCTGCCGAGACAACCGCTCCTAGCGTTTACCCTCTGGCTCCTGGCACAGCCCTGAAGT

CCAACTCTATGGTCACCCTGGGCTGCCTGGTCAAGGGCTACTTTCCTGAGCCTGTGACC

GTGACCTGGAACTCTGGTGCTCTGTCTAGCGGCGTGCACACCTTTCCAGCTGTGCTGCA

GAGCGGCCTGTACACCCTGACATCTAGCGTGACCGTGCCTTCCAGCACCTGGTCTAGTC

AGGCTGTGACCTGCAACGTGGCCCATCCTGCCTCTTCTACCAAGGTGGACAAGAAAATC

GTGCCCAGAGAGTGCAACACCATCAAGCCCTGTCCTCCATGCAAGTGCCCCGCTCCTAA

TCTGCTCGGAGGCCCTTCCGTGTTCATCTTCCCACCTAAGATCAAGGACGTGCTGATGA

TCTCCCTGTCTCCTATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGAC

GTGCAGATCAGTTGGTTCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACAC

ACAGAGAGGACTACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCAATCCAGCACCA

GGATTGGATGTCCGGCAAAGAATTCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCT

CCAATCGAGCGGACCATCTCTAAGCCTAAGGGCTCTGTGCGGGCTCCCCAAGTTTGTGT

TCTGCCTCCACCTGAGGAAGAGATGACCAAGAAACAAGTGACCCTGTCTTGTGCCGTG

ACCGACTTCATGCCCGAGGACATCTACGTGGAATGGACCAACAATGGCAAGACCGAGC

TGAACTACAAGAACACCGAGCCTGTGCTGGACTCCGACGGCTCCTACTTCATGGTGTCT

AAGCTGCGCGTCGAGAAGAAGAACTGGGTCGAGAGAAACTCCTACTCCTGCTCCGTGG

TGCACGAGGGCCTGCACAATCACCACACCACCAAGTCCTTCTCTCGGACCCCTGGCAAG

TGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 31
CGAGATCGTGCTGACCCAGTCTCCTACCACCATGGCTGCTAGCCCTGGCGAGAAAGTG

ACAATTACCTGCCGGGCCTCCTCCTCCACCAACTACATGTCCTGGTATCAGCAGAAGTC

CGGCGCCTCTCCTAAGCCTTGGATCTACGAGACATCCAAGCTGGCCTCTGGCGTGCCCG

ATAGATTTTCCGGCTCTGGCTCCGGCACCTCCTACAGCTTCACCATCTCCAGCATGGAA

ACAGAGGACGCCGCCACCTACTACTGCCACCAGTGGTCATCTACCCCTCTGACCTTTGG

CAGCGGCACCAAGCTGGAAATCAAGAGAGCTGACGCCGCTCCTACCGTGTCTATCTTCC

CTCCATCCATGGAACAGCTGACCTCCGGCGGAGCTACCGTCGTGTGTTTCGTGAACAAC

TTCTACCCTCGGGACATCTCCGTGAAGTGGAAGATCGACGGCTCTGAGCAGCGAGATG

GCGTGCTGGATTCTGTGACCGACCAGGACTCCAAGGACAGCACCTACTCCATGTCTAGC

ACCCTGAGCCTGACCAAGGTGGAATACGAGCGGCACAACCTGTATACCTGCGAGGTGG

TGCACAAGACCTCCAGCTCTCCCGTGGTCAAGTCCTTCAACCGGAACGAGTGCTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 32
CGAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTAAGCCTGGCGGCTCTCTGAGA

CTGTCTTGTGCCGCTTCTGGCTTCACCTTCTCCGCCTACGCCATGAACTGGGTCCGACAG

GCTCCTGGCAAAGGCCTGGAATGGGTCGGAAGAATCCGGACCAAGAACAACAACTACG

CCACCTACTACGCCGACTCCGTGAAGGACCGGTTCACCATCTCTCGGGACGACTCCAAG

AACACCCTGTACCTGCAGATGAACTCCCTGAAAACCGAGGACACCGCCGTGTACTACT

GCACCACCTTCTACGGCAATGGCGTGTGGGGACAGGGCACACTGGTTACCGTTTCTTCC

GCCTCCACCAAGGGACCCTCTGTGTTTCCTCTGGCTCCCTCCAGCAAGTCTACCTCTGGT

GGAACAGCTGCCCTGGGCTGCCTGGTCAAGGATTACTTTCCTGAGCCTGTGACCGTGTC

CTGGAACTCTGGCGCTCTGACATCTGGCGTGCACACCTTTCCAGCTGTGCTGCAGTCCT

CTGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCTCTGGGCACCCAGA

CCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTGGACAAGAGAGTGGA

ACCCAAGTCCTGCGACAAGACCCACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCG

GCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGG

ACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCACGAGGATCCCGAAGTGAAGT

TCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGA

ACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGC

TGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCTCCTATCGA

AAAGACCATCTCCAAGGCCAAGGGCCAGCCTAGGGAACCCCAGGTTTACACCCTGCCT

CCATGCCGGGAAGAGATGACCAAGAATCAGGTGTCCCTGTGGTGCCTCGTGAAGGGCT

TCTACCCTTCCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACTA

CAAGACAACCCCTCCTGTGCTGGACTCCGACGGCTCATTCTTCCTGTACTCCAAGCTGA

CAGTGGACAAGTCCAGATGGCAGCAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGA

GGCCCTGCACAATCACTACACCCAGAAGTCCCTGTCTCTGTCCCCTGGCAAGTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 33
CGACGTGGTCATGACACAGAGCCCTCTGTCTCTGCCCGTGACATTGGGACAGCCTGCCT

CCATCTCCTGCAAGTCCTCTCAGTCCCTGCTGGACTCTGACGGCAAGACCTTCCTGAAC

TGGTTCCAGCAGCGGCCTGGCCAGTCTCCTAGAAGGCTGATCTACCTGGTGTCCAAGCT

GGATTCTGGCGTGCCCGACAGATTCTCCGGCTCTGGCTCTGGCACCGACTTCACCCTGA

AGATCTCCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACTGTTGGCAGGGCACCCA

CTTTCCATACACCTTCGGCCAGGGCACCAGACTGGAAATCAAGAGAACCGTGGCCGCT

CCTTCCGTGTTCATCTTCCCACCTTCCGACGAGCAGCTGAAGTCCGGCACAGCTTCTGTC

GTGTGCCTGCTGAACAACTTCTACCCTCGGGAAGCCAAGGTGCAGTGGAAGGTGGACA

ATGCCCTGCAGTCCGGCAACTCCCAAGAGTCTGTGACCGAGCAGGACTCCAAGGACAG

CACCTACAGCCTGTCCAGCACACTGACCCTGTCCAAGGCCGACTACGAGAAGCACAAG

GTGTACGCCTGCGAAGTGACCCATCAGGGCCTGTCTAGCCCTGTGACCAAGTCTTTCAA

CCGGGGCGAGTGCTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 34
CGAAGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAG

GTGTCCTGCAAGGCTTCTGGCTACACCTTTACCGGCTACCACATGCACTGGGTCCGACA

GGCTCCAGGACAAGGCTTGGAATGGATGGGCTGGATCAACCCCAACTCCGGCGTGACC

AAATACGCCCAGAAATTCCAGGGCAGAGTGACCATGACCAGAGACACCTCCATCAACA

CCGCCTACATGGAACTGTCCCGGCTGAGATTCGACGACACCGACGTGTACTACTGTGCC

ACCGGCGGCTTTGGCTATTGGGGAGAGGGAACACTGGTCACCGTGTCCTCCGCTTCTAC

CAAGGGACCCTCCGTGTTTCCTCTGGCTCCTTCCAGCAAGTCTACCTCCGGTGGAACAG

CTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTGACCGTGTCTTGGAAC

TCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTGCTGCAATCCTCCGGCCT

GTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCTCTGGGCACCCAGACCTACAT

CTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTGGACAAGAGAGTGGAACCCAAG

TCCTGCGACAAGACCCACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC

TTCTGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGA

AGTGACCTGCGTGGTGGTGGATGTGTCTCACGAGGACCCAGAAGTGAAGTTCAATTGG

TACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTAC

AACTCCACCTACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACG

GCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGAC

CATCTCCAAGGCCAAGGGCCAGCCTAGGGAACCCCAGGTTTACACCCTGCCTCCATGCC

GGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGCCTCGTGAAGGGCTTCTACCC

TTCCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACA

ACCCCTCCTGTGCTGGACTCCGACGGCTCATTCTTCCTGTACTCCAAGCTGACAGTGGA

CAAGTCCAGATGGCAGCAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTG

CACAATCACTACACACAGAAGTCCCTGTCTCTGTCCCCTGGCAAGTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 35
ACTGCCCGTGTTGACCCAGCCTCCTAGCGTTTCCAAGGGCCTGAGACAGACCGCCACAC

TGACCTGTACCGGCAACTCTAACAACGTGGGCAATCAGGGCGCTGCCTGGTTGCAGCA

GCATCAGGGACAGCCTCCAAAGCTGCTGTCCTACCGGAACCACAACAGACCTAGCGGC

GTGTCCGAGCGGTTCAGCCCTTCTAGATCTGGCGACACCTCCAGCCTGACCATCACTGG

ACTGCAGCCTGAGGACGAGGCCGACTACTATTGTCTGGCCTGGGACAGCTCCCTGCGG

GCCTTTGTTTTTGGCACCGGCACCAAGCTGACCGTGCTGGGACAACCTAAGGCCAATCC

TACCGTGACACTGTTCCCTCCATCCTCCGAGGAACTGCAGGCCAACAAGGCTACCCTCG

TGTGCCTGATCTCCGACTTTTACCCTGGCGCTGTGACCGTGGCCTGGAAGGCTGATGGA

TCTCCTGTGAAGGCTGGCGTGGAAACCACCAAGCCTTCCAAGCAGTCCAACAACAAAT

ACGCCGCCTCCTCCTACCTGTCTCTGACCCCTGAACAGTGGAAGTCCCACCGGTCCTAC

AGCTGCCAAGTGACCCATGAGGGCTCCACCGTGGAAAAGACCGTGGCTCCTACCGAGT

GCTCCTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 36
ACAGGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAG

GTGTCCTGCAAGGCTTCCGGCTACACCTTCTCCAGCTACTACATGCACTGGGTCCGACA

GGCCCCTGGACAAGGATTGGAGTGGATGGGCATCATCAACCCCTCTGGCGGCAACACC

TCTTACGCCCAGAAATTCCAGGGCAGAGTGACCATGACCAGAGACACCTCCACCAGCA

CCGTGTACATGGAACTGTCCAGCCTGAGATCCGAGGACACCGCCGTGTACTACTGTGCC

AGAGGCGGATACCAGCTGCCTCACGGTAGAGCCAGAGCCTTCGATATGTGGGGCCAGG

GCACAATGGTCACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTC

CTTCCAGCAAGTCCACATCCGGTGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTAC

TTTCCTGAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACAC

ATTTCCAGCTGTGCTGCAGTCCTCCGGCCTGTACTCTCTGTCCTCTGTCGTGACCGTGCC

TTCCAGCTCTCTGGGAACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACA

CCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGACAAGACCCACACCTGTCCACC

ATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAA

GGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCCC

ACGAGGACCCAGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGC

CAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACA

AGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTAGGGA

ACCCCAGGTTTACACCCTGCCTCCATGCCGGGAAGAGATGACCAAGAACCAGGTGTCC

CTGTGGTGCCTCGTGAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGGAGAGCAA

TGGCCAGCCAGAGAACAACTACAAGACAACCCCTCCTGTGCTGGACTCCGACGGCTCA

TTCTTCCTGTACTCCAAGCTGACAGTGGACAAGTCCAGATGGCAGCAGGGCAACGTGTT

CTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACACAGAAGTCCCTGTCTC

TGTCCCCTGGCAAGTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACCGG

NO: 37
CGCCATCAGAATGACCCAGTCTCCACTGAGCCTGCCTGTGACATTGGGCCAGCCTGCCT

CTATCTCCTGCACCTCCTCTCAGTCTCTGGTGTACAGAGATGGCACCACCTACCTGAAC

TGGTTCCAGCAGAGGCCTGGCCAGTCTCCTAGACGGCTGATCTACAAGGTGTCCAACA

GAGACTCTGGCGTGCCCGACAGATTCACCGGCTCTGGCTCTGGCACCACATTCACCCTG

ACCATCTCCAGAGTGGAAGCCGAGGACGTGGGCATCTACTACTGTATGCAGGGCACCC

ACTGGCCTCTGACCTTTGGCCAGGGAACAAAGGTGGAAATCAAGCGGACCGTGGCCGC

TCCTTCCGTGTTCATCTTCCCACCTTCCGACGAGCAGCTGAAGTCTGGCACAGCCTCTGT

CGTGTGCCTGCTGAACAACTTCTACCCTCGGGAAGCCAAGGTGCAGTGGAAGGTGGAC

AATGCCCTGCAGTCCGGCAACTCCCAAGAGTCTGTGACCGAGCAGGACTCCAAGGACA

GCACCTACAGCCTGTCCTCCACACTGACCCTGTCCAAGGCCGACTACGAGAAGCACAA

GGTGTACGCCTGCGAAGTGACCCATCAGGGCCTGTCTAGCCCTGTGACCAAGTCTTTCA

ACCGGGGCGAGTGCTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 38
CGAGGTGCAGCTGGTTGAATCTGGCGGAGGATTGGTTCAGCCTGGCGGCTCTCTGAGA

CTGTCTTGTGTGGCCTCTGGCTTCACCTTCTCCGACTACTGGATGTCCTGGGTCCGACAG

GCTCCTGGCAAAGGACTGGAATGGGTCGCCAACATCAAGAAAGACGGCTCCGTGAACT

ACTACGTGGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACGCCAAGAACTC

CCTGTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGCACC

AGATTCGATTACTGGGGCCAGGGCACCCTGGTCACAGTGTCCTCTGCTTCTACCAAGGG

ACCCAGCGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACCTCTGGCGGAACAGCTGCTC

TGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTGACCGTGTCCTGGAACTCTGGC

GCTCTGACATCTGGCGTGCACACCTTTCCAGCTGTGCTGCAGTCCTCCGGCCTGTACTCT

CTGTCCTCTGTCGTGACCGTGCCTTCCAGCTCTCTGGGAACCCAGACCTACATCTGCAA

TGTGAACCACAAGCCTTCCAACACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGC

GACAAGACCCACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGT

GTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGA

CCTGCGTGGTGGTGGATGTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTG

GACGGCGTGGAAGTGCACAATGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCC

ACCTACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAG

AGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTC

CAAGGCCAAGGGCCAGCCTAGGGAACCCCAGGTTTACACCCTGCCTCCATGCCGGGAA

GAGATGACCAAGAACCAGGTGTCCCTGTGGTGCCTGGTTAAGGGCTTCTACCCCTCCGA

TATCGCCGTGGAATGGGAGTCTAATGGCCAGCCAGAGAACAACTACAAGACAACCCCT

CCTGTGCTGGACTCCGACGGCTCATTCTTCCTGTACTCCAAGCTGACAGTGGACAAGTC

CAGATGGCAGCAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAAT

CACTACACCCAGAAGTCCCTGTCTCTGTCCCCTGGCAAGTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 39
ACAGGCTGGCTTGACCCAGCCTCCTAGCGTTTCCAAGGGCCTGAGACAGACCGCCACA

CTGACCTGTACCGGCAACTCTAACAACGTGGGCAATCAGGGCGCTGCCTGGTTGCAGC

AGCATCAGGGACATCCTCCAAAGCTGCTGTTCTACCGGAACAACAACAGAGCCTCCGG

CATCTCCGAGCGGCTGTCTGCTTCTAGATCCGGCAATACCGCCAGCCTGACCATCACTG

GACTGCAGCCTGAGGACGAGGCCGACTACTATTGCCTGACCTGGGACTCCTCTCTGTCC

GTGGTGGTTTTTGGCGGAGGCACCAAGCTGACAGTGCTGGGACAGCCTAAGGCCAATC

CTACCGTGACACTGTTCCCTCCATCCTCCGAGGAACTGCAGGCCAACAAGGCTACCCTC

GTGTGCCTGATCTCCGACTTTTACCCTGGCGCTGTGACCGTGGCCTGGAAGGCTGATGG

ATCTCCTGTGAAGGCTGGCGTGGAAACCACCAAGCCTTCCAAGCAGTCCAACAACAAA

TACGCCGCCTCCTCCTACCTGTCTCTGACCCCTGAACAGTGGAAGTCCCACCGGTCCTA

CAGCTGCCAAGTGACCCATGAGGGCTCCACCGTGGAAAAGACCGTGGCTCCTACCGAG

TGCTCCTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 40
ACAGGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAG

GTGTCCTGCAAGGCTTCCGGCTACACCTTTACCAGCTACGACATCTCCTGGGTCCGACA

GGCTCCTGGACAAGGCTTGGAATGGATGGGCGTGATCTGGACCGATGGCGGCACCAAT

TACGCCCAGAAACTGCAGGGCAGAGTGACCATGACCACCGACACCTCTACCTCCACCG

CCTACATGGAACTGCGGTCCCTGAGATCTGACGACACCGCCGTGTACTACTGCGCCAGA

GATCAGCGGCTGTACTTCGATGTGTGGGGCCAGGGCACAACCGTGACAGTGTCCTCTGC

TTCCACCAAGGGACCCAGCGTTTTCCCTCTGGCTCCATCCTCCAAGTCTACCTCTGGCG

GAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTGACCGTGTCC

TGGAACTCTGGCGCTCTGACATCTGGCGTGCACACATTCCCTGCTGTGCTGCAGTCCTC

CGGCCTGTACTCTCTGTCCTCTGTGGTTACCGTGCCTTCCTCTAGCCTGGGCACCCAGAC

CTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTGGACAAGAGAGTGGAA

CCCAAGTCCTGCGACAAGACCCACACCTGTCCACCATGTCCTGCTCCAGAACTGCTCGG

CGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGA

CCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCACGAGGACCCAGAAGTGAAGTT

CAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGA

ACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGC

TGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCTCCTATCGA

AAAGACCATCTCCAAGGCCAAGGGCCAGCCTCGGGAACCTCAAGTCTGTACCCTGCCT

CCTAGCCGGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGCGCCGTGAAGGGCT

TCTACCCTTCTGATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCTGAGAACAACTA

CAAGACAACCCCTCCTGTGCTGGACTCCGACGGCTCATTCTTCCTGGTGTCCAAGCTGA

CAGTGGACAAGTCCAGATGGCAGCAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGA

GGCCCTGCACAATCACTACACACAGAAGTCCCTGTCTCTGTCCCCTGGCAAGTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACCGG

NO: 41
CGACATCCAGATGACCCAGTCTCCATCCTCTCTGTCCGCCTCTGTGGGCGACAGAGTGA

CCATCACCTGTAGAGCCTCCGAGGACGTGAACACCTACGTGTCCTGGTATCAGCAGAA

GCCCGGCAAGGCTCCCAAGCTGCTGATCTACGCCGCCTCTAACAGATACACCGGCGTG

CCCTCTAGATTCTCCGGCTCTGGCTCTGGCACCGACTTTACCCTGACAATCTCCAGCCTG

CAGCCTGAGGACTTCGCCACCTACTACTGCCAGCAGTCCTTCAGCTACCCCACCTTTGG

CCAGGGCACCAAGCTGGAAATCAAGCGGACAGTGGCCGCTCCTTCCGTGTTCATCTTCC

CACCTTCCGACGAGCAGCTGAAGTCCGGCACAGCTTCTGTCGTGTGCCTGCTGAACAAC

TTCTACCCTCGGGAAGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGTCCGGCA

ACTCCCAAGAGTCTGTGACCGAGCAGGACTCCAAGGACAGCACCTACAGCCTGTCCTC

CACACTGACCCTGTCCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTG

ACCCATCAGGGCCTGTCTAGCCCTGTGACCAAGTCTTTCAACCGGGGCGAGTGCTGATG

A

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 42
ACAGGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCTCCTCCGTGAAG

GTGTCCTGCAAGGCTTCTGGCTACACCTTTACCGACAACTACATGATCTGGGTCCGACA

GGCTCCTGGACAGGGACTTGAGTGGATGGGCGACATCAACCCTTACAACGGCGGCACC

ACCTTCAACCAGAAATTCAAGGGCAGAGTGACCATCACCGCCGACAAGTCTACCTCCA

CCGCCTACATGGAACTGTCCAGCCTGAGATCTGAGGACACCGCCGTGTACTACTGCGCC

AGAGAGTCCCCTTACTTCTCCAACCTGTACGTGATGGACTACTGGGGCCAGGGCACACT

GGTCACAGTGTCCTCTGCTTCCACCAAGGGACCCAGCGTTTTCCCTCTGGCTCCATCCTC

CAAGTCCACCTCTGGTGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTG

AGCCTGTGACCGTGTCCTGGAACTCTGGCGCTCTGACATCTGGCGTGCACACCTTTCCA

GCTGTGCTGCAGTCCTCCGGCCTGTACTCTCTGTCCTCTGTCGTGACCGTGCCTTCCAGC

TCTCTGGGAACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGT

CGACAAGAGAGTGGAACCCAAGTCCTGCGACAAGACCCACACCTGTCCACCTTGTCCT

GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACAC

CCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCACGAGG

ACCCAGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGAC

CAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCC

TGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTCGGGAACCTCA

AGTCTGTACCCTGCCTCCTAGCCGGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGC

TGCGCCGTGAAGGGCTTCTACCCTTCTGATATCGCCGTGGAATGGGAGAGCAACGGCC

AGCCAGAGAACAACTACAAGACAACCCCTCCTGTGCTGGACTCCGACGGCTCATTCTTC

CTGGTGTCCAAGCTGACAGTGGACAAGTCCAGATGGCAGCAGGGCAACGTGTTCTCCT

GCTCCGTGATGCACGAGGCCCTGCACAATCACTACACACAGAAGTCTCTGTCTCTGAGC

CCCGGCAAGTGATGA

SEQ ID
ATGGAAACCGACACACTGCTGCTGTGGGTGCTGCTCTTGTGGGTGCCAGGATCTACAGG

NO: 43
CGAGATCGTGCTGACCCAGTCTCCTGCCACACTGTCACTGTCTCCAGGCGAGAGAGCTA

CCCTGTCCTGCAAGGCTTCTCAGTCCGTGGACTACGACGGCGACAACTACATGAACTGG

TATCAGCAGAAGCCCGGCCAGGCTCCTAGACTGCTGATCTACGCCGCCTCCAACCTGGA

ATCTGGCATCCCCGCTAGATTCTCCGGCTCTGGCTCTGGCACAGACTTTACCCTGACCA

TCTCCAGCCTGGAACCTGAGGACTTCGCCGTGTACTACTGCCACCTGTCCAACGAGGAC

CTGTCCACATTTGGCGGAGGCACCAAGGTGGAAATCAAGCGGACAGTGGCCGCTCCTT

CCGTGTTCATCTTCCCACCTTCCGACGAGCAGCTGAAGTCTGGCACCGCTTCTGTCGTGT

GCCTGCTGAACAACTTCTACCCTCGGGAAGCCAAGGTGCAGTGGAAGGTGGACAATGC

CCTGCAGTCCGGCAACTCCCAAGAGTCTGTGACCGAGCAGGACTCCAAGGACAGCACC

TACAGCCTGTCCTCCACACTGACCCTGTCCAAGGCCGACTACGAGAAGCACAAGGTGT

ACGCCTGCGAAGTGACCCATCAGGGCCTGTCTAGCCCTGTGACCAAGTCTTTCAACCGG

GGCGAGTGCTGATGA

2. Expression and Purification.

The plasmids were co-transfected into either Expi293 cells (Life Technologies A14527) or ExpiCHO cells (Life Technologies A29127). Transfections were performed using 1 mg of total DNA for a multispecific construct with a 1:1 knob to hole heavy chain ratio and 3:2 light chain to heavy chain ratio. When biotinylation was required, 250 μg of BirA was added per liter in addition to the multispecific construct DNA. Transfection in Expi293 cells was done using linear 25,000 Da polyethylenimine (PEI, Polysciences Inc 23966) in a 3:1 ratio with the total DNA. The DNA and PEI were each added to 50 mL of OptiMem (Life Technologies 31985088) medium and sterile filtered. The DNA and PEI were combined for 10 minutes and added to the Expi293 cells with a cell density of 1.8-2.8×10⁶cells/mL and a viability of at least 95%. The ExpiCHO transfection was performed according to the manufacturer's instructions. Expi293 cells were grown in a humidified incubator at 37° C. with 8% CO₂for 5-7 days after transfection and ExpiCHO cells were grown for 14 days at 32° C. with 5% CO₂. The cells were pelleted by centrifugation at 4500×g and the supernatant was filtered through a 0.2 μm membrane. Protein A resin (GE 17-1279-03) was added to the filtered supernatant and incubated for 1-3 hours at room temperature. The resin was packed into a column, washed with 3×10 column volumes of Dulbecco's phosphate-buffered saline (DPBS, Life Technologies 14190-144). The bound protein was eluted from the column with 20 mM citrate, 100 mM NaCl, pH 2.9. When necessary, the proteins were further purified using ligand affinity and/or size exclusion chromatography on a Superdex 200 column with a running buffer of DPBS.

TABLE 8

Amino Acid Sequences.

SEQ

ID NO
Description
Amino Acid Sequence

SEQ ID
αCCR2
QVQLQESGPGLVQPSQTLSLTCTVSGFSLTDFSVHWVRQPPGKGLEW

NO: 44
MC12 VH
MGRIRSEGNTDYNSALKSRLSISRDTSKSQVFLKMNSLQTEDTAIYFC

TRGDILGFGYWGQGVMVTVSS

SEQ ID
αCCR2
DIVMTQSPLSVSVTPGESASISCRSSKSLLHFKGITFVYWYLQKPGQSP

NO: 45
MC12 VL
QLLIFRMSSLASGVPDRFSGSGSETDFTLKISRVEAEDVGTYYCGQLLE

NPYTFGAGTKLELK

SEQ ID
R2b CH1
AQTTAPSVYPLAPGCGDTTSSTVTLGCLVKGYFPEPVTVTWNSGALS

NO: 46

SDVHTFPAVLQSGLYTLTSSVTSSTWPSQTVTCNVAHPASSTKVDKK

VERR

SEQ ID
R2b CL
RADAAPTVSIFPPSMEQLTSGGATVVCFVNNFYPRDISVKWKIDGSEQ

NO: 47

RDGVLDSVTDQDSKDSTYSMSSTLSLTKVEYERHNLYTCEVVHKTSS

SPVVKSFNRNEC

SEQ ID
αmCSF1R
QVQLQQSGAELVKPGSSVKISCKASGYTFTSNFMHWIKQQPGNGLEW

NO: 48
VH
IGWIYPGDGDTEYNQKFNGKATLTADKSSSTAYMQLSSLTSEDSAVY

FCAVNYGGYVLDAWGQGASVTVSS

SEQ ID
R2a CH1
AETTAPSVYPLAPGTALKSNSMVTLGCLVKGYFPEPVTVTWNSGALS

NO: 49

SGVHTFPAVLQSGLYTLTSSVTVPSSTWSSQAVTCNVAHPASSTKVD

KKIVPRECN

SEQ ID
αhCCR2
EVQLVESGGGLVQPGGSLRLSCVASGFTFSDYWMSWVRQAPGKGLE

NO: 64
43G12 VH
WVANIKKDGSVNYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTA

VYYCTRFDYWGQGTLVTVSS

SEQ ID
αhCCR2
QAGLTQPPSVSKGLRQTATLTCTGNSNNVGNQGAAWLQQHQGHPPK

NO: 65
43G12 VL
LLFYRNNNRASGISERLSASRSGNTASLTITGLQPEDEADYYCLTWDS

SLSVVVFGGGTKLTVL

SEQ ID
αhCSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLE

NO: 66
emactuzumab
WMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTA

VH
VYYCARDQRLYFDVWGQGTTVTVSS

SEQ ID
αhCSF1R
DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLI

NO: 67
emactuzumab
YAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTF

VL
GQGTKLEIK

SEQ ID
hFc Hole
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE

NO: 68

DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQ

VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKL

TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX, wherein X is

K or absent

SEQ ID
αhCSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLE

NO: 69
cabiralizumab
WMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAV

VH
YYCARESPYFSNLYVMDYWGQGTLVTVSS

SEQ ID
αhCSF1R
EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQ

NO: 70
cabiralizumab
APRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSN

VL
EDLSTFGGGTKVEIK

TABLE 9

Protein sequences for full heavy and light chains.

Sequence ID
Variable
Constant
Fc

SEQ ID NO: 71
SEQ ID NO: 44
SEQ ID NO: 46
SEQ ID NO: 52

SEQ ID NO: 72
SEQ ID NO: 45
SEQ ID NO: 47

SEQ ID NO: 73
SEQ ID NO: 48
SEQ ID NO: 49
SEQ ID NO: 53

SEQ ID NO: 74
SEQ ID NO: 50
SEQ ID NO: 51

SEQ ID NO: 75
SEQ ID NO: 54
SEQ ID NO: 55
SEQ ID NO: 56

SEQ ID NO: 76
SEQ ID NO: 57
SEQ ID NO: 58

SEQ ID NO: 77
SEQ ID NO: 59
SEQ ID NO: 55
SEQ ID NO: 56

SEQ ID NO: 78
SEQ ID NO: 60
SEQ ID NO: 61

SEQ ID NO: 79
SEQ ID NO: 62
SEQ ID NO: 55
SEQ ID NO: 56

SEQ ID NO: 80
SEQ ID NO: 63
SEQ ID NO: 58

SEQ ID NO: 81
SEQ ID NO: 64
SEQ ID NO: 55
SEQ ID NO: 56

SEQ ID NO: 82
SEQ ID NO: 65
SEQ ID NO: 58

SEQ ID NO: 83
SEQ ID NO: 66
SEQ ID NO: 55
SEQ ID NO: 68

SEQ ID NO: 84
SEQ ID NO: 67
SEQ ID NO: 58

SEQ ID NO: 85
SEQ ID NO: 69
SEQ ID NO: 55
SEQ ID NO: 68

SEQ ID NO: 86
SEQ ID NO: 70
SEQ ID NO: 58

TABLE 10

Amino acid sequences of the chains used to construct multispecific molecules.

Sequence ID
Amino Acid Sequence

SEQ ID NO: 71
QVQLQESGPGLVQPSQTLSLTCTVSGFSLTDFSVHWVRQPPGKGLEWMGRIRSEGNT

DYNSALKSRLSISRDTSKSQVFLKMNSLQTEDTAIYFCTRGDILGFGYWGQGVMVTV

SSAQTTAPSVYPLAPGCGDTTSSTVTLGCLVKGYFPEPVTVTWNSGALSSDVHTFPA

VLQSGLYTLTSSVTSSTWPSQTVTCNVAHPASSTKVDKKVERRTIKPCPPCKCPAPNL

LGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTH

REDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVY

VLPPCEEEMTKKQVTLWCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSY

FMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

SEQ ID NO: 72
DIVMTQSPLSVSVTPGESASISCRSSKSLLHFKGITFVYWYLQKPGQSPQLLIFRMSSL

ASGVPDRFSGSGSETDFTLKISRVEAEDVGTYYCGQLLENPYTFGAGTKLELKRADA

APTVSIFPPSMEQLTSGGATVVCFVNNFYPRDISVKWKIDGSEQRDGVLDSVTDQDS

KDSTYSMSSTLSLTKVEYERHNLYTCEVVHKTSSSPVVKSFNRNEC

SEQ ID NO: 73
QVQLQQSGAELVKPGSSVKISCKASGYTFTSNFMHWIKQQPGNGLEWIGWIYPGDG

DTEYNQKFNGKATLTADKSSSTAYMQLSSLTSEDSAVYFCAVNYGGYVLDAWGQG

ASVTVSSAETTAPSVYPLAPGTALKSNSMVTLGCLVKGYFPEPVTVTWNSGALSSGV

HTFPAVLQSGLYTLTSSVTVPSSTWSSQAVTCNVAHPASSTKVDKKIVPRECNTIKPC

PPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVE

VHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPK

GSVRAPQVCVLPPPEEEMTKKQVTLSCAVTDFMPEDIYVEWTNNGKTELNYKNTEP

VLDSDGSYFMVSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

SEQ ID NO: 74
EIVLTQSPTTMAASPGEKVTITCRASSSTNYMSWYQQKSGASPKPWIYETSKLASGV

PDRFSGSGSGTSYSFTISSMETEDAATYYCHQWSSTPLTFGSGTKLEIKRADAAPTVSI

FPPSMEQLTSGGATVVCFVNNFYPRDISVKWKIDGSEQRDGVLDSVTDQDSKDSTYS

MSSTLSLTKVEYERHNLYTCEVVHKTSSSPVVKSFNRNEC

SEQ ID NO: 75
EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKN

NNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQG

TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH

TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

KAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKT

TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX,

wherein X is K or absent

SEQ ID NO: 76
DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSK

LDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIKRTV

AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD

SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID NO: 77
EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYHMHWVRQAPGQGLEWMGWINPN

SGVTKYAQKFQGRVTMTRDTSINTAYMELSRLRFDDTDVYYCATGGFGYWGEGTL

VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT

FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP

PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK

GQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX,

wherein X is K or absent

SEQ ID NO: 78
LPVLTQPPSVSKGLRQTATLTCTGNSNNVGNQGAAWLQQHQGQPPKLLSYRNHNRP

SGVSERFSPSRSGDTSSLTITGLQPEDEADYYCLAWDSSLRAFVFGTGTKLTVLGQPK

ANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQ

SNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

SEQ ID NO: 79
QVQLVQSGAEVKKPGASVKVSCKASGYTFSSYYMHWVRQAPGQGLEWMGIINPSG

GNTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGYQLPHGRARA

FDMWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN

SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP

KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF

NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP

APIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS

LSPGX, wherein X is K or absent

SEQ ID NO: 80
AIRMTQSPLSLPVTLGQPASISCTSSQSLVYRDGTTYLNWFQQRPGQSPRRLIYKVSN

RDSGVPDRFTGSGSGTTFTLTISRVEAEDVGIYYCMQGTHWPLTFGQGTKVEIKRTV

AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD

SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID NO: 81
EVQLVESGGGLVQPGGSLRLSCVASGFTFSDYWMSWVRQAPGKGLEWVANIKKDG

SVNYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRFDYWGQGTLVTV

SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA

VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP

APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN

AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL

DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX, wherein X

is K or absent

SEQ ID NO: 82
QAGLTQPPSVSKGLRQTATLTCTGNSNNVGNQGAAWLQQHQGHPPKLLFYRNNNR

ASGISERLSASRSGNTASLTITGLQPEDEADYYCLTWDSSLSVVVFGGGTKLTVLGQP

KANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSK

QSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

SEQ ID NO: 83
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDG

GTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQG

TTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH

TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

KAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKT

TPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX,

wherein X is K or absent

SEQ ID NO: 84
DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTG

VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIKRTVAAPSVFIF

PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS

LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID NO: 85
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYN

GGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDY

WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL

TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD

KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY

VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE

KTISKAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN

YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

X, wherein X is K or absent

SEQ ID NO: 86
EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAAS

NLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIKRTVA

APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS

KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

TABLE 11

Sequences used to generate αCCR2/αCSF1R multispecific molecules.

Multispecific

Molecule
Heavy Chain 1
Light Chain 1
Heavy Chain 2
Light Chain 2

1
SEQ ID NO: 71
SEQ ID NO: 72
SEQ ID NO: 73
SEQ ID NO: 74

2
SEQ ID NO: 75
SEQ ID NO: 76
SEQ ID NO: 83
SEQ ID NO: 84

3
SEQ ID NO: 75
SEQ ID NO: 76
SEQ ID NO: 85
SEQ ID NO: 86

4
SEQ ID NO: 77
SEQ ID NO: 78
SEQ ID NO: 83
SEQ ID NO: 84

5
SEQ ID NO: 77
SEQ ID NO: 78
SEQ ID NO: 85
SEQ ID NO: 86

6
SEQ ID NO: 79
SEQ ID NO: 80
SEQ ID NO: 83
SEQ ID NO: 84

7
SEQ ID NO: 79
SEQ ID NO: 80
SEQ ID NO: 85
SEQ ID NO: 86

8
SEQ ID NO: 81
SEQ ID NO: 82
SEQ ID NO: 83
SEQ ID NO: 84

9
SEQ ID NO: 81
SEQ ID NO: 82
SEQ ID NO: 85
SEQ ID NO: 86

Example 2. Generation of Multiple αCCR2/αCSF1R Bispecific Antibody Molecules
1. Construction of the Plasmids.

2. Expression and Purification.

TABLE 12

Amino Acid Sequences.

SEQ ID

NO
Description
Amino Acid Sequence

SEQ ID
Ig Kappa
METDTLLLWVLLLWVPGSTG

NO: 116
Signal

Peptide

SEQ ID
hCH1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT

NO: 55

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD

KRVEPKSC

SEQ ID
hFc Knob
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH

NO: 56

EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW

LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREEMTK

NQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL

YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX,

wherein X is K or absent

SEQ ID
G Linker
G

NO: 127

SEQ ID
4GS Linker
GGGGS

NO: 128

SEQ ID
GGSGG
GGSGG

NO: 129
Linker

SEQ ID
GGSGGS
GGSGGS

NO: 130
Linker

SEQ ID
GGGSGG
GGGSGGG

NO: 131
G Linker

SEQ ID
GGGGSG
GGGGSGGGG

NO: 132
GGG

SEQ ID
3x4GS
GGGGSGGGGSGGGGS

NO: 133
Linker

SEQ ID
4x4GS
GGGGSGGGGSGGGGSGGGGS

NO: 134
Linker

SEQ ID
hCLIg_vk
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL

NO: 58

QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG

LSSPVTKSFNRGEC

SEQ ID
hCLIg_vl
GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGS

NO: 61

PVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEG

STVEKTVAPTECS

SEQ ID
α-hCSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLE

NO: 66
emactuzumab
WMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTA

VH
VYYCARDQRLYFDVWGQGTTVTVSS

SEQ ID
α-hCSF1R
DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLL

NO: 67
emactuzumab
IYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPT

VL
FGQGTKLEIK

SEQ ID
hFc Hole
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH

NO: 68

EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW

LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTK

NQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLV

SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX, wherein

X is K or absent

SEQ ID
α-hCSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGL

NO: 69
cabiralizumab
EWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDT

VH
AVYYCARESPYFSNLYVMDYWGQGTLVTVSS

SEQ ID
α-hCSF1R
EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQ

NO: 70
cabiralizumab
APRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLS

VL
NEDLSTFGGGTKVEIK

SEQ ID
α-hPDL1
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLE

NO: 113
avelumab
WVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAV

VH
YYCARIKLGTVTTVDYWGQGTLVTVSS

SEQ ID
α-hPDL1
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPK

NO: 114
avelumab
LMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTS

VL
SSTRVFGTGTKVTVL

SEQ ID
TGFβR1
MEAAVAAPRPRLLLLVLAAAAAAAAA

NO: 191
leader

sequence

SEQ ID
TGFβR1
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIA

NO: 135

EIDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

PVE

SEQ ID
TGFβR2
MGRGLLRGLWPLHIVLWTRIAS

NO: 136
leader

sequence

SEQ ID
TGFβR2
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM

NO: 100

SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDA

ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD

SEQ ID
α-PDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGL

NO: 109
durvalumab
EWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDT

VH
AVYYCAREGGWFGELAFDYWGQGTLVTVSS

SEQ ID
α-PDL1
EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLL

NO: 110
durvalumab
IYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLP

VL
WTFGQGTKVEIK

SEQ ID
α-PDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLE

NO:
atezolizumab
WVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA

111
VH
VYYCARRHWPGGFDYWGQGTLVTVSS

SEQ ID
α-PDL1
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKL

NO: 112
atezolizumab
LIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHP

VL
ATFGQGTKVEIK

SEQ ID
TGFβR3
GPEPGALCELSPVSASHPVQALMESFTVLSGCASRGTTGLPQEVHVL

NO: 108

NLRTAGQGPGQLQREVTLHLNPISSVHIHHKSVVFLLNSPHPLVWHL

KTERLATGVSRLFLVSEGSVVQFSSANFSLTAETEERNFPHGNEHLLN

WARKEYGAVTSFTELKIARNIYIKVGEDQVFPPKCNIGKNFLSLNYL

AEYLQPKAAEGCVMSSQPQNEEVHIIELITPNSNPYSAFQVDITIDIRP

SQEDLEVVKNLILILKCKKSVNWVIKSFDVKGSLKIIAPNSIGFGKESE

RSMTMTKSIRDDIPSTQGNLVKWALDNGYSPITSYTMAPVANRFHLR

LENNAEEMGDEEVHTIPPELRILLDPGALPALQNPPIRGGEGQNGGLP

FPFPDISRRVWNEEGEDGLPRPKDPVIPSIQLFPGLREPEEVQGSVDIA

LSVKCDNEKMIVAVEKDSFQASGYSGMDVTLLDPTCKAKMNGTHF

VLESPLNGCGTRPRWSALDGVVYYNSIVIQVPALGDSSGWPDGYED

LESGDNGFPGDMDEGDASLFTRPEIVVFNCSLQQVRNPSSFQEQPHG

NITFNMELYNTDLFLVPSQGVFSVPENGHVYVEVSVTKAEQELGFAI

QTCFISPYSNPDRMSHYTIIENICPKDESVKFYSPKRVHFPIPQADMDK

KRFSFVFKPVFNTSLLFLQCELTLCTKMEKHPQKLPKCVPPDEACTSL

DASIIWAMMQNKKTFTKPLAVIHHEAESKEKGPSMKEPNPISPPIFHG

LDTLTV

TABLE 13

Amino acid sequences of the chains used to construct multispecific molecules.

SEQ

ID NO
Description
Amino Acid Sequence

SEQ
α-hPDL1
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWV

ID NO:
avelumab VH-
SSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

137
hCH1-hFc_Knob-
ARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA

3x4GS linker-α-
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP

hCSF1R
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG

emactuzumab
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

VH-4x4GS linker-
NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE

α-hCSF1R
KTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEW

emactuzumab VL
ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPG

ASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKL

QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTT

VTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITC

RASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTGVPSRFSGSGSGTDF

TLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIK

SEQ
α-hPDL1
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKL

ID NO:
avelumab VL-
MIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSS

138
hCLIg_vl
STRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFY

PGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSH

RSYSCQVTHEGSTVEKTVAPTECS

SEQ
α-hPDL1 VH-
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWV

ID NO:
hCH1-hFc_Knob-
SSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

139
3x4GS linker-α-
ARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA

hCSF1R
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP

cabiralizumab
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG

VH-4x4GS linker-
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

α-hCSF1R
NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE

cabiralizumab VL
KTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEW

ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPG

SSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQK

FKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDY

WGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGE

RATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPAR

FSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK

SEQ
TGFβR1-4GS
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
linker-hCH1-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

140
hFc_Hole
PVEGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK

PSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI

SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVC

TLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV

LDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP

GX, wherein X is K or absent

SEQ
TGFβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hCLIg_vk
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

141

PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSRT

VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG

NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV

TKSFNRGEC

SEQ
TGFβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hFc_Knob-3x4GS
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

142
linker-α-hPDL1
PVEGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT

VH-4x4GS linker-
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV

α-hPDL1 VL
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRE

EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGS

GGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVR

QAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSL

RAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSGGGGSGGGGSGGGG

SGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHP

GKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYC

SSYTSSSTRVFGTGTKVTVL

SEQ
TGFβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hFc_Hole-3x4GS-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

143
α-hCSF1R
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSDK

emactuzumab
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

VH-4x4GS-α-
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE

hCSF1R
YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLS

emactuzumab VL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDK

SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGS

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWM

GVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

RDQRLYFDVWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSP

SSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYT

GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLE

IK

SEQ
TGFβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hFc_Hole-3x4GS-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

144
α-hCSF1R
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSDK

cabiralizumab
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

VH-4x4GS-α-
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE

hCSF1R
YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLS

cabiralizumab VL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDK

SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGS

QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWM

GDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYC

ARESPYFSNLYVMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEI

VLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRL

LIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNED

LSTFGGGTKVEIK

SEQ
α-hCSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWM

ID NO:
emactuzumab
GVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

145
VH-hCH1-
RDQRLYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL

hFc_Knob-3x4GS-
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL

α-PDL1 VH-
GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF

4x4GS-α-PDL1 VL
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

KAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNG

QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH

NHYTQKSLSLSPGKGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLR

LSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGR

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTL

VTVSSGGGGSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCT

GTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGN

TASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL

SEQ
α-hCSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWM

ID NO:
cabiralizumab
GDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYC

146
VH-hCH1-
ARESPYFSNLYVMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT

hFc_Knob-3x4GS-
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT

α-PDL1 VH-
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL

4x4GS-α-PDL1 VL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP

IEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSEVQLLESGGGLVQ

PGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYA

DTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDY

WGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQS

ITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFS

GSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL

SEQ
α-hCSF1R
DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLI

ID NO:
emactuzumab
YAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPT

147
CLIg_vk
FGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK

VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA

CEVTHQGLSSPVTKSFNRGEC

SEQ
α-hCSF1R
EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAP

ID NO:
cabiralizumab
RLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSN

148
CLIg_vk
EDLSTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY

PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEK

HKVYACEVTHQGLSSPVTKSFNRGEC

SEQ
α-hPDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWV

ID NO:
durvalumab VH-
ANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC

149
hCH1-hFc_Knob-
AREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA

3x4GS linker-α-
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV

hCSF1R
PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG

emactuzumab
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV

VH-4x4GS linker-
HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI

α-hCSF1R
EKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVE

emactuzumab VL
WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM

HEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQVQLVQSGAEVKKP

GASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQK

LQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGT

TVTVSSDIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGK

APKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ

SFSYPTFGQGTKLEIK

SEQ
α-hPDL1
EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLL

ID NO:
durvalumab VL-
IYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLP

150
hCLIg_vk
WTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRE

AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV

YACEVTHQGLSSPVTKSFNRGEC

SEQ
α-hPDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWV

ID NO:
atezolizumab VH-
AWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYC

151
hCH1-hFc_Knob-
ARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG

3x4GS linker-α-
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS

hCSF1R
SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS

emactuzumab
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA

VH-4x4GS linker-
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT

α-hCSF1R
ISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWES

emactuzumab VL
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGAS

VKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQG

RVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVT

VSSDIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPK

LLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFS

YPTFGQGTKLEIK

SEQ
α-hPDL1
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLI

ID NO:
atezolizumab VL-
YSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPA

152
hCLIg_vk
TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA

KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY

ACEVTHQGLSSPVTKSFNRGEC

SEQ
α-CSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWM

ID NO:
emactuzumab
GVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

153
VH-hCH1-
RDQRLYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL

hFc_knob-
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL

3x4GS-α-PDL1
GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF

durvalumab VH-
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT

4x4GS-α-PDL1
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

durvalumab VL
KAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNG

QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH

NHYTQKSLSLSPGKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLR

LSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGR

FTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGT

LVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLS

CRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGT

DFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK

SEQ
α-CSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWM

ID NO:
emactuzumab
GVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

154
VH-hCH1-
RDQRLYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL

hFc_knob-
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL

3x4GS-α-PDL1
GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF

atezolizumab VH-
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT

4x4GS-α-PDL1
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

atezolizumab VL
KAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNG

QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFScSVMHEALH

NHYTQKSLSLSPGKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLR

LSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGR

FTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVT

VSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRA

SQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTL

TISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK

SEQ
α-CSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWM

ID NO:
cabiralizumab
GDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYC

155
VH-hCH1-
ARESPYFSNLYVMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT

hFc_knob-
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT

3x4GS-α-PDL1
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL

durvalumab VH-
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE

4x4GS-α-PDL1
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP

durvalumab VL
IEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSEVQLVESGGGLVQ

PGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYV

DSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFD

YWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPG

ERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFS

GSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK

SEQ
α-CSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWM

ID NO:
cabiralizumab
GDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYC

156
VH-hCH1-
ARESPYFSNLYVMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT

hFc_knob-
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT

3x4GS-α-PDL1
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL

atezolizumab VH-
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE

4x4GS-α-PDL1
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP

atezolizumab VL
IEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSEVQLVESGGGLVQ

PGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYA

DSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWG

QGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRV

TITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGS

GTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hFc_Knob-3x4GS-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

157
α-PDL1
PVEGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT

durvalumab VH-
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV

4x4GS-αPDL1
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRE

durvalumab VL
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLV

ESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQ

DGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGG

WFGELAFDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSP

GTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRA

TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTK

VEIK

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hFc_Knob-3x4GS-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

158
α-PDL1
PVEGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT

atezolizumab VH-
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV

4x4GS-αPDL1
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRE

atezolizumab VL
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGS

GGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVR

QAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSL

RAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSG

GGGSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAP

KLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYL

YHPATFGQGTKVEIK

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hFc_Knob-3x4GS-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

159
α-CSF1R
PVEGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT

emactizumab
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV

VH-4x4GS-
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRE

αCSF1R
EMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF

emactizumab VL
FLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGS

GGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVR

QAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLR

SDDTAVYYCARDQRLYFDVWGQGTTVTVSSGGGGSGGGGSGGGGSGGG

GSDIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKL

LIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSY

PTFGQGTKLEIK

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hFc_Knob-3x4GS-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

160
α-CSF1R
PVEGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT

cabiralizumab
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV

VH-4x4GS-
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRE

αCSF1R
EMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF

cabiralizumab VL
FLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGS

GGGGSGGGGSQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVR

QAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSL

RSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSSGGGGSGGGGSGG

GGSGGGGSEIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWY

QQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFA

VYYCHLSNEDLSTFGGGTKVEIK

SEQ
TGFβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
CLIg_vk
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

161

PVEGGGGSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ

WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE

VTHQGLSSPVTKSFNRGEC

SEQ
TGFβR2-4GS
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
linker-hCH1-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

162
hFc_Hole
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSAS

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV

EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMT

KNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLV

SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGX,

wherein X is K or absent

SEQ
TGFβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hFc_Knob-3x4GS-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

163
αPDL1 avelumab
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSDK

VH-4x4GS-
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

αPDL1 avelumab
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE

VL
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLW

CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK

SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGS

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWV

SSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

ARIKLGTVTTVDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSQSAL

TQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYD

VSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRV

FGTGTKVTVL

SEQ
TGFβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hFc_Knob-3x4GS-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

164
αPDL1
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSDK

durvalumab VH-
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

4x4GS-αPDL1
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE

durvalumab VL
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLW

CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK

SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGS

EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWV

ANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC

AREGGWFGELAFDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIV

LTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYD

ASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTF

GQGTKVEIK

SEQ
TGFβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hFc_Knob-3x4GS-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

165
αPDL1
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSDK

atezolizumab VH-
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

4x4GS-αPDL1
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE

atezolizumab VL
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLW

CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK

SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGS

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWV

AWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYC

ARRHWPGGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQ

SPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFL

YSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGT

KVEIK

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hCH1-hFc_Knob-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

166
3x4GS-α-PDL1
PVEGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

avelumab VH-
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK

4x4GS-α-PDL1
PSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI

avelumab VL
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY

TLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV

LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP

GKGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSS

YIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTL

YLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSGGGGSGG

GGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYV

SWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAE

DEADYYCSSYTSSSTRVFGTGTKVTVL

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hCH1-hFc_Knob-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

167
3x4GS-α-PDL1
PVEGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

durvalumab VH-
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK

4x4GS-α-PDL1-
PSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI

durvalumab VL
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY

TLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV

LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP

GKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSR

YWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSL

YLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSGGGGSG

GGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQRVSSSYL

AWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPE

DFAVYYCQQYGSLPWTFGQGTKVEIK

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hCH1-hFc_Knob-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

168
3x4GS-α-PDL1
PVEGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

atezolizumab VH-
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK

4x4GS-α-PDL1
PSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI

atezolizumab VL
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY

TLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV

LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP

GKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSD

SWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTA

YLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSGGGGSGGGG

SGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQ

QKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFAT

YYCQQYLYHPATFGQGTKVEIK

SEQ
TFGβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hCH1-hFc_Knob-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

169
3x4GS-α-PDL1
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSAS

avelumab VH-
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

4x4GS-α-PDL1
HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV

avelumab VL
EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREEMT

KNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGG

GSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAP

GKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAE

DTAVYYCARIKLGTVTTVDYWGQGTLVTVSSGGGGSGGGGSGGGGSGG

GGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKA

PKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSY

TSSSTRVFGTGTKVTVL

SEQ
TFGβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hCH1-hFc_Knob-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

170
3x4GS-α-PDL1
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSAS

durvalumab VH-
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

4x4GS-α-PDL1
HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV

durvalumab VL
EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREEMT

KNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGG

GSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAP

GKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAE

DTAVYYCAREGGWFGELAFDYWGQGTLVTVSSGGGGSGGGGSGGGGSG

GGGSEIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQA

PRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQY

GSLPWTFGQGTKVEIK

SEQ
TFGβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hCH1-hFc_Knob-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

171
3x4GS-α-PDL1
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSAS

atezolizumab VH-
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

4x4GS-α-PDL1
HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV

atezolizumab VL
EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREEMT

KNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFScSVMHEALHNHYTQKSLSLSPGKGGGGSGGG

GSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAP

GKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAE

DTAVYYCARRHWPGGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGG

SDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLL

IYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHP

ATFGQGTKVEIK

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hCH1-hFc_Hole-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

172
3x4GS-α-CSF1R
PVEGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

emactuzumab
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK

VH-4x4GS-
PSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI

aα-CSF1R
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR

emactuzumab VL
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVC

TLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV

LDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP

GKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTS

YDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAY

MELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSSGGGGSGGGGSG

GGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQK

PGKAPKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYY

CQQSFSYPTFGQGTKLEIK

SEQ
TFGβR1-4GS-
LLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAE

ID NO:
hCH1-hFc_Hole-
IDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLG

173
3x4GS-α-CSF1R
PVEGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

cabiralizumab
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK

VH-4x4GS-
PSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI

α-CSF1R
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR

cabiralizumab VL
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVC

TLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV

LDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP

GKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGSSVKVSCKASGYTFTD

NYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTA

YMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSSGGGGS

GGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCKASQSVDYDG

DNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISS

LEPEDFAVYYCHLSNEDLSTFGGGTKVEIK

SEQ
TFGβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hCH1-hFc_Hole-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

174
3x4GS-αCSF1R
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSAS

emactuzumab
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

VH-4x4GS-
HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV

α-CSF1R
EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

emactuzumab VL
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMT

KNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLV

SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGG

GSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAP

GQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDD

TAVYYCARDQRLYFDVWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSD

IQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIY

AASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTF

GQGTKLEIK

SEQ
TFGβR2-4GS-
TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSN

ID NO:
hCH1-hFc_Hole-
CSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS

175
3x4GS-α-CSF1R
PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSAS

cabiralizumab
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

VH-4x4GS-
HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV

α-CSF1R
EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

cabiralizumab VL
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMT

KNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLV

SKLTVDKSRWQQGNVFScSVMHEALHNHYTQKSLSLSPGKGGGGSGGG

GSGGGGSQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAP

GQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSE

DTAVYYCARESPYFSNLYVMDYWGQGTLVTVSSEIVLTQSPATLSLSP

GERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIP

ARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK

SEQ
α-PDL1 avelumab
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWV

ID NO:
VH-CH1-
SSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

176
hFc_Knob-3x4GS-
ARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA

TGFβR1
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP

SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE

KTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEW

ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSLLPGATALQCFCHLC

TKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPS

SKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE

SEQ
α-PDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWV

ID NO:
durvalumab VH-
ANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC

177
CH1-hFc_Knob-
AREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA

3x4GS-TGFβR1
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV

PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI

EKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVE

WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM

HEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSLLPGATALQCFCHL

CTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAP

SSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE

SEQ
A-PDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWV

ID NO:
atezolizumab VH-
AWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYC

178
CH1-hFc_Knob-
ARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG

3x4GS-TGFβR1
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS

SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT

ISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSLLPGATALQCFCHLCTK

DNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSK

TGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE

SEQ
α-PDL1 avelumab
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWV

ID NO:
VH-CH1-
SSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

179
hFc_Knob-3x4GS-
ARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA

TGFβR2
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP

SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE

KTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEW

ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMI

VTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCV

AVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETF

FMCSCSSDECNDNIIFSEEYNTSNPD

SEQ
α-PDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWV

ID NO:
durvalumab VH-
ANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC

180
CH1-hFc_Knob-
AREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA

3x4GS-TGFβR2
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV

PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI

EKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVE

WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM

HEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDM

IVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVC

VAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGET

FFMCSCSSDECNDNIIFSEEYNTSNPD

SEQ
α-PDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWV

ID NO:
atezolizumab VH-
AWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYC

181
CH1-hFc_Knob-
ARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG

3x4GS-TGFβR2
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS

SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT

ISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMIVT

DNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAV

WRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM

CSCSSDECNDNIIFSEEYNTSNPD

SEQ
α-PDL1 avelumab
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWV

ID NO:
VH-CH1-
SSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

182
hFc_Knob-3x4GS-
ARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA

TGFβR3
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP

SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE

KTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEW

ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGPEPGALCELSPVSA

SHPVQALMESFTVLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQREV

TLHLNPISSVHIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLVSE

GSVVQFSSANFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELKI

ARNIYIKVGEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSSQP

QNEEVHIIELITPNSNPYSAFQVDITIDIRPSQEDLEVVKNLILILKC

KKSVNWVIKSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDIPST

QGNLVKWALDNGYSPITSYTMAPVANRFHLRLENNAEEMGDEEVHTIP

PELRILLDPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGED

GLPRPKDPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAVEK

DSFQASGYSGMDVTLLDPTCKAKMNGTHFVLESPLNGCGTRPRWSALD

GVVYYNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDASLFT

RPEIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQGVF

SVPENGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIENI

CPKDESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQCEL

TLCTKMEKHPQKLPKCVPPDEACTSLDASIIWAMMQNKKTFTKPLAVI

HHEAESKEKGPSMKEPNPISPPIFHGLDTLTV

SEQ
α-PDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWV

ID NO:
durvalumab VH-
ANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC

183
CH1-hFc_Knob-
AREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA

3x4GS-TGFβR3
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV

PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI

EKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVE

WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM

HEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGPEPGALCELSPVS

ASHPVQALMESFTVLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQRE

VTLHLNPISSVHIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLVS

EGSVVQFSSANFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELK

IARNIYIKVGEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSSQ

PQNEEVHIIELITPNSNPYSAFQVDITIDIRPSQEDLEVVKNLILILK

CKKSVNWVIKSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDIPS

TQGNLVKWALDNGYSPITSYTMAPVANRFHLRLENNAEEMGDEEVHTI

PPELRILLDPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGE

DGLPRPKDPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAVE

KDSFQASGYSGMDVTLLDPTCKAKMNGTHFVLESPLNGCGTRPRWSAL

DGVVYYNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDASLF

TRPEIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQGV

FSVPENGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIEN

ICPKDESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQCE

LTLCTKMEKHPQKLPKCVPPDEACTSLDASIIWAMMQNKKTFTKPLAV

IHHEAESKEKGPSMKEPNPISPPIFHGLDTLTV

SEQ
α-PDL1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWV

ID NO:
atezolizumab VH-
AWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYC

184
CH1-hFc_Knob-
ARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG

3x4GS-TGFβR3
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS

SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT

ISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGPEPGALCELSPVSASH

PVQALMESFTVLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQREVTL

HLNPISSVHIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLVSEGS

VVQFSSANFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELKIAR

NIYIKVGEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSSQPQN

EEVHIIELITPNSNPYSAFQVDITIDIRPSQEDLEVVKNLILILKCKK

SVNWVIKSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDIPSTQG

NLVKWALDNGYSPITSYTMAPVANRFHLRLENNAEEMGDEEVHTIPPE

LRILLDPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGEDGL

PRPKDPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAVEKDS

FQASGYSGMDVTLLDPTCKAKMNGTHFVLESPLNGCGTRPRWSALDGV

VYYNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDASLFTRP

EIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQGVFSV

PENGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIENICP

KDESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQCELTL

CTKMEKHPQKLPKCVPPDEACTSLDASIIWAMMQNKKTFTKPLAVIHH

EAESKEKGPSMKEPNPISPPIFHGLDTLTV

SEQ
α-CSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWM

ID NO:
emactuzumab
GVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

185
VH-CH1-
RDQRLYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL

hFc_Hole-3x4GS-
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL

TGFβR1
GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF

LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

KAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG

QPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALH

NHYTQKSLSLSPGKGGGGSGGGGSGGGGSLLPGATALQCFCHLCTKDN

FTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTG

SVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE

SEQ
α-CSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWM

ID NO:
cabiralizumab
GDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYC

186
VH-H1-
ARESPYFSNLYVMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT

hFc_Hole-3x4GS-
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT

TGFβR1
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL

GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP

IEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAV

EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSLLPGATALQCFCH

LCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCA

PSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE

SEQ
α-CSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWM

ID NO:
emactuzumab
GVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

187
VH-CH1-
RDQRLYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL

hFc_Hole TGFβR2
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL

GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF

LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

KAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG

QPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALH

NHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMIVTDN

NGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWR

KNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCS

CSSDECNDNIIFSEEYNTSNPD

SEQ
α-CSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWM

ID NO:
cabiralizumab
GDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYC

188
VH-CH1-
ARESPYFSNLYVMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT

hFc_Hole-3x4GS-
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT

TGFβR2
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL

GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP

IEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAV

EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNND

MIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEV

CVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGE

TFFMCSCSSDECNDNIIFSEEYNTSNPD

SEQ
α-CSF1R
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWM

ID NO:
emactuzumab
GVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

189
VH-CH1-
RDQRLYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL

hFc_Hole-3x4GS-
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL

TGFβR3
GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF

LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

KAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG

QPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFScSVMHEALH

NHYTQKSLSLSPGKGGGGSGGGGSGGGGSGPEPGALCELSPVSASHPV

QALMESFTVLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQREVTLHL

NPISSVHIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLVSEGSVV

QFSSANFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELKIARNI

YIKVGEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSSQPQNEE

VHIIELITPNSNPYSAFQVDITIDIRPSQEDLEVVKNLILILKCKKSV

NWVIKSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDIPSTQGNL

VKWALDNGYSPITSYTMAPVANRFHLRLENNAEEMGDEEVHTIPPELR

ILLDPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGEDGLPR

PKDPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAVEKDSFQ

ASGYSGMDVTLLDPTCKAKMNGTHFVLESPLNGCGTRPRWSALDGVVY

YNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDASLFTRPEI

VVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQGVFSVPE

NGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIENICPKD

ESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQCELTLCT

KMEKHPQKLPKCVPPDEACTSLDASIIWAMMQNKKTFTKPLAVIHHEA

ESKEKGPSMKEPNPISPPIFHGLDTLTV

SEQ
α-CSF1R
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWM

ID NO:
cabiralizumab
GDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYC

190
VH-CH1-
ARESPYFSNLYVMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT

hFc_Hole-3x4GS-
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT

TGFβR3
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL

GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP

IEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAV

EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGPEPGALCELSPV

SASHPVQALMESFTVLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQR

EVTLHLNPISSVHIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLV

SEGSVVQFSSANFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTEL

KIARNIYIKVGEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSS

QPQNEEVHIIELITPNSNPYSAFQVDITIDIRPSQEDLEVVKNLILIL

KCKKSVNWVIKSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDIP

STQGNLVKWALDNGYSPITSYTMAPVANRFHLRLENNAEEMGDEEVHT

IPPELRILLDPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEG

EDGLPRPKDPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAV

EKDSFQASGYSGMDVTLLDPTCKAKMNGTHFVLESPLNGCGTRPRWSA

LDGVVYYNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDASL

FTRPEIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQG

VFSVPENGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIE

NICPKDESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQC

ELTLCTKMEKHPQKLPKCVPPDEACTSLDASIIWAMMQNKKTFTKPLA

VIHHEAESKEKGPSMKEPNPISPPIFHGLDTLTV

TABLE 14

Sequences used to generate multispecific molecules.

Multispecific Molecule

Represented by

Identification
Comprising SEQ IDs
FIG. Number

Multispecific molecule 1
SEQ ID NOs: 176, 138, 185, 147
FIG. 1A

Multispecific molecule 2
SEQ ID NOs: 176, 138, 186, 148
FIG. 1A

Multispecific molecule 3
SEQ ID NOs: 176, 138, 187, 147
FIG. 1A

Multispecific molecule 4
SEQ ID NOs: 176, 138, 188, 148
FIG. 1A

Multispecific molecule 5
SEQ ID NOs: 176, 138, 189, 147
FIG. 1A

Multispecific molecule 6
SEQ ID NOs: 176, 138, 190, 148
FIG. 1A

Multispecific molecule 7
SEQ ID NOs: 177, 150, 185, 147
FIG. 1A

Multispecific molecule 8
SEQ ID NOs: 177, 150, 186, 148
FIG. 1A

Multispecific molecule 9
SEQ ID NOs: 177, 150, 187, 147
FIG. 1A

Multispecific molecule 10
SEQ ID NOs: 177, 150, 188, 148
FIG. 1A

Multispecific molecule 11
SEQ ID NOs: 177, 150, 189, 147
FIG. 1A

Multispecific molecule 12
SEQ ID NOs: 177, 150, 190, 148
FIG. 1A

Multispecific molecule 13
SEQ ID NOs: 178, 152, 185, 147
FIG. 1A

Multispecific molecule 14
SEQ ID NOs: 178, 152, 186, 148
FIG. 1A

Multispecific molecule 15
SEQ ID NOs: 178, 152, 187, 147
FIG. 1A

Multispecific molecule 16
SEQ ID NOs: 178, 152, 188, 148
FIG. 1A

Multispecific molecule 17
SEQ ID NOs: 178, 152, 189, 147
FIG. 1A

Multispecific molecule 18
SEQ ID NOs: 178, 152, 190, 147
FIG. 1A

Multispecific molecule 19
SEQ ID NOs: 179, 138, 185, 147
FIG. 1A

Multispecific molecule 20
SEQ ID NOs: 179, 138, 186, 148
FIG. 1A

Multispecific molecule 21
SEQ ID NOs: 179, 138, 187, 148
FIG. 1A

Multispecific molecule 22
SEQ ID NOs: 179, 138, 188, 148
FIG. 1A

Multispecific molecule 23
SEQ ID NOs: 179, 138, 189, 147
FIG. 1A

Multispecific molecule 24
SEQ ID NOs: 179, 138, 190, 148
FIG. 1A

Multispecific molecule 25
SEQ ID NOs: 180, 150, 185, 147
FIG. 1A

Multispecific molecule 26
SEQ ID NOs: 180, 150, 186, 148
FIG. 1A

Multispecific molecule 27
SEQ ID NOs: 180, 150, 187, 147
FIG. 1A

Multispecific molecule 28
SEQ ID NOs: 180, 150, 188, 148
FIG. 1A

Multispecific molecule 29
SEQ ID NOs: 180, 150, 189, 147
FIG. 1A

Multispecific molecule 30
SEQ ID NOs: 180, 150, 190, 148
FIG. 1A

Multispecific molecule 31
SEQ ID NOs: 181, 152, 185, 147
FIG. 1A

Multispecific molecule 32
SEQ ID NOs: 181, 152, 186, 148
FIG. 1A

Multispecific molecule 33
SEQ ID NOs: 181, 152, 187, 147
FIG. 1A

Multispecific molecule 34
SEQ ID NOs: 181, 152, 188, 148
FIG. 1A

Multispecific molecule 35
SEQ ID NOs: 181, 152, 189, 147
FIG. 1A

Multispecific molecule 36
SEQ ID NOs: 181, 152, 190, 148
FIG. 1A

Multispecific molecule 37
SEQ ID NOs: 145, 147, 140, 161
FIG. 2A

Multispecific molecule 38
SEQ ID NOs: 153, 147, 140, 161
FIG. 2A

Multispecific molecule 39
SEQ ID NOs: 154, 147, 140, 161
FIG. 2A

Multispecific molecule 40
SEQ ID NOs: 146, 148, 140, 161
FIG. 2A

Multispecific molecule 41
SEQ ID NOs: 155, 148, 140, 161
FIG. 2A

Multispecific molecule 42
SEQ ID NOs: 156, 148, 140, 161
FIG. 2A

Multispecific molecule 43
SEQ ID NOs: 145, 147, 140, 141
FIG. 2B

Multispecific molecule 44
SEQ ID NOs: 153, 147, 140, 141
FIG. 2B

Multispecific molecule 45
SEQ ID NOs: 154, 147, 140, 141
FIG. 2B

Multispecific molecule 46
SEQ ID NOs: 146, 148, 140, 141
FIG. 2B

Multispecific molecule 47
SEQ ID NOs: 155, 148, 140, 141
FIG. 2B

Multispecific molecule 48
SEQ ID NOs: 156, 148, 140, 141
FIG. 2B

Multispecific molecule 49
SEQ ID NOs: 145, 147, 162, 161
FIG. 2C

Multispecific molecule 50
SEQ ID NOs: 153, 147, 162, 161
FIG. 2C

Multispecific molecule 51
SEQ ID NOs: 154, 147, 162, 161
FIG. 2C

Multispecific molecule 52
SEQ ID NOs: 146, 148, 162, 161
FIG. 2C

Multispecific molecule 53
SEQ ID NOs: 155, 148, 162, 161
FIG. 2C

Multispecific molecule 54
SEQ ID NOs: 156, 148, 162, 161
FIG. 2C

Multispecific molecule 55
SEQ ID NOs: 145, 147, 162, 141
FIG. 2D

Multispecific molecule 56
SEQ ID NOs: 153, 147, 162, 141
FIG. 2D

Multispecific molecule 57
SEQ ID NOs: 154, 147, 162, 141
FIG. 2D

Multispecific molecule 58
SEQ ID NOs: 146, 148, 162, 141
FIG. 2D

Multispecific molecule 59
SEQ ID NOs: 155, 148, 162, 141
FIG. 2D

Multispecific molecule 60
SEQ ID NOs: 156, 148, 162, 141
FIG. 2D

Multispecific molecule 61
SEQ ID NOs: 137, 138, 140, 161
FIG. 3A

Multispecific molecule 62
SEQ ID NOs: 139, 138, 140, 161
FIG. 3A

Multispecific molecule 63
SEQ ID NOs: 149, 150, 140, 161
FIG. 3A

Multispecific molecule 64
SEQ ID NOs: 151, 152, 140, 161
FIG. 3A

Multispecific molecule 65
SEQ ID NOs: 137, 138, 140, 141
FIG. 3B

Multispecific molecule 66
SEQ ID NOs: 139, 138, 140, 141
FIG. 3B

Multispecific molecule 67
SEQ ID NOs: 149, 150, 140, 141
FIG. 3B

Multispecific molecule 68
SEQ ID NOs: 151, 152, 140, 141
FIG. 3B

Multispecific molecule 69
SEQ ID NOs: 137, 138, 162, 161
FIG. 3C

Multispecific molecule 70
SEQ ID NOs: 139, 138, 162, 161
FIG. 3C

Multispecific molecule 71
SEQ ID NOs: 149, 150, 162, 161
FIG. 3C

Multispecific molecule 72
SEQ ID NOs: 151, 152, 162, 161
FIG. 3C

Multispecific molecule 73
SEQ ID NOs: 137, 138, 162, 141
FIG. 3D

Multispecific molecule 74
SEQ ID NOs: 139, 138, 162, 141
FIG. 3D

Multispecific molecule 75
SEQ ID NOs: 149, 150, 162, 141
FIG. 3D

Multispecific molecule 76
SEQ ID NOs: 151, 152, 162, 141
FIG. 3D

Multispecific molecule 77
SEQ ID NOs: 166, 161, 172, 161
FIG. 4A

Multispecific molecule 78
SEQ ID NOs: 167, 161, 172, 161
FIG. 4A

Multispecific molecule 79
SEQ ID NOs: 168, 161, 172, 161
FIG. 4A

Multispecific molecule 80
SEQ ID NOs: 166, 161, 173, 161
FIG. 4A

Multispecific molecule 81
SEQ ID NOs: 167, 161, 173, 161
FIG. 4A

Multispecific molecule 82
SEQ ID NOs: 168, 161, 173, 161
FIG. 4A

Multispecific molecule 83
SEQ ID NOs: 169, 141, 174, 141
FIG. 4B

Multispecific molecule 84
SEQ ID NOs: 170, 141, 174, 141
FIG. 4B

Multispecific molecule 85
SEQ ID NOs: 171, 141, 174, 141
FIG. 4B

Multispecific molecule 86
SEQ ID NOs: 169, 141, 175, 141
FIG. 4B

Multispecific molecule 87
SEQ ID NOs: 170, 141, 175, 141
FIG. 4B

Multispecific molecule 88
SEQ ID NOs: 171, 141, 175, 141
FIG. 4B

Multispecific molecule 89
SEQ ID NOs: 166, 161, 174, 141
FIG. 4C

Multispecific molecule 90
SEQ ID NOs: 167, 161, 174, 141
FIG. 4C

Multispecific molecule 91
SEQ ID NOs: 168, 161, 174, 141
FIG. 4C

Multispecific molecule 92
SEQ ID NOs: 166, 161, 175, 141
FIG. 4C

Multispecific molecule 93
SEQ ID NOs: 167, 161, 175, 141
FIG. 4C

Multispecific molecule 94
SEQ ID NOs: 168, 161, 175, 141
FIG. 4C

Multispecific molecule 95
SEQ ID NOs: 166, 141, 174, 161
FIG. 4D

Multispecific molecule 96
SEQ ID NOs: 167, 141, 174, 161
FIG. 4D

Multispecific molecule 97
SEQ ID NOs: 168, 141, 174, 161
FIG. 4D

Multispecific molecule 98
SEQ ID NOs: 166, 141, 175, 161
FIG. 4D

Multispecific molecule 99
SEQ ID NOs: 167, 141, 175, 161
FIG. 4D

Multispecific molecule 100
SEQ ID NOs: 168, 141, 175, 161
FIG. 4D

Multispecific molecule 101
SEQ ID NOs: 142, 143
FIG. 5A

Multispecific molecule 102
SEQ ID NOs: 142, 144
FIG. 5A

Multispecific molecule 103
SEQ ID NOs: 157, 143
FIG. 5A

Multispecific molecule 104
SEQ ID NOs: 157, 144
FIG. 5A

Multispecific molecule 105
SEQ ID NOs: 158, 143
FIG. 5A

Multispecific molecule 106
SEQ ID NOs: 158, 144
FIG. 5A

Multispecific molecule 107
SEQ ID NOs: 163, 143
FIG. 5B

Multispecific molecule 108
SEQ ID NOs: 163, 144
FIG. 5B

Multispecific molecule 109
SEQ ID NOs: 164, 143
FIG. 5B

Multispecific molecule 110
SEQ ID NOs: 164, 144
FIG. 5B

Multispecific molecule 112
SEQ ID NOs: 165, 143
FIG. 5B

Multispecific molecule 113
SEQ ID NOs: 165, 144
FIG. 5B

Example 3. Inhibition of TGFβ Signaling Using TGFβ Trap

This study examines three TGFβ-trap constructs for their ability to inhibit TGFβ signaling. The first construct, “Single TGFβ Fab-trap” shown in FIG. 7, comprises two chains: the first chain comprises from N-terminus to C-terminus a first TGFBR2 ECD, a first linker, and a heavy chain constant region 1 (CH1); and the second chain comprises from N-terminus to C-terminus a second TGFBR2 ECD, a second linker, and a light chain constant region (CL). This construct does not comprise any targeting domains. The second construct, “Anti-PDL1×TGGβ-trap” shown in FIG. 7, comprises an anti-PDL1 antibody fused, at the C-terminus of its two Fc regions, to a TGFBR2 ECD homodimer. The third construct, “Anti-CCR2×anti-CSF1R×TGFβ-trap” shown in FIG. 7, comprises an anti-CCR2×anti-CSF1R bispecific antibody fused, at the C-terminus of its two Fc regions, to a TGFBR2 ECD homodimer. In addition, a fourth construct, “Anti-CCR2×anti-CSF1R” in FIG. 7, which is an anti-CCR2×anti-CSF1R bispecific antibody without a TGFβ-trap, was used as a negative control.

Briefly, HEK-Blue TGF-b cells were treated with the four constructs described above in a dose dependent manner in the presence of 0.5 ng/ml of TGF-β1 for 20-22 hours. TGF-β1 binds to receptors on HEK-Blue cells and induces activation of the TGF-β/Smad pathway leading to the formation of a Smad3/Smad4 complex. This heterocomplex enters the nucleus and binds SBE (Smad3/4-binding elements) sites inducing production of SEAP (secreted embryonic alkaline phosphatase). SEAP secreted in the supernatant was quantified by colormetric enzymatic assays (QUANTI-Blue). As shown in FIG. 7, TGF-β1-mediated SEAP production was reduced by all three TGFβ-trap constructs tested here. The anti-CCR2×anti-CSF1R bispecific antibody without a TGFβ-trap did not reduce TGF-β1 signaling (FIG. 7).

INCORPORATION BY REFERENCE

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

MULTISPECIFIC MOLECULES AND USES THEREOF

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

RELATED APPLICATION

PCT Information

Provisional Applications (1)